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Abstract 
Approximately 35 million cases of significant skin loss require clinical intervention 
annually. Tissue engineering has shown promise in the development of therapies to regenerate 
full-thickness skin wounds. Here we present the design of a novel cell-derived extracellular 
matrix scaffold with antimicrobial properties for dermal wound healing. We optimized 
decellularization methods, cultured dermal fibroblast sheets, cloned a cathelicidin construct, and 
expressed cathelicidin in a model cell type as steps toward achieving an antimicrobial dermal 
scaffold with tailored mechanical strength and bioactivity. 
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1  Introduction 
Skin is the body’s main protective barrier against environmental insults. As the largest 
organ in the body, skin maintains thermoregulation, blood vessel dilation, and the secretion of 
sweat. Significant skin wounds, caused by burns, physical trauma, surgery, and underlying 
pathologies, affect more than 35 million people annually in the United States(Clark, Ghosh, & 
Tonnesen, 2007). Of these, 20% develop into chronic, difficult-to-heal wounds, overall costing 
the U.S. more than $25 billion annually (Sen et al., 2009). Due to the extensive loss of tissue 
and damage to subcutaneous layers, such as fat, muscle, and bone, full-thickness wounds lead 
to impaired tissue regeneration and loss of barrier function (Hess, 2005). 
Scaffolds have been explored as a therapeutic method for regenerating, rather than 
repairing, skin at the wound site. In repair, a large amount of granulation tissue is synthesized to 
fill in the wound void, leading to scarring and impaired tissue functionality. Instead, scaffolds 
provide a three-dimensional support through which cells can migrate, adhere, and regenerate a 
functional new tissue (O'Brien, 2011). Current scaffolds, however, are plagued by inadequate 
biocompatibility and biodegradability, mechanical and structural mismatch with the native tissue, 
and susceptibility to infection (James, 2009). 
 Extracellular matrix (ECM) is an appealing scaffold material that provides several 
advantages over other natural and synthetic polymers currently used for skin therapies including 
structural support in the wound bed with mechanical properties closely matching those of native 
tissue. The ECM in skin is produced mainly by fibroblasts which reside in the dermal layer. The 
matrix is a biological substance composed of fibers and an interfibrillary matrix of 
glycosaminoglycans (GAGs) and proteoglycans, adhesive glycoproteins, solutes, and water. 
The ECM structurally supports the keratinocytes of the epidermal layer and provides a matrix to 
which keratinocytes can adhere and differentiate (Badylak, 2007). Furthermore, ECM scaffolds 
provide growth factors and cytokines that mediate cellular migration, proliferation, and 
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differentiation, thereby stimulating the natural wound healing response (Liu, Xia, & Czernuszka, 
2007; Macri & Clark, 2009). 
In this study, we designed a novel cell-derived ECM scaffold. Our goal was to address 
the limitations of current scaffolds by creating a product that (1) provides the structural and 
mechanical properties of native dermis and (2) actively prevents wound infection. Our approach 
follows a stepwise design process towards achieving a scaffold with antimicrobial activity and 
tailored mechanical properties. To accomplish goal (1), human dermal fibroblasts were cultured 
into tissue sheets in media supplemented with ascorbic acid in order to increase collagen 
expression. To accomplish goal (2), this process will be iterated and fibroblasts will be 
genetically modified to produce an antimicrobial protein that adheres to the ECM. In the end, the 
modified ECM scaffold will be isolated from the cell-derived tissue through decellularization. 
To produce a scaffold entirely from ECM, we cultured dermal fibroblasts into cell sheets 
and subjected them to different decellularization techniques in order to optimize the removal of 
cellular debris. A gene construct was developed to produce human cathelicidin (LL-37), an 
antimicrobial protein (AMP) that is naturally synthesized in the epidermis (Heilborn et al., 2003). 
The AMP was also designed to include the collagen-binding domain (CBD) of either 
collagenase or fibronectin to allow fibroblasts to express, secrete, and tether the protein within 
the ECM.  
The following chapters describe the clinical significance of fabricating a novel cell-
derived matrix for dermal wound healing, our project approach, and the validation testing of our 
design. The results describe how we were able to fabricate fibroblast sheets in the presence of 
ascorbic acid, assess mechanical strength of the fibroblast sheets, optimize decellularization 
protocols, and verify cathelicidin expression in a model cell type. Lastly, we provide an analysis 
of our final design and recommendations for future work. 
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2 Literature Review 
Literature research was conducted to become familiar with the project and understand 
current technology, protocols, and results. The following sections give a general overview of the 
of the project, including details about skin as an organ, the importance of scaffolds for wound 
healing, and rationale for using cell-derived matrices. 
2.1 Scaffolds for Tissue Engineering 
The number of organs and tissue needed to maintain control over treatment for current 
diseases and trauma greatly exceeds the number available for transplantation (Saltzman, 
2004). Shortcomings in donor sources have led to progress in the field of tissue engineering 
(TE), which is aimed at regenerating new, healthy tissue. TE has the potential to be an 
alternative to drug therapy, gene therapy, and whole-organ transplantation; a method to control 
the normal processes of tissue repair and healing; and a means to replace missing cells from 
functional tissue or organ (Saltzman, 2004). TE is a tri-faceted approach to regenerating native 
tissue. It requires a scaffold, which acts as a template to guide newly forming tissue, growth 
factors to provide chemical signals, and cells, to reconstruct tissue (O'Brien, 2011).  
2.1.1 Improved Wound Healing 
In tissue engineering, scaffolds are ultimately a three-dimensional support structure for 
new tissue growth. Scaffolds provide a support system for migrating cells to adhere and grow to, 
while providing a template for the forming tissue (O'Brien, 2011). These structures, however, are 
paramount for normal wound healing. As discussed later, there are three classic states of 
wound healing: inflammation, new tissue formation, and remodeling (Gurtner, Werner, 
Barrandon, & Longaker, 2008). The importance of scaffolds lies within the new tissue formation 
phase. In normal healing, fibroblasts and vascular endothelial cells begin synthesize new 
stroma, also referred to as granulation tissue, around four days post-injury (Singer & Clark, 
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1999). The granulation tissue eventually replaces the fibrin clot that was initially produced to 
shield the wound and act as a provisional matrix (Martin, 1997). Collagen, mostly type III 
initially, and proteoglycans are synthesized at the wound site by the fibroblasts, while the 
endothelial cells begin recreating the vasculature system in the wounded area (Morgan, 
Sheridan, Tompkins, Yarmush, & Burke, 2004). 
Scaffolds are a key factor in establishing regeneration versus repair during wound 
healing. In repair, large amounts of granulation tissue are synthesized to fill in the wound void, 
leading to scarring (Morgan et al., 2004). If a scaffold is placed in the void instead, the cells are 
able to recognize the temporary structure filling in the defect and control the rate of granulation 
tissue deposition. Scaffolds provide the opportunity for regeneration of the tissue, instead of 
simply plugging the hole, resulting in scar tissue. 
2.1.2 Considerations and Characteristics 
There are several design considerations when selecting a scaffold—biocompatibility, 
biodegradability, mechanical properties, scaffold architecture, bioactivity, and manufacturing 
technology (Ma, 2004). These factors will determine the most appropriate material for the 
application and how it should be fabricated. In regard to biocompatibility, if the material is toxic 
to the cells and native tissue, then the material should not be used for biomedical applications. 
Non-biocompatibility can elicit a chornic inflammatory response or severe immune response, 
ultimately resulting in rejection of the scaffold and physiological complications in the patient. In 
addition, if cells will not adhere to the surface or migrate through the scaffold, the material is not 
suitable for the application (Ma, 2004; O'Brien, 2011). This is extremely important when tissue 
engineering skin. The native cells must be able to integrate into the scaffold and begin 
degrading the fibers and synthesizing new matrix in order restore the lost functions that skin 
regulate (MacNeil, 2008). Scaffolds for tissue engineering applications can be permanent 
implants, but they are typically temporary guides to enhance tissue regeneration. For this 
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reason, the material must also be biodegradable so that it gradually reduces its influence as 
cells begin synthesizing their own matrix at the wound site (Yoon & Fisher, 2009). It is crucial 
that the material does not release toxic, highly acidic, or highly basic by-products as it degrades, 
which is commonly observed in synthetic materials (Liu et al., 2007). Another criteria, 
mechanical properties and integrity. Strength, stiffness, and shear resistance are key properties 
and should be consistent between the scaffold and native tissue. Insufficient properties may 
hinder cellular ingrowth, vascularization, uniform healing, and may result in damage of the 
scaffold upon handling (O'Brien, 2011). The scaffold should also demonstrate a porous 
structure to permit cellular permeability, diffusivity of molecular substrates and nutrients, and 
vascularization throughout the material (Place, George, & Williams, 2009). Developing a 
scaffold for tissue engineering applications however, can be a complex challenge as  positively 
affecting one category may be detrimental to the other.  For example, improving porosity to 
enhance biological processes can compromise the mechanical integrity of the scaffold (Place et 
al., 2009; Yoon & Fisher, 2009). A final consideration for selecting a scaffold is manufacturing 
capacity and technology. For a TE scaffold to be commercially available as a possible therapy, 
the scaffold should be cost effective and it should be possible to scale-up the production from 
one-at-a-time in a research laboratory or small batch production (O'Brien, 2011). 
2.1.3 Common Scaffold Materials 
There are two main groups of biomaterials in TE applications: synthetic materials, 
including ceramics, and natural or biological materials. Ceramic polymers are typically not used 
in soft tissue applications (O'Brien, 2011) and are thus not discussed in the context of this 
paper.  
2.1.3.1 Synthetic Materials and Limitations 
Synthetic materials for tissue engineering applications typically include, poly(L-lactide) 
(PLA), polyglycolic acid (PGA), and poly-DL-lactic-co-glycolic acid (PLGA) (Liu et al., 2007; 
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O'Brien, 2011). Synthetical materials are advantageous because their composition and 
subsequent properties, including porosity, strength, stiffness, and degradation rate, can be 
tailored according to need and function (Yoon & Fisher, 2009). Moreover, these materials offer 
the advantage of easy processing, permitting  for a reproducible manufacturing process. This 
ultimately results in the control and predictability of properties from batch-top-batch (Liu et al., 
2007). 
However, synthetic materials are limited by bioactivity and biocompatibility. The majority 
of synthetic polymers for TE degrade by bulk degradation (Liu et al., 2007). For the polymers 
that are hydrolyzed in the body, such as PGA and PLA, acidic by-products are released into the 
surrounding tissue, which lowers the pH of the area, possibly creating an inflammatory response 
and potentially killing the cells and tissue  (Lavik & Langer, 2004). Unlike natural materials, 
synthetic materials lack biological recognition. Without any biological signaling from the scaffold, 
cell ingrowth, proliferation, and differentiation may be negatively impacted. Cells rely on 
anchoring sites for attachment and cell-material interactions for guidance. Without these 
components, the material may present itself as a foreign object, creating a severe inflammatory 
response or even apoptosis (Liu et al., 2007). 
2.1.3.2 Natural Materials and Limitations 
Based on the limitations of synthetic scaffolds, research started to focus on using natural 
materials for biological applications. Natural materials are bioactive and provide the essential 
biological cues, biofunctional molecules, and signaling required for cell adhesion, growth, and 
function (Yoon & Fisher, 2009). Because these materials are natural, they are less likely to 
induce an inflammatory response, and the material can be enzymatically degraded as in normal 
processes without the release of toxic by-products (O'Brien, 2011). Natural polymers for tissue 
engineering can be broken down into two categories, polysaccharides, which are chains of 
sugar units, or polypeptides, which are chains of amino acid units. Examples of polysaccharide 
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materials include agarose, alginate, hyaluronic acid, and chitosan. Hyaluronic acid is of 
particular interest because of its extracellular matrix origin and critical role in wound healing 
(Yoon & Fisher, 2009). Polypeptide examples include gelatin, silk, and the commonly used 
collagen for its impact on cell funtion and strength. 
Current research is exploring the use of the extracellular matrix as a natural material due 
to its assortment of biological and wound healing properties. The ECM already has innate 
adhesion domains, diverse molecules, and the signaling needed to support cellular processes. 
The ECM can provide structure and constructive remodeling in tissue engineering applications, 
similar to its native functions within tissue. Stephen Badylak, a leader in ECM research, 
suggests that the extracellular matrix is “nature’s ideal biologic scaffold material” (Badylak, 
2007). Using ECM as a scaffold is discussed further in section 2.6. 
There are unfortunately several concerns when using natural materials. One of the main 
drawbacks of natural materials is that their mechanical properties are outperformed by both 
synthetic polymers and native tissue (Liu et al., 2007). Unlike synthetic materials, natural 
materials cannot be easily processed or reproduced, and there is little flexibility in varying 
mechanical and structural properties (O'Brien, 2011). Also, the in vivo rate of degradation 
cannot be controlled as easily as in synthetic materials, and there is difficulty in accurately 
quantifying the expected lifespan of these materials after implantation (Yoon & Fisher, 2009). 
There is also the concern of antigenicity and immunogenicity. Depending on the host organism, 
there is the potential for pathogen transmission and consequently immune reactions (Liu et al., 
2007).  
2.2 Skin 
Skin is the largest organ of the human body, occupying over 2.0m2 in (Rouabhia, 1997) 
and more mass than all other organs (Goldsmith, 1983). Integument, or skin, is multifunctional, 
with its primary functions in thermoregulation, physical protection from external stimuli, and 
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sensation. Skin helps to maintain internal stability and regulates the dilation of blood vessels, as 
well as the secretion of sweat. It acts as a barrier from the external environment to protect the 
body from mechanical and thermal insults, UV irradiation, hazardous chemicals, water and ionic 
loss, and very importantly, infection. Skin also acts in the production of vitamin D, waste and 
glandular secretions, and sensing for touch, pain, heat, and cold (Flynn & Woodhouse, 2009). 
2.2.1 Structure and Composition  
Skin is organized into three distinct layers (see Figure 1). The outermost layer is the 
epidermis and protects the body against external factors.  The middle layer is the dermis, which 
is a layer of dense connective tissue. The inner layer is the hypodermis, also known as 
subcutaneous fat, and consists of loose fatty connective tissue (Hendriks, 2005). A basement 
membrane binds the epidermal and dermal layers (Shier, Butler, & Lewis, 2009) 
 
Figure 1: Three-Dimensional View of Skin (Seal, Otero, & Panitch, 2001) 
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2.2.1.1 Epidermis 
The epidermis is the outermost part of the skin and is roughly 75-150um in thickness 
(Goldsmith, 1983). The epidermis is mainly cellular with little vasculature and consists of several 
layers: the stratum corneum, the stratum granulosum, the stratum spinosum, and the stratum 
germinativum. Keratinocytes reside in the deeper regions of the epidermis, whereas cornified 
cells predominate in the upper regions (Rouabhia, 1997). Together, these continually renewing 
compacted layers act in the protective functions of skin. 
2.2.1.2 Dermis 
The dermis is a fibroelastic layer approximately 1-4mm in thickness and consists of the 
extracellular matrix of cells, primarily collagen fibers. The dermal layer comprises the majority of 
skin and has various irregularities within the layer, as well as protruding from the layer. These 
components include blood and lymph vessels, nerve endings, hair follicles, and glands 
(Hendriks, 2005). The blood vessels in the dermis supply nutrients to both the dermal and 
epidermal layers. The dermis is mostly acellular and the few residing cells are fibroblasts, which 
synthesize the extracellular matrix (ECM) that constitutes the dermal layer (Zhong, Zhang, & 
Lim, 2010).  
The dermis consists of the three fibrous proteins collagen, elastin, and reticulin, as well 
surrounding   glycosaminoglycans (GAGs) and polysaccharides. Collagen bundles run almost 
parallel to the epidermis in an irregular network, occupying roughly 75% of dermal volume. 
Elastin occupies only about 1% of the dermal volume, but it provides the recoiling capacity of 
the tissue after deformation from external mechanical stresses. These fibers are positioned 
amongst the collagen bundles. The collagen is responsible for the strength of the skin and 
elastin is responsible for preventing permanent deformation when stresses are applied 
(Hendriks, 2005). 
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The dermal layer is composed of two regions: the papillary dermis and the reticular 
dermis. The papillary layer is the thin, outermost (upper) layer of the dermis and interacts with 
the epidermis through the basement membrane (Rouabhia, 1997). Constituting about 10% of 
the full dermal thickness, the collagen fibrils in this region are typically type III collagen and are 
packed into fibers of 0.3um-3um in diameter (Silver, Freeman, & DeVore, 2001). The fibers are 
loosely distributed within the layer, along with the elastin fibers (Goldsmith, 1983). The bulk of 
the dermis is the reticular layer, which lies beneath the papillary region and above arteries and 
postcapillary venules (Rouabhia, 1997) contains collagen fibers 10-40um in diameter (silver). 
These fibrils are predominately type I collagen, which are stronger than the type III collagen, 
providing the majority of dermal strength (Silver et al., 2001).  
2.2.2 Mechanical Properties 
Several studies were completed in the 1970’s to the mid-1980’s by Cook, Wan Abas, 
Barbanel, and many others, who collectively found that human skin is nonhomogeneous and 
also anisotropic (Alexander & Cook, 1977; Wan Abas & Barbenel, 1982). The mechanical 
properties of skin can differ based on various factors, including the location on the body where 
the skin is tested/derived from (ex. abdomen, leg, upper arm, etc.), the type and method of 
testing, temperature, humidity, and the age and health of the patient. Although values of skin 
have been published, these factors make it difficult to determine one exact value for the 
properties of skin, including strength, stiffness, and shear resistance (Hendriks, 2005; Lacroix & 
Planell, 2009). 
Skin is a viscoelastic material with an internal framework designed to minimize strain. 
Skin exhibits creep, in which strain increases at a constant stress, and relaxation, in which the 
stress required to maintain a constant strain is reduced (Edwards & Marks, 1995). However, 
creep and relaxation resistance decreases with age, as explained in the following paragraphs.  
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Common mechanical testing methods for skin include tensile testing, torsion testing, 
suction, and indentation. Tensile testing is a widely used method where the skin is loaded 
parallel to its surface and a tab is attached to either side of the sample, pulling the sample 
outward. In torsion testing, a guard ring and intermediary disc are attached to the skin and a 
constant torque/rotation is applied. The suction method applies a partial vacuum to the sample 
and measures the resulting elevation. For indentation experiments, an indenter is applied to the 
sample at a known force (Hendriks, 2005). 
Damien Lacroix and Josep Planell stretched skin at a slow rate of 5 cm/min and found 
that the tensile strength of skin ranges from 5-30MPa (Lacroix & Planell, 2009). The average of 
the experiments showed a maximum of 21MPa at 8 years of age that decreased to 17MPa for 
95 years of age. The ultimate strain varied from 35-115% with a mean value around 70% 
(Lacroix & Planell, 2009). The shear modulus ranges from 435-6620 Pa (Holt, Tripathi, & 
Morgan, 2008) and the ultimate modulus of elasticity ranges from 15-150MPa, with a mean 
value of 70MPa at 11 years of age and a value of 60MPa at 95 years of age (Edwards & Marks, 
1995).  Manschot and Brakkee performed unixial tensile tests on human calf skin and concluded 
a maximum strain of 32% and Young’s modulus of 4MPa across the tibia axis; a maximum 
strain of 30% and Young’s modulus of 20MPa was found across the tibia axis (Manschot & 
Brakkee, 1986). Silver and Freeman reported a similar modulus of 18.8MPa for human skin 
obtained from the thoracic and abdominal areas in patients 47-86 years of age (Silver et al., 
2001). Other testing methods produce significantly lower values for the modulus. For the torsion 
tests, Agache et al. reports stiffness values of 0.42-1.12MPa, which is supported by similar 
values of 0.4-0.85 MPa from other literature (Agache, Monneur, Leveque, & De Rigal, 1980). 
Barel et al. reported a stiffness of 1.12 MPa for suction testing, which is slightly greater than 
other values of literature (Hendriks, 2005; Zahouani et al., 2009). However, the values obtained 
were based on locations dissimilar than the tensile experiments. These reports confirm the 
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anisotropic properties of skin as determined years ago, which is demonstrated by differing 
strengths with different force directions. 
2.3 The Extracellular Matrix 
The extracellular matrix (ECM) is a dynamic, biological substance composed of fibers 
and an interfibrillary matrix of glycosaminoglycans (GAGs) and proteoglycans, adhesive 
glycoproteins, solutes, and water. The ECM is synthesized by cells and deposited in the 
intracellular space so that it resides amongst the cells. The ECM structurally supports cells, 
provides a matrix to which cells can adhere, and provides biological cues and signaling that can 
influence cell behavior (Badylak, 2007). According to Schoen and Mitchell, the ECM has seven 
principle functions: (1) mechanical support for the cell, (2) determination of cell orientation, (3) 
control of cell growth, (4) maintenance of cell differentiation, (5) scaffolding for orderly tissue 
renewal, (6) establishment of tissue microenvironment, and (7) sequestration, storage, and 
presentation of soluble regulatory molecules (Schoen & Mitchell, 2004). 
The cells within the tissues not only synthesize and secrete the matrix, but they also 
remodel it. The composition of the ECM is modified according to stimuli that instruct the cells to 
reorganize and reconstitute the matrix. Fibroblasts and smooth muscle cells predominately 
synthesize interstitial ECM, and epithelial cells typically synthesize the matrix for the basement 
membrane of the tissue. Almost all cells, however, are capable of secreting and breaking down 
ECM, to an extent (Schoen & Mitchell, 2004) 
Cell-cell and cell-ECM communications are crucial for cellular survival and tissue 
formation. The matrix can be characterized by the secreted constituents that contribute to this 
cell-ECM signaling; they are collagen, elastin, glycosaminoglycans (GAGs) and proteoglycans, 
and adhesive glycoproteins (Rosso, Giordano, Barbarisi, & Barbarisi, 2004). Collagen is the 
dominant protein within the ECM (Badylak, 2002) and provides the extracellular framework for 
all multicellular organisms. Collagen not only serves as the mechanical strength and structural 
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organization of the matrix, but it also influences cell spreading and movement (Rosso et al., 
2004). Elastin is also present in the matrix and gives tissues the ability to passively recoil due to 
its capability to stretch. Although minute quantities exist in the matrix of most tissues, elastin is 
typically found in larger quantities in the matrix of heart valves, the aorta, and in the walls of 
arteries (Schoen & Mitchell, 2004). 
The nonfibrilliar components (GAGs, proteoglycans, and adhesive glycoproteins) of the 
matrix have various functions, including lubrication, cell movement and differentiation, cell 
growth, and cell attachment (Rosso et al., 2004; Schoen & Mitchell, 2004). GAGs are long-
chained polysaccharides, that when bound to proteins, are termed proteoglycans (Schoen & 
Mitchell, 2004). They contribute to pressure resistance, water retention, and very importantly, 
the binding of growth factors and cytokines (Badylak, 2002). Common GAGs include hyaluronic 
acid, chondroitin sulfate and dermatan sulfate, heparin sulfate and heparin, and keratin sulfate 
(Schoen & Mitchell, 2004). Without the signaling from the growth factors and cytokines, cellular 
processes would be impeded.  
 Fibronectin and laminin are two very common adhesive proteins within the matrix. 
Fibronectin is no longer purely characterized by its structural properties, but also by its ability to 
facilitate cell behavior (Badylak, 2002). Fibronectin is of significant importance in binding cells to 
the matrix and is essential for cell movement, and differentiation (Rosso et al., 2004; Schoen & 
Mitchell, 2004). It also helps form fibrin clots (Schoen & Mitchell, 2004), making it a crucial 
component of wound healing and necessity for an ECM scaffold for dermal wound healing. 
Laminin, on the other hand, not only assists in cell sitting and tissue remodeling (Schoen & 
Mitchell, 2004), but it is paramount for the formation and regulation of vascular constructs within 
the matrix (Badylak, 2002). As will be discussed later, vascularization in TE-scaffolds is a 
complex challenge; laminin provides one technique to help induce this property.   
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2.4 Dermal Injury 
In fulfilling its role as a barrier between the body and the environment, skin is exposed to 
many external insults. The most common causes of cutaneous wounds are burns, physical 
trauma, surgery, and pathologically induced chronic ulcerations (Macri & Clark, 2009). It is 
estimated that there are approximately 35 million cases of significant skin loss annually which 
require clinical intervention (Clark et al., 2007). Of these, 20% develop into chronic, difficult-to-
heal, wounds. In the United States alone, approximately 6.5 million patients suffer from chronic 
wounds, and it is estimated that more than $25 billion is spent annually for the treatment of 
chronic wounds in the US (Sen et al., 2009).   
2.4.1 Natural Course of Wound Healing 
When a wound occurs and the epidermal barrier is broken, the body responds by initiating 
a cascade of events to maintain homeostasis.  If it is an acute wound, it tends to undergo a 
natural, non-pathological course of repair. The natural process of wound healing is a highly 
organized and dynamic series of events involving three interdependent stages: inflammation, 
tissue formation/proliferation, and tissue remodeling. Each phase is marked by a series of 
complex interactions between different cells and biochemical signals (Freinkel & Woodley, 
2001).  
        
Figure 2: Three phases of natural wound healing. (A) Inflammation, (B) tissue formation/proliferation, and (C) 
tissue remodeling 
  
A B C 
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2.4.1.1 Inflammation 
The phase of inflammation (see Figure 2) begins immediately after an injury and often 
lasts for 4-6 days (Shai, 2005). The cascade of events is initiated by the disruption of blood 
vessels and the subsequent accumulation of platelets in the site of the injury. The platelets are 
responsible for forming a fibrin-rich clot to act as a barrier between the blood stream and the 
external environment. The fibrin clot also acts as a provisional matrix for supporting the later 
phases of wound healing (Freinkel & Woodley, 2001). The activated platelets also play a major 
biochemical role by releasing numerous growth factors and cytokines to recruit and activate 
neutrophils, monocytes, keratinocytes, and fibroblasts to the wound site (Macri & Clark, 2009). 
The structural cues and chemoattractants which are presented by the provisional matrix are 
thus crucial for initiating a natural course of wound healing.  
Neutrophils migrate into the wound scene within minutes of the injury and remain there 
for 1-2 days, clearing infections and cellular debris by phagocytosis. As the wound is cleared, 
neutrophils reduce in number and slowly recruit macrophages. Both neutrophils and 
macrophages are responsible for releasing many cytokines and chemoattractants into the 
wound, including tumor necrosis factor-α (TNF- α), transforming growth factor-α (TGF-α), TGF-
β, interleukin-1, and fibroblast growth factor (Freinkel & Woodley, 2001). These chemical signals 
bring in keratinocytes and fibroblasts for re-epithelialization and matrix synthesis. 
2.4.1.2 Tissue Formation and Proliferation 
The tissue formation phase involves many major events including re-epithelialization, 
extracellular matrix formation, and angiogenesis. The main contributors of this phase are the 
keratinocytes and fibroblasts. Re-epithelialization overlaps greatly with the inflammatory phase, 
beginning within hours of the injury. Re-epithelialization is marked by the migration of 
keratinocytes from the surrounding epidermis to the surface of the wound. Keratinocytes 
express integrins α5 β1 and α2 β1, which are important for their migration onto fibronectin and 
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collagen filaments, respectively. Ideally, the body seeks to close the wound with an epithelial 
layer before it begins to structurally rebuild the inner dermal tissue (Shai, 2005). One or two 
days after the injury, the surface keratinocytes begin to proliferate and cover the wound 
(Freinkel & Woodley, 2001). Fibroplasia begins within 2 days of the injury. It is characterized by 
the formation of granulation tissue and reconstruction of the dermal matrix (Macri & Clark, 
2009). Fibroblasts are the main directors of this process, replacing the fibrin-fibronectin 
provisional matrix with more stable extracellular components.  Upon migrating and repopulating 
the wound, they begin to reconstitute the dermal matrix and synthesize numerous extracellular 
components including types I and III collagen, elastin, glycosaminoglycans, and proteoglycans 
(Freinkel & Woodley, 2001).  
Angiogenesis refers to the process of new vessel formation and is also known as 
neovascularization. This process occurs simultaneously with fibroplasia and is directed by 
endothelial cells.  The migration and proliferation of endothelial cells in the wound site is 
dependent on several chemotactic signals. Fibronectin and heparin are responsible for the 
migration of the cells into the wound, while TGF-β, FGF, and VEGF stimulate angiogenesis 
(Freinkel & Woodley, 2001). The TGF-β family of growth factors is in part responsible for many 
of the physiologic processes during wound healing. It plays a role in fibroblast proliferation and 
ECM production, mediates the differentiation of fibroblasts, and enhances angiogenesis (Shai, 
2005). 
After the reconstitution of much of the matrix, the wound begins to contract. Contraction 
is mediated by fibroblasts which undergo a phenotypic change into myofibroblasts. These cells 
are actin-rich and morphologically similar to smooth muscle cells. Their contraction of the wound 
is the primary factor responsible for wound closure. Depending on the depth of the wound, 
contraction can contribute to approximately 40% reduction of wound size (Freinkel & Woodley, 
2001). 
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2.4.1.3 Tissue Remodeling 
The third and final stage of wound healing is tissue remodeling. It begins at the same time 
as tissue formation and continues for months. During this time, type I collagen replaces the type 
III collagen of granulation tissue, eventually forming more stable scar tissue. Within one month, 
the tissue will have regained 40% of its original strength, and over time it can regain as much as 
70-80% of its tensile strength as compared to pre-injured skin (Shai, 2005). The remodeling 
phase is directed by both matrix-degrading metalloproteinases (MMPs), which break down 
collagen, and by fibroblasts, which replace the type III collagen with type I. The actions of these 
contributors are dependent on a number of growth factors, as well as the ECM itself. Interleukin-
1 stimulates the synthesis of MMPs, while natural polymers such as fibronectin and hyaluronic 
acid provide a foundation for the production of collagen and cellular locomotion (Freinkel & 
Woodley, 2001).  
2.4.2 Chronic Wounds 
 A chronic wound is defined as any wound which fails to progress through the natural 
phases of wound healing, and therefore remains in a pathologic state of inflammation (Menke, 
Ward, Witten, Bonchev, & Diegelmann, 2007). The degree of chronicity of a wound is defined by 
many factors, but it is generally agreed upon that if a wound does not heal within 3-4 months, 
then it can be defined as a “chronic cutaneous ulcer” (Shai, 2005). In contrast to an acute 
wound, a chronic ulcer occurs as a result of an underlying pathology. Acute wounds can 
develop into chronic non-healing ulcers in patients with diabetes mellitus, venous insufficiency, 
or immobility (Macri & Clark, 2009; Shai, 2005).  In the United States 2-3 million individuals are 
at risk of developing chronic diabetic ulcers; 600,000 of developing venous leg ulcers; and 2-3 
million of developing pressure ulcers as a result of immobility (Macri & Clark, 2009). 
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2.4.3 Wound Infection 
Infection is a major problem faced by patients with chronic wounds, often leading to 
morbidity and mortality (Siddiqui & Bernstein, 2010). It is responsible for 75% of all deaths in 
patients with burns wounds exceeding 40% TBSA (Rode, Vale, & Millar, 2008).  
The presence and activity of various microbes on a wound determines whether or not an 
infection will occur. The concentration of bacteria and the significance of their proliferation 
results in different levels of chronicity, as shown on Figure 3 (Siddiqui & Bernstein, 2010). 
Contamination is the transient presence of non-multiplying bacteria on a wound. This can occur 
in almost all wounds. Colonization occurs when bacteria are multiplying but do not initiate any 
pathogenic response from the host. Critical colonization is the point at which the bacteria 
contact healthy tissue, initiating a host response and causing the wound to enter a non-healing, 
chronic inflammatory state. Symptoms of critical colonization include deterioration of granulation 
tissue, discoloration of tissue to deep red or gray color, increased wound friability, and 
increased drainage (Siddiqui & Bernstein, 2010). Infection occurs when the bacterial 
proliferation rate surpasses host response, resulting in direct injury to the deep tissues of the 
host. Clinically, infection is defined by a deep tissue quantitative microbial count of >105 cfu/ml 
(colony-forming units/ml tissue) (Landis, 2008). 
 
 
 
 
 
 
Figure 3: Spectrum of Bacterial Contamination-to-Infection (adapted from Siddiqui & 
Bernstein, 2010) 
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The necrotic tissue in wounds provides a favorable niche for bacterial colonization and 
proliferation. The dead tissue provides a rich source of protein for bacterial growth and is 
inaccessible by both the circulatory and immune systems, allowing infections to develop 
undetected. The colonized bacteria may produce biofilms which further protect them from host 
defense mechanisms. These biofilms can develop within 10-72hrs (Rode et al., 2008).  
In burn wounds, gram-positive bacteria, including Staphylococcus and Enterococcus 
strains, are the first to colonize because they are normally present in the glands and hair 
follicles of healthy skin (Landis, 2008). Within one week, gram-negative bacteria, such as 
Pseudomonas, Klebsiella and Escherichia species can overpopulate the wound. These species 
are natively in the respiratory and gastrointestinal tracts, but tend to spread in the hospital 
environment. They present the most concerning clinical burden in wounds, as they often have 
high virulence and possess antimicrobial resistant traits (Church, Elsayed, Reid, Winston, & 
Lindsay, 2006). 
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Table 1: Microorganisms Causing Invasive Wound Infections (adapted from Church et al., 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The prevelant bacterial species found in wounds are Staphylococcus aureus, present in 
93.5% of wounds; Enterococcus faecalis, present in 71.7% of wounds; and Pseudomonas 
aeruginosa, present in 52.2% of wounds (Gjodsbol et al., 2006). Fungal wound infections also 
occur, and are most commonly caused by Candida species. Fungal infections occur in 30% of 
burn wounds, and are usually prevelant after patients have undergone treatment with broad-
spectrum antibiotics. Their presence in wounds increases the risk of mortality for the patient 
(Rode et al., 2008). Other species of microbes which contribute to wound infections are listed in 
Table 1. 
Group Species 
Gram-positive Staphylococcus aureus 
Methicillin-resistant S. aureus 
Coagulase-negative staphylococci 
Enterococcus spp. 
Vancomycin-resistant enterococci 
 
Gram-negative Pseudomonas aeruginosa 
Escherichia coli 
Klebsiella pneumoniae 
Serratia marcescens 
Enterobacter spp. 
Proteus spp. 
Acinetobacter spp. 
Bacteroides spp. 
 
Fungi Candida spp. 
Aspergillus spp. 
Fusarium spp. 
Alternaria spp. 
Rhizopus spp. 
Mucor spp 
 
Viruses Herpes simplex 
virus 
Cytomegalovirus 
Varicella-zoster virus 
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2.5 Current Treatments 
 In choosing the proper treatment for a wound, the wound depth is one of the most 
important factors to be considered (James, 2009). Wounds can be classified as either partial-
thickness, where the injury extends through a portion of the dermis, or full-thickness, where the 
entire dermis and parts of the subcutaneous layers are damaged While most acute and 
superficial wounds can be treated with topical medication and dressings, full-thickness wounds 
and chronic ulcers require more localized regenerative therapies to achieve healthy wound 
healing (Téot, 2010). If left untreated, the damaged tissue of a full-thickness wound begins to 
break down within 24-48h and becomes highly susceptible to bacterial infection (James, 2009). 
Depending on the condition of the wound and whether or not necrotic and infected tissue is 
present, the physician may need to debride the wound.  
2.5.1 Debridement 
Debridement involves the removal of devitalized and infected tissue to stimulate wound 
healing (Shai, 2005). Common methods of debridement include surgical removal, hydration or 
absorption to control the moisture of the wound, and enzymatic or chemical break down of 
necrotic material (Shai, 2005). Following debridement, the wound is left clean with the potential 
to undergo a natural course of repair. The use of skin substitutes and grafts is often required to 
support the normal wound healing process (Shai, 2005). 
2.5.2 Antimicrobial Treatments 
As mentioned earlier, the presence of necrotic tissue is the major predisposing factor for 
the onset of bacterial wound infections. Thus, when a wound contains devitalized tissue, topical 
antimicrobial treatments alone are not always effective. Wound site excision or debridement is 
often required to clean the wound and expose living and active dermal tissue. Antimicrobial 
treatments are only applied once the wound has been cleaned and excess surface bacteria is 
removed (Rode et al., 2008).  
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Antimicrobial treatments can be categorized into two types: antiseptics and antibiotics. 
Antiseptics are chemicals which have a broad spectrum of toxicity against microbes, whereas 
antibiotics are characterized by more specific mechanisms of action which target a narrow-
spectrum of microbes (Siddiqui & Bernstein, 2010). Antiseptics, usually used topical treatments, 
are usually alcohols (ethanol, isopropanol), biguanides (chlorhexidine, polyhexadine), sodium 
hypochlorite solutions, halogen compounds (pyrrolidone iodine), heavy metals (silver), or 
peroxygens (hydrogen peroxide). Topical antiseptics are used in fresh wounds to prevent 
infection, or in more established wounds to reduce bacterial count below 105cfu/mL of tissue 
(Rode et al., 2008). A list of commonly used antiseptics is summarized in Table 2. These 
antimicrobial treatments are not universally effective; each treatment having its own spectrum of 
activity, as well as corresponding limitations. Although they can reduce microbial burden, these 
treatments are not able to sterilize the wound. Use of any one agent for an extended period of 
time can often cause bacterial resistance, so it is usually recommended that patients rotate 
between using different agents. Because of this, antimicrobial therapies often require the use of 
multiple types of antiseptic agents. Finally, a closed dressing is required to maintain continuous 
contact between the antimicrobial agent and the burn wound (Rode et al., 2008). 
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Table 2: Types of Topical Antiseptic Treatments (adapted from Rode et al., 2008) 
Agent Application 
Frequency 
Escher  
Penetration 
Action 
Sodium hypochloride (NaOCl 
0.025%) 
 
Daily for 20 - 
30 minutes 
Surface action Bactericidal to Gram (+) and (-) organisms 
including MRSA and Pseudomonas 
 
Silver-sulphadiazine 1% 
 
12-hourly 
liberal application 
Limited Bactericidal for many Gram (+) and (-) 
organisms 
including yeasts 
Povidine iodine 
 
6 hourly Limited Bactericidal, broad-spectrum bacterial and 
antifungal activity 
Mupirocin 
 
Daily Excellent Bactericidal, broad-spectrum bacterial and 
antifungal activity 
Chlorhexidine 
 
Daily  Bactericidal, especially against 
Pseudomonas 
Nanocrystalline silver 
 
3 - 4 days Excellent Bactericidal to more than 150 bacteria and 
yeasts 
 
Systemic antimicrobial treatments, or antibiotics, have received some controversy in 
relation to their effectiveness and accompanying risks. Although antibiotics are often used to 
treat or prevent invasive systemic infections, they have not proven to be any more effective than 
topical antiseptics in treating the actual wound site (Rode et al., 2008). In addition to this doubt, 
there is the concern associated with the risk of producing antimicrobial resistant bacteria. 
Because wounds host an environment for polymicrobial growth, there is ample opportunity for 
microbes to share genes for antimicrobial-resistance. This issue is a growing concern for public 
health, and thus use of systemic antibiotics is under more regulation. Systemic antibiotics are 
only used in cases where wound infection cannot be controlled by topical intervention. These 
cases include sepsis, cellulitis, lymphangitis, abscess formation, and when tissues present signs 
of an invasive microbial species (Siddiqui & Bernstein, 2010). 
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2.5.3 Skin Grafting 
Full-thickness wounds with large voids and extensive tissue loss exhibit impaired wound 
healing because the native parenchymal cells cannot completely rebuild the original structure of 
the tissue. Instead, a large amount of granulation tissue is applied to fill  the defect. If left to heal 
naturally, the granulation tissue leads to scar formation and hypercontraction(Morgan et al., 
2004), leaving the wound site mechanically compromised. In the case of wounds near joints, 
such as the wrist or hand, the contracted scar tissue can distort the natural position of the joint 
and even limit its mobility (Klein, 2010). 
In order to reduce scar formation and support functional regeneration of the dermis, skin 
grafts are often recommended for use in full-thickness wound healing. Skin grafts are referred to 
as “biological dressings” used for wound coverage, wound closure, or both. Epidermal grafts are 
developed for partial thickness coverage, while dermal grafts are intended for full-thickness 
wound closure. For purpose of this review, dermal substitutes are described in context of their 
general use for wound closure. There are currently several substitutes commercially available 
for patients. These products range in functional depth, source type, duration of coverage, and 
overall composition. The most common types are listed in Table 3. 
2.5.3.1 Autografts  
The gold standard for dermal substitution is via an autograft, where healthy skin is 
harvested from a patient’s own body and transplanted to the wound site. Using autologous skin 
eliminates both the search for a donor and the possibility of immunological rejection. A 
drawback with using a patient’s own skin arises when  wounds cover more than 50% of the total 
body surface area such as in burn victims (Klein, 2010). Another limitation with transplanted skin 
flaps is its conditional success. In order for an autograft to be successful, the transplanted skin 
needs to be re-vascularized at the wound site. If the transplant does not “take,” or become 
incorporated with its new environment, then the tissue will become necrotic. The use of 
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autologous grafts can create multiple wound sites, results in slow recovery in areas with high 
mesh expansion rations, and ultimate scarring and disfiguration of the skin (James, 2009). 
Other, similar options include autologous cultured skin substitutes, such as Epicel 
(Genzyme Biosurgery). Autologous based cell-derived products require a skin biopsy, as well as 
several weeks of culturing (Shores, Gabriel, & Gupta, 2007).. Leaving a full-thickness wound 
untreated for more than 48 hours, however, can result in the breakdown of damaged tissue, and 
an increased risk of infection (James, 2009). Another disadvantage is the high cost associated 
with the customized treatment;~$13,000 per 1%TBSA (Clark et al., 2007). Despite, the apparent 
advantages of using one’s own skin for regeneration, patients with pathological or extensive 
wounds are often prompted to choose from several other clinically available substitutes.  
2.5.3.2 Allogeneic Grafts 
Allogeneic grafts  are donated from  individuals for transplanation onto another pateint’s 
wound site. Using living cadaver skin as an allograft provides natural qualities, however these 
kinds of  substitute need to be removed 10-21 days after application because they tend to elicit 
an immune response.In order for these products to be successfully accepted by the host, they 
need to be processed and decellularized prior to transplantation. (Van der Veen, 2011). Some 
commerially available human allografts include AlloDerm (Life Cell), and GraftJacket (Wright 
Medical Technology).  
 Acellular dermal allografts consist of decellularized dermis obtained from human 
cadaveric donors. The scaffolds are cryopreserved, lyophilized and glycerolized to reduce 
immunogenic response, but preserve the structural and functional integrity of the graft.  In a 
wound, they serve as a template for the ingrowth of fibroblasts, as well as vascularization. 
These products are available commercially from skin-banks. The drawback with these products 
is that they are dependent on the availibilty of cadaveric donors (James, 2009). There is also 
the risk of infectious disease transmission and immunorejection from cellular remnants. Both 
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Alloderm and GraftJacket show remnants of donor DNA, which could result in disease 
transmission (Shores et al., 2007). 
 . 
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Table 3: Dermal Substitutes (James, 2009) 
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2.5.3.3 Xenografts 
 Xenografts are tissues obtained from other species. Most commonly, dermal substitutes 
are isolated from porcine and bovine tissues. Some commercially available xenogafts include 
OASIS (Healthpoint Ltd) and Permacol (Tissue Science Laboratories). OASIS is decellularized 
porcine submucosa, while Permacol is decellularized and crosslinked porcine collagen dermis. 
Xenografts are usually temporary grafts and require changing every 2-4days (Shores et al., 
2007).  
2.5.3.4 Natural and Synthetic Scaffolds  
Other commercially available products, include natural and synthetic scaffolds  such as 
Apligraf (Organogenesis) and Integra (Integra Neurosciences) are aimed at providing a stuctural 
base for dermal regeneration.  Both of these products use bovine collagen. Integra includes a 
synthetic silicone layer to act as a permanent barrier at the wound site.  Apligraf is seeded with 
both neonatal fibroblasts and neonatal keratinocytes, giving it a shelf life of approximately 
~5days. Because of its living components, the cost of this graft is among the highest, ~$30/cm2. 
In addition, it often requires multiple applications for wound treatment every 4-6 weeks (Shores 
et al., 2007). 
2.6 ECM Scaffolds for Dermal Regneration 
The extracellular matrix (ECM) is an appealing alternative material for scaffolds over 
many other biological and synthetic polymers for skin therapies. Not only does the ECM provide 
structural support in the wound bed for cell proliferation, migration, and differentiation, but it also 
has mechanical properties and fiber orientation that matches the native tissue. Furthermore, 
ECM scaffolds provide the biological growth factors and cytokines that modulate and propagate 
signals of the wound healing response (Liu et al., 2007; Lu, Hoshiba, Kawazoe, Song, & Chen, 
2011; Macri & Clark, 2009).  
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2.6.1 Decellularized Tissue-Derived ECM 
The initial and most widely used method to isolate ECM for acellular scaffolds is the 
decellularization of tissues and organs. Many of these tissue-derived ECM scaffolds have been 
successfully applied in human clinical applications, including but not limited to scaffolds for 
tissue reconstruction, urethral repair, tendon ruptures, rotator-cuff repairs, and for full-thickness 
burns (Gilbert, Sellaro, & Badylak, 2006). Extensive research has also been conducted using 
decellularized heart valves, blood vessels, urinary bladder, small intestine submucosa, and liver 
(Gilbert et al., 2006). For skin, cadaver or bovine skin is commonly decellularized to create an 
ECM scaffold (Zhong et al., 2010). The assumption for animal skin is that extracellular 
components are conserved among species, allowing the acellular graft to be tolerated by 
xenogeneic graft recipients. The goal of decellularization is to remove all of the cellular and 
nuclear components of the tissue to circumvent the foreign body response that plagues many of 
the synthetic materials and allogenic or xenogenic grafts used for therapeutic regeneration 
(Gilbert et al., 2006).  
2.6.2 Decellularization Process 
There are varieties of different decellularization techniques that can be used to isolate 
the extracellular matrix from the cellular components in tissues (Table 4). Each step of the 
process has the potential to impact the composition or structure of the desired ECM; therefore, 
depending on the desired biochemical composition and structure, biological activity, and 
mechanical behavior to be retained in the scaffold, techniques that minimize damage to these 
properties should be selected (Gilbert et al., 2006). The method proceeds by disrupting the cell 
membrane, separating the cellular components, and then removing the cellular debris. Physical, 
chemical, and enzymatic treatments are used to ensure that all cells are adequately exposed 
and removed from the scaffold (Gilbert et al., 2006). 
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Table 4: Various Decellularization Methods (Gilbert et al., 2006) 
Technique Mode of action Effects on ECM 
Chemical Agents   
Sodium dodecyl sulfate 
(SDS) – Ionic detergent 
Solubilize cell and nucleic 
membranes, can denature 
proteins 
Effectively removes nuclear 
remnants and cytoplasmic 
proteins from dense tissues, 
removes GAG and growth 
factors and damages collagen 
Hypertonic / Hypotonic 
Solutions 
Cell lysis by osmotic shock, 
disrupts DNA-protein 
interactions 
Effectively lyses cells 
Does not effectively remove 
cellular residues 
Triton X-100 (Non-ionic 
detergent) 
Disrupt DNA-protein 
interactions, disrupt lipid-lipid 
and lipid-protein interactions, 
and sometimes protein-protein 
interactions  
More effective cell removal on 
thin tissues, some disruption 
of ultrastructure and removal 
of GAG, less effective than 
SDS 
Biologic Agents   
Nucleases (enzyme) Catalyze the hydrolysis of 
ribonucleotide and 
deoxynucleotide chains 
Mixed results with efficacy 
dependent on tissue, dense 
tissues lost collagen but 
impact on mechanical 
strength was minimal 
Trypsin (enzyme) Cleaves peptide bonds on the 
C-side of Arg and Lys 
Prolonged exposure can 
disrupt ECM ultrastructure, 
removes ECM constituents 
(collagen, laminin, fibronectin, 
elastin, and GAG), slower 
removal of GAG compared to 
detergents 
Chelating Agents (EDTA) Bind metallic ions to disrupt 
cell adhesion to the ECM 
Ineffective when used alone 
Physical Agents   
Temperature (Freezing and 
thawing) 
Intracellular ice crystals 
disrupt cell membrane 
Can disrupt or fracture ECM 
Direct application of force Removal of tissue eliminates 
cells and force can burst 
remaining cells 
Can directly damage ECM 
Pressure Burst cells and aid in cellular 
removal 
Can disrupt ECM 
Electroporation (Pulsed 
electrical fields) 
Disrupt cell membranes Can disrupt ECM 
 
The purpose of physical decellularization treatments is to disrupt the cell membrane so 
that cellular components are released and washed away. Agitation, sonication, mechanical 
pressures, or freeze and thaw cycles can cause physical disruption. Physical treatments do not 
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remove all of the cellular components and must be combined with chemical treatments for 
complete decellularization. Enzymes, such as trypsin, and chemicals, including ionic solutions, 
detergents, and chaotropic agents, are used to disrupt the membranes and break the bonds 
between intracellular and extracellular components (Gilbert et al., 2006). It is extremely 
important that none of the chemicals remain in the tissue after treatment. A high concentration 
of chemical residues will cause the scaffold to be toxic to the host (Gilbert et al., 2006). 
Unfortunately, both physical and chemical treatments used to remove the cells have the 
potential for disrupting the 3D architecture of the scaffold (Gilbert et al., 2006). A variety of 
histological stains can be used to verify the preservation of tissue architecture as well as the 
removal of cellular components. Hematoxylin and Eosin (H&E) can be used to validate the 
removal of nuclear structures as well as observe the structure of the tissue. Masson’s Trichome, 
Movat’s Pentachrome, or Safrin O can be used to identify cytoplasmic and extracellular 
molecules remaining in the matrix. Picrosirius Red can be used to observe and subsequently 
verify the amount of collagen retained in the decellularized tissue. DNA can be identified using 
the fluorescent molecules DAPI or Hoechst, which have an affinity for double stranded DNA 
(Gilbert et al., 2006). 
Similarly, a variety of techniques are needed to quantify the retention of components in 
the matrix. This data can be achieved by using identification assays for GAGs, growth factors, 
adhesion proteins, elastin, and collagen. The integrity of the ECM structure can also be 
examined using mechanical testing (Gilbert et al., 2006). 
Typically, the best strategy is to use the mildest available decellularization approach first 
to minimize disruption of the extracellular matrix (Gilbert et al., 2006) These include hypotonic or 
hypertonic solutions. For the decellularization of fibroblasts for cell-derived ECM scaffolds, Lu et 
al. used freeze-thaw cycling and NH4OH aqueous solution treatment (Liu et al., 2007; Lu et al., 
2011). The free-thaw cycles create intracellular ice crystals that disrupt the cell membrane, and 
43 
 
the ammonium hydroxide solubilizes cytoplasmic components of the cell and disrupts nucleic 
acids (Gilbert et al., 2006). 
However, decellularizing tissue to derive ECM scaffold has limitations.  When allogenic 
or xenogenic tissue are used, there is the potential for host rejection or the transfer of 
pathogens from the host to the patient (Gilbert et al., 2006; Lu et al., 2011). 
2.6.3 Advantages of cultured cell-derived extracellular matrix scaffolds 
Cultured cells provide an alternative source of tissue for therapeutic scaffolds. These 
cell-derived tissues can be decellularized to isolate the extracellular matrix produced by the 
cells. Preparing ECM in this way provides numerous advantages over using decellularized 
human or animal skin. First, the three-dimensional architecture of the scaffold enhances the 
activity of the cells seeded on to it. Cukierman et al. showed that cell-derived 3D matrices were 
more effective than 2D substrates for fibroblast attachment, migration, proliferation, and 
characteristic in vivo morphology. Additionally, there are techniques available for screening 
cultured cells for pathogens and maintaining them in a pathogen-free condition. Cell-derived 
ECM scaffolds also provide the option of using the patient’s own autologous cells, which can be 
expanded in the laboratory for scaffold fabrication. Although the decellularization method should 
be sufficient to remove foreign material, these autologous cell-derived ECM scaffolds avoid any 
undesired host responses that can be induced by allogenic or xenogenic materials. In addition, 
the procedure for isolating patient cells is much less invasive than taking an autologous graft, 
and can be beneficial for patients with limited undamaged donor sites. Therapeutic ECM 
scaffolds are not limited to autologous cells; a variety of cell types including mesenchymal stem 
cells (MSC), chondrocytes, and fibroblasts have been explored for their ECM matrix effects on 
cell function and tissue regeneration (Lu et al., 2011). However, there are still limitations with 
cell-derived matrixes. Fabricating the scaffolds from cells takes more time than decellularizing 
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tissue.  Additionally, the decellularization and processing methods can affect the structure and 
mechanical strength of the scaffold (Gilbert et al., 2006). 
2.6.4 Strategies for enhancing extracellular matrix scaffolds  
Many techniques have been explored to enhance the wound regeneration capabilities of 
both synthetic and natural scaffolds. These techniques can be applied to tailor ECM scaffolds to 
enhance their therapeutic efficiency.  
2.6.4.1 Growing cell-derived scaffolds on 3D matrices 
One of the desired characteristics of a scaffold includes the formation of a 
physiologically and anatomically similar architecture to native skin. For cell-derived tissues, 
removable substrates can be used as a templates to encourage three-dimensional (3D) cell 
culture (Lu et al., 2011). The three-dimensional architecture has numerous advantages over a 
scaffold produced by two-dimensional growth on a flat surface. In the case of skin, three-
dimensional substrates affect the presentation of fibroblast focal adhesions, and subsequently 
keratinocyte attachment, proliferation, and differentiation. The limitation with two-dimensional 
growth of fibroblasts is the production of an artificial polarity that is not normally present, 
affecting the morphology and migration of the fibroblasts (Cukierman, Pankov, Stevens, & 
Yamada, 2001). Cukierman, et al. tested a variety of 2D and 3D matrices to determine which 
was the most effective at mediating cell adhesion, enhancing migration and proliferation rates, 
and achieving an accelerated rate of fibroblastic spindle-shaped morphology.  The substrates 
that were tested were cell-derived 3D matrices, tissue-derived 3D matrices, 3D collagen gels, 
and 2D ECM substrates of fibronectin, laminin, and collagen I.  After exploring their interaction 
with fibroblasts, cell-derived 3D matrices were the most effective at the abovementioned tasks. 
In these  three-dimensional cell-derived structures, α5 integrin, paxillin, and fibronectin triple co-
localize; this may be a more physiologically similar matrix adhesion, which accounts for the 
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enhanced cell interactions seen on the cell-derived 3D matrices as opposed to matrices derived 
from tissue, collagen, or 2D ECM substrates (Cukierman et al., 2001). 
2.6.4.2 Cell-specific ECM Production 
The most common cell types used for skin scaffold fabrication are skin cells themselves: 
the keratinocytes of the epidermal layer and the fibroblasts of the dermis. Using the cell type 
naturally found in the tissue of interest will provide the most natural three-dimensional structure, 
mechanical properties, and chemical cues to promote proper regeneration. Researchers have 
used fibroblasts to make cell-derived dermal substitutes as well as acellular scaffolds (Lu et al., 
2011; Tremblay, Hudon, Berthod, Germain, & Auger, 2005). Dermal fibroblasts are not only 
easily isolated from neonatal foreskin, but they also maintain steady collagen synthesis and 
growth rate until passage 14 (Ahlfors & Billiar, 2007; Lu et al., 2011).  
One of the advantages of using cell-derived tissues is that a variety of cells can be used 
to obtain the optimal scaffold. ECM production can be mixed by the in vitro culture of different 
cell types to produce the desired ECM proteins (Lu et al., 2011).  
2.6.4.3 Pre-vascular Networks 
Multiple strategies have been used to induce angiogenesis in scaffolds. Delayed 
vascularization is one of the leading problems with skin substitutes that are currently used for 
full-thickness wounds (Tremblay et al., 2005).  A lack of vasculature leads to poor graft take and 
ultimately graft necrosis. In fact, when Krejci et al. implanted decellularized dermis with 
keratinocytes into mice, they found that it took up to 15 days for neovascularization to occur 
(Krejci, Cuono, Langdon, & McGuire, 1991). This process is limited by the thickness of the graft, 
and relies on passive diffusion of nutrients from the wound bed to the graft to be sufficient for 
graft survival. To solve this problem, researchers have been exploring methods to create a 
prevascular network in scaffolds that can promote blood supply through faster connection to the 
host’s vascular system. This fact makes decellularized tissue an appealing therapy, because of 
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the pre-existing capillary network. It also brings forth the possibility of encouraging the growth of 
a vascular network during the culture of cell-derived tissues. Tremblay et al. proved that this 
method is possible. The researchers seeded a 1:1 ratio of human fibroblasts and human 
umbilical vein endothelial cells onto a collagen/glycosaminoglycan/chitosan biopolymer scaffold. 
After 5 days, keratinocytes were added to the culture. When these living cellular grafts were 
implanted into mice wounds, Tremblay et al. showed that complete inosculation of human 
vessels from the graft to mice vessels in the wound bed occurred within 2 to 5 days. Their study 
highlights the significance of growing an in vitro capillary network prior to scaffold implantation. 
Because cell-derived ECM scaffolds are cultured in vitro, methods for the growth of a 
vascular network should be taken into consideration. Success would make the cell-derived ECM 
just as capable of rapid revascularization as decellularized cadaver skin. The addition of 
angiogenic growth factors, such as VEGF, may not lead to proficient vascularization, since the 
thickness of the dermal component will deter growth factor diffusivity (Tremblay et al., 2005). To 
date, no cell-derived ECM scaffold has been created with a prevascular network for improved 
angiogenesis. 
2.6.4.4 Antimicrobial Peptides 
Antimicrobial peptides (AMPs) are an emerging source for treatment of infections 
(Hancock & Sahl, 2006). AMPs are naturally occurring small molecular weight proteins, which 
possess a broad spectrum of antimicrobial activity against bacteria, fungi, and viruses 
(Izadpanah & Gallo, 2005). They are usually between 10 and 50 amino acids long, and overall 
cationic. Their amphiphilic structures allow them to target a broad range of microbes by 
electrostatically attaching to their surfaces (Hancock & Sahl, 2006).  
Mammals produce a variety of AMPs which mostly fall into the categories of defensins or 
cathelicidins (Yang, Biragyn, Hoover, Lubkowski, & Oppenheim, 2004). These AMPs are most 
often expressed by epithelial cells as host-defense molecules. The human cathelicidin peptide, 
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LL-37, encoded by hCAP-18 has drawn considerable interests because of its expression by 
epidermal keratinocytes. In particular, the expression of LL-37 is upregulated in keratinocytes 
after a skin injury (Heilborn et al., 2003).  
All cathelicidins contain an N-terminal signal peptide (pre-region), a conserved cathelin-
like domain (proregion), and a microbiocidal peptide sequence along their C-terminus. “LL-37” 
refers to the microbiocidal domain of the human cathelicidin. After the expression and secretion 
of cathelicidin, proteinase-3 acts to cleave the proregion, leaving behind the cationic alpha 
helical LL-37. The broad range of bacteriocidal activities of LL-37 are summarized in Table 5. 
Cathelicidin is effective against a variety of both Gram-positive and Gram-negative bacteria, as 
well as Candida species of yeast.  
Table 5: Range of Microbiocidal Activity of LL-37 (adapted from De Smet & Contreras, 2005) 
Peptide Organism Gram-Stain MIC (μg/ml) 
LL-37 Listeria monocytogenes Positive 1.5 
 Staphylococcus epidermis Positive 7.6 
 Staphylococcus aureus Positive 3.6 
 MRSA Positive 3.4 
 Bacillus subtilis Positive 2.7 
 VREF Positive 3.5 
 Escherichia coli Negative 0.1 
 Salmonella typhimurium Negative 0.4 
 Pseudomonas aeruginosa Negative 4.7 
 Burkholderia cepacia Negative >79.1 
 Stenotrophomonas maltophilia Negative 1.9 
 Proteus mirabilis Negative 5.7 
 Proteus vulgaris Negative 2.5 
 Candida albicans Yeast >250 
 
In addition to its antimicrobial properties, it has been determined that LL-37 also 
promotes wound healing (Carretero et al., 2007). It acts as a chemoattractant for immune cells 
and has shown to directly induce chemokines on macrophage receptors. It also increases the 
production of several cytokines, including IL-6, IL-8, and TNF-α  (Carretero et al., 2007). Several 
studies have determined that LL-37 also contributes to neovascularization, as well as cellular 
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growth (Bucki, Leszczynska, & Namiot, 2010). These unique properties show that cathelicidin 
has the potential to be used as a powerful tool in dermal regeneration. 
The previous literature review was conducted to gain insight on dermal wound healing and 
the advantages and limitations of current therapies. Understanding the components of the ECM 
and the wound healing response is critical to fabricating a successful dermal template for tissue 
regeneration. The literature review will serve as the foundation for the design and fabrication an 
extracellular matrix scaffold that surpasses current limitations in dermal wound healing skin 
substitutes.  
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3 Project Definition and Strategy 
 In the United States alone, approximately 6.5 million patients suffer from chronic 
wounds, and it is estimated that more than $25 billion is spent annually for the treatment of 
chronic wounds in the US (Sen et al., 2009). There are currently numerous dermal substitutes 
commercially developed for healing full-thickness wounds; however, these products are limited 
by donor supply, potential for transmission of disease, and are not cost-effective.  There is 
currently a need for an ideal scaffold which is durable, cost effective, biocompatible, while also 
promoting regeneration, providing a barrier against water loss and microbes, promoting a new 
vascular network, and having the mechanical integrity and structural composition of the native 
dermis. The ultimate goal of our project is to meet these needs by developing a novel scaffold 
for dermal regeneration. 
3.1 Initial Client Statement 
At the start of this project, the client presented the design team with the following initial 
client statement: 
“Design and fabricate a series [of] protocols and devices to produce a novel cell-derived 
matrix scaffold with structural, mechanical and biochemical properties that emulates the 
properties of a highly functional dermal regeneration scaffold.” 
The goals of the project are to (1) design and create an experimental approach for fabricating a 
cell-derived matrix (CDM) with mechanical properties that mimic those of the natural dermis; (2) 
design the CDM to include angiogenic and antimicrobial properties that promote dermal 
regeneration with the scaffold; and (3) design a series of in vitro assays for analyzing the 
mechanical, angiogenic, and antimicrobial properties of the novel CDM scaffold.  
3.2 Initial Approach 
The design team first sought to gain a better understanding of the client statement. One 
of the first approaches the team used was to gather a large amount of background information. 
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The team used multiple sources to gain knowledge about extracellular matrix scaffolds, its 
importance to the tissue engineering field, its current use, and existing limitations with its design 
for dermal wound therapies. To achieve this goal, the team performed an extensive literature 
review by searching through electronic search engines such as Science Direct, Pubmed, and 
Google Scholar. These databases were used by searching keywords such as “extracellular 
matrix,” “dermal,” “scaffold,” “design,” “cell-derived,” “decellularized,” “regeneration,” “wound 
healing,” or any combination of those terms. The team also used the library catalogue to explore 
books related to scaffolds for tissue engineering, as well as two initial meetings with the client to 
gain an in-depth understanding of the goals of the design project. 
3.3 Attributes List 
After conducting the scientific literature review and initial meetings with the client, the 
design team approached the client’s problem statement by brainstorming the objectives of the 
design project. According to Dym and Little, an objective is “something toward which effort is 
directed” or “an aim or end of action.” In other words, objectives can be thought of as goals for 
the behavior or features that the client or user desires for the device. With this in mind, the 
design team formulated an initial attributes list for the bioactive scaffold described by the client 
statement. 
List 1: Biological Scaffold Attributes List 
 Non-viable scaffold 
 Angiogenic 
 Antimicrobial 
 Structurally similar to native dermis 
o Porosity  
o Density 
o Thickness 
o Degradation rate 
 Mechanical similar to native dermis 
o Tensile strength 
o Stiffness 
o Shear resistance 
 Preservable  
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 Can be stored for extended time periods (up to years) 
 Can be handled without fracture 
 Simple in-vivo attachment/easy implantation 
 No rejection 
 Improved healing quality 
 Quick wound healing 
 Undergoes constructive/uniform remodeling 
 Decreases formation of granulation tissue and scar formation 
 Induces cellular migration 
 Minimal preparation from shelf to body 
 Non toxic 
 Incorporation into native tissue 
 Tailorable (shape, matrix components) to various wounds 
 Only requires one application 
 Human cell derived 
 Low cost production 
 Easy manufacturability 
 
3.3.1 Pruned Objectives  
The list was brought to the client for feedback and discussion. The client and design 
team eliminated the attributes which were constraints or functions and decided on five major 
goals for the characteristics of the ECM scaffold. These higher level objectives revert back to 
the original client statement, while the sub-objectives better define the major goals. 
List 2: Biological Scaffold Attributes Indented Objectives List 
0. A novel cell-derived matrix scaffold for wound healing  
1. Ease of production 
1.1 Can be manufactured in large quantities 
1.2 Minimize production costs 
1.2.1 Minimal use of materials for scaffold production 
1.2.2 Minimal time required to complete all steps for fabricating matrix 
scaffold 
2. Structurally and mechanically similar to native dermal tissue 
2.1 Permeable to cells 
2.2 Thickness of dermis 
2.3 Biomolecules should be able to diffuse at natural rate  
2.4 Tensile strength 
2.5 Stiffness 
2.6 Shear resistant 
2.7 Suture pullout strength 
2.8 Adhesion to wound bed 
3. Clinical Ease of Use  
3.1 Ease of implantation 
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3.1.1 Minimal preparation from shelf to body 
3.1.2 Can be handled without tearing 
3.1.3 Simple in-vivo attachment to wound bed 
3.2 Minimal number of applications 
3.3 Applicable to various wound sizes and shapes 
3.4 Can be stored for extended time periods (up to years) 
4. Ease of Laboratory Processing 
4.1 Minimize the difficulty of process steps 
4.2 Minimize the equipment and technology required 
4.3 Minimize the production area (laboratory/bench space) 
4.4 Minimize production costs 
4.4.1 Minimal use of laboratory consumables for cell culture 
4.4.2 Minimal time required to complete all steps for fabricating matrix 
scaffold 
4.5 Repeatable process to minimize variation in results 
5. Bioactive 
5.1 Promotes angiogenesis 
5.2 Actively inhibits microbial infections 
5.3 Improved wound healing 
5.3.1 Incorporation and attachment into native tissue 
5.3.2 Permeable to migrating cells 
5.3.3 Heals with uniform surface topography  
5.3.4 Uniform rate of wound healing 
5.3.5 Decreases formation of granulation tissue and scar formation 
5.3.6 Similar degradation rate to rate of wound healing 
 
From the indented objectives list, five major objectives were identified for the desired 
behavior of the client’s proposed scaffold design. These objectives include ease of production, 
structurally and mechanically similar to native dermal tissue, clinical ease of use, ease of 
laboratory processing, and bioactive. The hierarchy of the objectives can be visualized in the 
following objectives tree (see Figure 4). 
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Figure 4: The Objectives Tree for the Design of a Novel ECM Ccaffold 
It was also noted that one of the client’s goals was to create a series of in vitro assays 
for analyzing the device. After discussion, brainstorming, and pruning, the design team created 
an indented objectives list for the goals pertaining to the in vitro assays. The hierarchy of these 
objectives can be visualized in the following objectives tree (see Figure 5). 
List 3: In Vitro Assays Indented Objectives List 
0. In vitro assays to analyze the mechanical, angiogenic and antimicrobial 
properties of the ECM scaffold 
1. Should be low in cost 
2. Should require attainable supplies 
3. Should be feasible 
3.1 Should be achievable in short periods of time 
3.2 Should not require extensive training or expertise 
4. Should be accurate 
5. Should be precise  
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Figure 5: The Objectives Tree for the Design of in vitro Assays to Analyze the Properties of the Novel ECM 
Scaffold 
3.3.2 Ranking the Objectives 
To better understand the client’s and the design team’s expectations for the scaffold, the 
two stakeholders filled out separate pairwise comparison charts (PCCs) to numerically rank the 
objectives based on importance. PCCs were completed for the five top-tier objectives of the 
bioactive scaffold characteristics, the sub-objectives for each of those top-tier objectives, and 
the objectives for the in vitro assays.  
Bioactive (see Table 6) includes the angiogenic and antimicrobial properties that are 
outlined in the client goals, as well as improved wound healing. Angiogenic properties should 
speed up the rate at which the scaffold is vascularized once implanted into the wound bed. 
Antimicrobial properties should protect the wound against infection. Improved wound healing 
includes incorporation and attachment into native tissue the following characteristics which 
promote successful dermal regeneration: permeable to migrating cells, heals with uniform 
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surface topography, uniform rate of wound healing, decreases formation of granulation tissue 
and scar formation, and similar degradation rate to rate of wound healing. 
Table 6: Overall Scaffold Characteristics PCC Results 
Overall Scaffold Characteristics 
 Design Team Client 
Bioactive 3 3 
Structurally and 
mechanically similar to 
native dermis 
4 4 
Clinical ease of use 2 1 
Ease of lab processing 1 2 
Ease of production 0 0 
 
Ease of production (see Table 7) includes minimized production costs and 
manufacturability in large quantities. Costs that should be minimized include the use of 
materials to produce the scaffold as well as the time required to complete all steps for 
fabricating the matrix scaffold. The scaffold should have the ability of being manufactured in 
large amounts for successful sales and distribution. 
Table 7: Ease of Production PCC Results 
Ease of Production 
 Design Team Client 
Minimize production costs 1 1 
Can be manufactured in 
large quantities 
0 0 
 
The scaffold should be structurally and mechanically similar to the native dermis such 
that the tensile strength, shear resistance, stiffness, thickness, diffusivity of biomolecules, and 
permeability for infiltrating cells are the same or close to the properties of native dermis (see 
Table 8). The scaffold should also have reliable suture pull-out strength for successful clinical 
use, as well as proper adhesion to the wound bed. 
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Table 8: Structurally and Mechanically Similar to Native Dermal Tissue PCC Results 
Structurally and Mechanically Similar to Native Dermal 
Tissue 
 Design Team Client 
Tensile Strength 6.5 6.5 
Shear resistance 6.5 4.0 
Adhesion to wound bed 5 0.5 
Permeability 4 3.5 
Diffusivity 3 3.5 
Stiffness 2 6.5 
Thickness 1 3.0 
Suture pull-out strength 0 0.5 
 
The scaffold should be able to be used for clinical applications such that it is easy to 
implant, it does not require a number of applications or surgeries, and it can be applied to 
various wound sizes and shapes (see Table 9). The scaffold should be able to be stored for 
extended periods of time so that it can be used immediately. 
Table 9: Clinical Ease of Use PCC Results 
Clinical Ease of Use 
 Design Team Client 
Ease of implantation 3 2.5 
Can be stored for extended 
time periods   
2 0.0 
Minimal number of 
applications 
1 1.0 
Applicable to various 
wound sizes and shapes 
0 2.5 
 
The scaffold should be able to be fabricated easily in the laboratory (see Table 10). This 
includes minimizing the difficulty of fabrication steps, minimizing the equipment and technology 
required for production, minimizing the area over which production will occur, and minimizing 
the variation in the resulting scaffold by creating a repeatable process. Laboratory production 
costs should also be minimized such that fabrication requires the minimal use of laboratory 
consumables for cell culture and minimal time required to complete the fabrication steps. 
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Table 10: Ease of Laboratory Processing PCC Results 
Ease of Laboratory Processing 
 Design Team Client 
Repeatable to minimize 
variation 
4 4.0 
Minimize equipment and 
technology required 
3 1.0 
Minimize difficulty of steps 2 0.0 
Minimize production costs 1 3.0 
Minimize production area  0 2.0 
 
The scaffold should be bioactive (see Table 11) such that it promotes angiogenesis, it 
actively inhibits microbial infections, and it enhances the wound healing response. To enhance 
wound healing, the scaffold should incorporate and attach into the native tissue, it should be 
permeable to migrating cells, it should heal with uniform surface topography at a uniform rate, it 
should degrade with a degradation rate comparable to the rate of regeneration, and it should 
decrease the formation of granulation tissue and scar formation. 
Table 11: Bioactive PCC Results 
Bioactive 
 Design Team Client 
Inhibits microbial infections 2 1 
Improved wound healing 1 0 
Promotes angiogenesis 0 2 
 
The in vitro assays (see Table 12) used to analyze the scaffold should be precise, 
accurate, and low in cost. The assays should be feasible such that they do not require long 
periods of time or extensive training. The supplies required for the assays should be easily 
obtainable. 
Table 12: In Vitro Assays Characteristics PCC Results 
In Vitro Assays Characteristics 
 Design Team Client 
Feasible 3 3.5 
Precise 3 3.5 
Accurate 3 1.0 
Easily Attainable Supplies 1 0.0 
Low in cost  0 2.0 
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3.3.3 Finalizing the Priority of Objectives 
After discussing the ranked objectives with the client, compromises were made to decide 
the final ranking of the objectives. Both the client and the design team discussed their rationale 
behind their ranking, which led to an in-depth discussion of the importance of each objective 
relative to the client statement.  
The client and the design team agreed that a successful scaffold must have the proper 
mechanical and structural properties to be handled properly; this is the most important objective 
of the project. Bioactive was the next ranked objective, since bioactivity lends itself to the overall 
purpose of the scaffold, which is a reliable wound healing response. Within the bioactive 
objective, however, the design team felt that antimicrobial was the most important component, 
whereas the clients felt that angiogenic was the most important component. After discussion, 
both parties agreed that antimicrobial was more significant because proper wound healing 
cannot occur in infected tissues. In addition, the design team felt that the client was correct 
when proposing that ease of production and clinical ease of use were beyond the scope of this 
design project. The design team gave these two objectives the lowest ranking. 
The results of the finalized priority of objectives that have been approved by the design 
team and the clients (see Table 13).  
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Table 13: Summary of Overall Prioritized Objectives 
 
 
3.4 Constraints 
There are several constraints that limit the design space and that the team must 
consider through the design of the product. A brief list is presented below. These constraints not 
only minimize the design space, but correspond to the success of the final product. If the binary 
constraints of cell-derived, acellular, biodegradable, and biocompatible are not followed, the 
design will fail. 
List 4: Constraints 
 Budget ($368 USD) 
 Time (21 weeks) 
 Must be a cell-derived tissue 
 Must be acellular 
 Must be biodegradable 
 Must be biocompatible 
 Assays must not harm scaffold 
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From a logistics point of view, the design team is limited by a budget of $156 per team 
member, minus $100 for usage fees, leaving a total of $368 total for all design, fabrication, and 
testing needs. The team is also restricted to a timeline of 21 weeks, from A Term beginning in 
August 2011 through the end of C Term in the first week of March 2012. The scaffold design is 
limited by how it will respond in vivo. It must be biodegradable so that the scaffold material 
degrades as new matrix and tissue is established, and the release by-products must not be 
toxic to the surround cells or remaining tissue. It must be biocompatible such that a chronic 
inflammatory or immune response is not provoked, cell adhesion and growth is not reduced, 
and toxic components are not included. For the scaffold source, the initial tissue must be cell-
derived, but the final scaffold must be acellular and free of cells. A final constraint corresponds 
to the validation of the final product; the in vitro assays for product verification must not injure 
the scaffold such that data is compromised. 
3.5 Revised Client Statement 
In order to clarify the initial client statement, the design team reviewed current literature, 
conducted a series of client interviews, and developed a list of ranked objectives. Based on the 
analysis of design requirements and considering the priorities set by the client, a revised client 
statement was developed: 
“Design and fabricate a highly functional and bioactive cell-derived matrix scaffold with 
antimicrobial and angiogenic properties as an enhanced dermal regenerative therapy for 
full-thickness wounds. Design the scaffold with structural, mechanical, and biochemical 
properties that emulate those of the native dermis; and devise protocols and devices for 
scaffold fabrication, as well as a series of in vitro assays to analyze and verify the 
scaffold’s properties.” 
The revised client statement represents a more specific scope of the project.  
3.6 Project Approach 
Figure 6 illustrates the basic approach to the project. The black boxes represent the 
sequential milestones to create the final product. Functions will be developed for each of these 
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stages. The triangles represent the processes required to achieve each milestone. These 
processes are tools that are related to the objectives of the project and can be used to achieve 
the goals of the project, as shown below. Means will be established for each process in order to 
determine the most appropriate methods to achieve the corresponding milestones.  
 
 
Genetic engineering can be used to accomplish goals 1 and 2. This technique can be 
potentially used to modify cells for improving mechanical and structural properties, inducing 
antimicrobial responses, or improving angiogenic properties. Cell culture can also be used to 
accomplish the first goal, such that cell type of choice will produce an ECM scaffold with the 
desired mechanical and structural properties. Using decellularization as a method to isolate the 
ECM will achieve the overall production goal of an acellular scaffold. Finally, a proper set of in 
vitro assays will provide validation of the design and its achievement of meeting the prioritized 
objectives. In Appendix A, a Gantt chart shows the sequence of steps for this approach for the 
following 7 week design period (October-December). 
  
Figure 6: Project Approach 
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4 Alternative Designs 
4.1 Generation of Alternative Designs 
After ranking the design objectives and developing the client statement, the design team 
began to organize a list of functions for the scaffold that would satisfy the desired objectives. 
The team began by drawing from the literature review to brainstorm an initial list of functions 
and design specifications. Brainstorming with the client was used to inspire means and 
approaches to the conception of the scaffold. Afterwards, a preliminary functions and means list 
was generated and eventually pruned to better fit the client objectives. 
4.1.1 Initial Functions List 
The design team created an initial functions list for the actions of the scaffold that meet 
the designed design objectives. To stay within the scope of the deliverables for the client, 
functions were identified that complement the two highest-ranked objectives: structurally and 
mechanically similar to native dermal tissue and bioactive. 
List 5: Initial Functions List 
1. Resists comparable mechanical forces to which the native dermis is subjected 
2. Actively inhibits microbial infection 
3. Actively establishes new blood vessel formation 
4. Discourages foreign body response 
5. Actively promotes cellular migration 
In order for the scaffold to be structurally and mechanically similar to native dermis, the 
design team felt that the scaffold must be as robust as native dermis by resisting comparable 
mechanical forces to which the dermis is subjected. To address the bioactive objective and sub-
objectives, four more functions were conceptualized. To resist infection, the scaffold should 
actively inhibit microbial growth. To promote angiogenesis, the scaffold should actively establish 
new blood vessel formation when it implanted in the patient. This will also assist in enhancing 
the wound healing response. To improve wound healing, the scaffold must not elicit a foreign 
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body response as well as actively promote fibroblast and keratinocyte migration for enhanced 
healing. 
4.1.2 Initial Specifications/Requirements 
Drawing from the literature review and laboratory experience, the design team created a 
list of prescriptive and performance requirements for the acellular scaffold. Prescriptive 
requirements describe the characteristics of the scaffold. Performance requirements dictate the 
specific actions of the scaffold.   
The design team brainstormed prescriptive requirements to conceptualize what the 
scaffold will look like. Since the normal thickness of the dermis is 1mm, the design team decided 
that the acellular scaffold should attain a thickness of 1mm as well. Ultimately, the design team 
imaged the scaffold as being any length and width so that it could be applied to all sizes of skin 
injuries. Looking ahead to in vitro testing of the scaffold, the design team came up with two 
possible diameters. If the final design includes using a cyclic biaxial stretch machine to cyclically 
condition the tissue, the tissue will need a diameter of 35 mm (Balestrini & Billiar, 2006). If the 
scaffold is subjected to biaxial inflation testing to measure mechanical properties, the scaffold 
must have a diameter of at least 1 cm (Billiar, Throm, & Frey, 2005). The design team felt that 
the scaffold should have porosity similar to that of native dermis. Therefore, pore size should be 
between 20-125 μm to promote fibroblast and endothelial cell in-growth (Yannas, Lee, Orgill, 
Skrabut, & Murphy, 1989). The composition of the scaffold should also mimic that of native 
dermis. The scaffold should have at least 70% of its protein content as collagen type I 
(Mansbridge et al., 1999). 
Prescriptive requirements for the scaffold aim to surpass the properties of current dermal 
scaffolds. The tensile strength of the scaffold should be within 5-30 MPa (Edwards & Marks, 
1995) and the shear strength should be within 435-6620 Pa (Holt et al., 2008). The scaffold 
should encourage typical speeds of cellular migration, including fibroblasts at 0.5 μm/min and 
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endothelial cells at 300 μm/min (Saltzman, 2004). Additionally, the scaffold should be able to kill 
99.9% (minimum bactericidal concentration) of streptococcus aureus, enteroccus faecalis, and 
pseudomonas aeruginosa to effectively inhibit microbial infection (Dowling, 2012). 
4.1.3 Development of Conceptual Designs 
The team conducted a brainstorming session with the client to produce 
conceptual designs for the scaffold (see Figure 7 and Figure 8). One person started a 
design, and others added to the idea as they saw fit. This resulted in the accumulation 
of a number of conceptual designs to address the initial functions list. The following 
figures show the progression of conceptual designs during the brainstorming session, 
including 15 different designs that are described below. The conceptual designs are 
organized with pictures and descriptions in Appendix D: Conceptual Designs.  
 
Figure 7: Brainstorming Session (a) 
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Figure 8: Brainstorming Session (b) 
Design number 1 shows AMP-producing fibroblasts. Genetically modified human dermal 
fibroblasts produce antimicrobial peptides that bind to the extracellular matrix. The tissue is then 
decellularized, resulting in a cell-derived matrix (CDM) with bound anti-microbial peptides 
(AMPs). 
Design number 2 shows the exogenous addition of AMPs to the CDM. Human dermal 
fibroblasts (HDFs) produce a CDM. After decellularization, growth factors and AMPs are cross-
linked to the matrix. Additionally, the fibroblasts can be cultured in chemically defined media to 
increase matrix production. 
Design number 3 shows a CDM with enhanced keratinocyte binding sites. Genetically 
modified fibroblasts that produce AMPs and keratinocytes are co-cultured until they form a 
tissue. The tissue is then decellularized. Keratinocytes may deposit proteins or encourage the 
formation of binding sites that are conducive to their attachment. 
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Design number 4 shows a prevascular network in the CDM. The HDFs and endothelial 
cells are co-cultured until they form a tissue. The tissue is then decellularized. The addition of 
endothelial cells may form tubular constructs (the prevascular network) that will enhance 
angiogenesis during implantation. 
Design number 5 shows the addition of porogens. Microparticles are added to the cells, 
which are cultured until they form a tissue. The tissue is decellularized, and the microparticles 
are removed. This may retain a pore size in the matrix that is conducive to cellular migration. 
Design number 6 shows the tissue being grown as a cellular tube in a bioreactor. The 
cells are grown in a sheet around a silicone solid mandrel in a bioreactor. The sheet is cut to 
flatten out, and then the tissue is decellularized. The bioreactor may increase matrix production 
and strength. Cell tubes for bioreactor conditioning can be constructed by fusing rings, rolling 
tissue sheets, or growing cells directly on the mandrel. 
Design number 7 shows a two-layer cell tube. The HDFs are cultured around a tubular 
bioreactor to benefit from mechanical conditioning. The tissue is cut, flattened, and continued to 
culture as a sheet to encourage planar formation. Keratinocytes are added at this point and 
allowed to culture. The tissue is then decellularized. 
 Design number 8 shows cells being cultured around a porous mandrel tube in static 
conditions. The tissue is then cut, flattened, and decellularized to produce the CDM. 
 Design number 9 shows cells being cultured around a luminar flow tube in dynamic 
conditions. The tissue is then cut, flattened, and decellularized to produce the CDM. 
 Design number 10 shows the 3D culture of the tissue on a micro-patterned substrate. 
The cells are grown on a micro-patterned PDMS substrate. The substrate may influence matrix 
alignment that is conducive to fibroblast re-population.  
 Design number 11 shows the 3D culture of the tissue in a hydrogel. The hydrogel is 
removed after culture, and the tissue is decellularized. 
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 Design number 12 shows a growth factor soak. The tissue is first decellularized, and 
then submerged in fibronectin or another desired growth factor.  
 Design number 13 shows crosslinking. The tissue is first decellularized. Then the CDM 
is crosslinking using chemical or physical methods 
 Design number 14 also shows crosslinking, but before decellularization. A chemical or 
enzymatic crosslinking agent is added to the tissue to crosslink the ECM. The tissue is then 
decellularized. Crosslinking the tissue beforehand may allow for the use of harsher methods of 
decellularization, such as physical methods, that might greatly disrupt the matrix. 
 Design number 15 shows cells grown on a micro-patterned silicone solid mandrel in a 
bioreactor. After the tissue forms, the sheet is cut, flattened, and then decellularized. 
 Brainstorming conceptual designs in the manner opened the design space for the team, 
and allowed the team to delve into creative solutions. These designs initiated the discussion on 
realistic functions and means for the final scaffold design. 
4.1.4 Preliminary Functions and Means 
The brainstorming session with the client lead to the development of an initial functions 
and means list. The preliminary list helped the team pair the means developed from the 
brainstorming session with each of the functions.  
List 6: Preliminary Functions and Means  
1. Resists comparable mechanical forces to which the native dermis is subjected 
1.1 Structurally mimic the dermis 
1.1.1 Modify level of crosslinking fibers using chemical agents 
1.1.2 Modify level of crosslinking fibers using physical agents 
1.1.3 Genetically modify cells to produce more of a certain matrix 
component 
1.1.4 Vary pore size 
1.1.4.1 Add polymer microparticles 
1.1.4.2 Add acrylic nanoparticles 
1.1.4.3 Add salt 
1.1.4.4 Use decellularization methods that do not affect the 
structure 
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1.1.5 Vary cell type to vary ECM composition (strength contributing 
fibers) 
1.2 Mechanically stimulate cell in bioreactor 
1.2.1 Tensile forces 
1.2.2 Shear forces 
1.2.3 Compressive forces 
1.2.4 Cyclic forces (fatigue) 
1.3 Vary components in cell culture media 
1.3.1 Ascorbic acid 
1.3.2 Protease inhibitors that prevent collagen breakdown 
1.3.3 Growth factors 
2. Actively inhibits microbial infection 
2.1 Antimicrobial peptides 
2.1.1 Genetically modified cells produce AMP in ECM 
2.1.2 Exogenously add AMPs to ECM 
2.1.3 Exogenously add inducer of AMP 
2.2  Antibiotic 
2.2.1 Conjugate drug to ECM 
2.3 Metals (silver, copper, zinc) 
2.3.1 Exogenously add metallic beads 
2.3.2 Exogenously add Beta-glucan silver-silver chloride nanospheres 
2.4 Chemicals 
2.4.1 Exogenously add terpenes 
3. Actively establishes new blood vessel formation 
3.1 Angiogenic promoting proteins 
3.1.1 Genetically modified cells to produce angiogenic protein 
3.1.2 Exogenous addition of angiogenic protein 
3.1.3 Induce cellular production of angiogenic protein 
3.1.3.1 Mechanical condition 
3.1.3.2 Hypoxic culture 
3.2 Prevascular network 
3.2.1 Endothelial cells during culture of ECM 
3.2.2 Grown in an animal model 
4. Discourages foreign body response 
4.1 Decellularization of the tissue 
4.2 Exogenously add immunosuppressant 
4.3 Complete removal of substrate material 
4.4 Complete removal of decellularization chemicals (if applicable) 
5. Actively promotes cellular migration 
5.1 Presentation of binding domains 
5.1.1 Over-express fibronectin 
5.1.2 Over-express RGD peptides 
5.2 Topography that promotes cell migration 
5.2.1 Modify internal structure by altering pore size 
5.2.1.1 Vary cell type to vary ECM composition 
5.2.1.2 Crosslinking of fibers 
5.2.1.3 Decellularization method that does not disrupt structure 
5.2.1.4 Add microparticles 
5.2.2 Modify surface topography 
5.2.2.1 Substrate material 
5.2.2.1.1 Hydrogel 
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5.2.2.1.2 PDMS 
5.2.2.2 Substrate topography 
5.2.2.2.1 Nanogrooves 
5.3 Genetically modify cells to produce chemo-attractants 
5.4 Vary cell culture conditions 
5.4.1 Addition of growth factors 
5.4.2 Physical stimulation to produce specific factors 
 
The first function is “resists comparable mechanical forces to which the native dermis is 
subjected” (see List 6). From our brainstorming discussion, the design team grouped together 
means into three groups to accomplish this function. The first idea is that the scaffold will have 
similar mechanical properties to the dermis if it is also structurally similar. To do this the design 
team came up with five means, including modifying the level of crosslinking fibers using 
chemical or physical agents, genetically modifying the cells to produce more of a certain matrix 
component, varying the pore size of the scaffold by the addition of porogens, such as polymer 
microparticles, acrylic nanoparticles, or salt, or varying the cell type to vary the composition of 
the deposited ECM. The porogens would be added during culture so that the cells would deposit 
ECM around them. The design team also noted that a decellularization method should be 
chosen that does not damage the structure of the matrix. Our second method for the scaffold to 
obtain comparable mechanical strength to dermis is to mechanically stimulate the cells in a 
bioreactor. The bioreactor can exert one of the following forces: tensile, shear, compressive, or 
cyclic. The third method is to vary components in the cell culture medium. This includes adding 
ascorbic acid, adding protease inhibitors that prevent collagen breakdown, or adding growth 
factors that increase matrix production. 
The second function is “actively inhibits microbial infection.” We identified four different 
methods for addressing this function, including antimicrobial peptides, antibiotics, metals, and 
chemicals. Means for adding antimicrobial peptides (AMPs) to the CDM scaffold include 
genetically modifying the cells to produce AMPs, exogenously adding the AMPs to the ECM, or 
exogenously adding an inducer that will catalyze cell production of the AMP. The team also 
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considered adding antibiotics to the scaffold to make it resist microbial infection. To do this, the 
team would conjugate the drug to the ECM. A third method is to add metals, such as silver, 
copper, and zinc, to the scaffold that have been shown to inhibit microbial infection. Metals 
could be added exogenously as beads, or beta-glucan silver-silver chloride nanospheres could 
be exogenously added to the scaffold. The last mean was to exogenously add a chemical, such 
as terpenes, to the scaffold. 
The third function is “actively establishes new blood vessel formation.” One method is to 
present angiogenic promoting proteins, such as vascular endothelial growth factor (VEGF), in 
the scaffold so that the scaffold enhances angiogenesis once implanted. Means to add these 
proteins include genetically modifying cells to produce and conjugate the protein to the matrix, 
exogenously adding the angiogenic protein to the scaffold, or inducing cellular production of the 
angiogenic protein, such as through mechanical or hypoxic conditioning. Another method is to 
create a vascular network in the tissue before decellularization, so that the resulting tubular 
constructs will enhance endothelial in-growth once implanted. Means to do this include using 
endothelial cells during the culture of the ECM, as well as growing the tissue in an animal 
model.  
The fourth function is “discourages foreign body response.” One mean to address this 
function is decellularization of the tissue. This will rid the scaffold of any genetic material that 
can potentially cause an immune response or host rejection. Another mean is to exogenously 
add an immunosuppressant to the scaffold. The team also noted that it will be necessary to 
completely remove any substrate material from the scaffold, such as if the tissue is grown in a 
hydrogel, as well as any of the chemicals that are used during the decellularization method. 
The fifth function is “actively promotes cellular migration.” One method is to ensure the 
presentation of binding domains to assist or enhance cellular migration into the scaffold. To do 
this, adhesion proteins or binding domains, such as fibronectin or RGD peptides, could be over-
expressed in the scaffold. Another method is to enhance the topography of the scaffold to 
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promote cell migration. One approach is to modify the internal structure by altering pore size 
that is conducive to cellular migration.  As mentioned before, pore size can be retained in the 
matrix by adding porogens, such as gelatin microspheres, during tissue culture. Pore size can 
also be altered by the type of cell used to form the tissue, by the structure disturbance caused 
by the decellularization method, or by crosslinking the fibers. Another approach is to modify the 
surface topography of the scaffold. This can be done by altering substrate material, such as 
hydrogels or PDMS, as well as the topography of these substrates, such as the addition of 
micropatterns (Bush, 2009). A third method to promote cellular migration is to genetically modify 
cells to produce chemo-attractants. A fourth method includes varying cell culture conditions that 
enhance growth factor expression in the CDM scaffold. These means include the exogenous 
addition of growth factors to the matrix, as well as physical stimulation of the tissue to induce the 
cells to produce specific growth factors. 
4.2 Evaluation of Alternative Designs 
From the brainstorming session, the team compiled a number of alternative designs, or 
means, to address each function. Each alternative design was rated against each other using a 
set of metrics and prioritized objectives in an evaluation matrix. The top-rated alternative design 
for each function was compiled into a final design. 
4.2.1 Generation of final functions and means 
The design team reevaluated the initial functions and means list to focus the attributes of 
the scaffold on the ranked objectives. Specifically, “discourages foreign body response” and 
“actively promotes cellular migration” were eliminated from the list. The design team felt that 
discouraging foreign body response was more of a constraint for the scaffold. The scaffold will 
not be successful if it is rejected in any way by the body. The design team also felt that the main 
function of the scaffold was not to enhance cellular migration. The clients clearly communicated 
the need for a mechanically strong scaffold above all other attributes, with antimicrobial and 
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angiogenic properties as secondary objectives. Therefore, enhancing cellular migration is 
outside of the scope of the client statement, and was eliminated from the list.  
List 7: Final Functions & Means 
1. Withstands mechanical forces similar to native dermis  
1.1 Modify matrix 
1.1.1 Crosslinking 
1.1.1.1 Chemically (formaldehyde, hexamethylene-diisocyanate, 
gluteradehyde, poly-epoxy compounds) 
1.1.1.2 Physically (UV, gamma, heat) 
1.1.1.3 Biologically (Lysyl-oxidase, tissue transglutaminase) 
1.1.2 Improve/add matrix components 
1.1.2.1 Add proteoglycans 
1.1.3 Grow cells on a substrate  
1.2 Modifying cells that produce matrix 
1.2.1 Improve/add matrix components 
1.2.1.1 Increase collagen production 
1.2.1.1.1 Stimulation in bioreactor 
1.2.1.1.2 Ascorbic acid in media 
1.2.1.2 Maximize extracellular matrix retention 
1.2.1.2.1 Protease inhibitors 
2. Actively inhibits microbial infection 
2.1 Modify cells  
2.1.1 Genetically modified cells produce AMP in ECM 
2.1.2 Exogenous addition of inducer of AMP 
2.2 Modify matrix 
2.2.1 Conjugate antibiotic to ECM 
2.2.2 Exogenous addition of metallic beads (silver, copper, zinc) 
2.2.3 Exogenously add terpenes  
2.2.4 Exogenous addition of  AMPs to ECM 
3. Actively establishes new blood vessel formation 
3.1 Modify cells 
3.1.1 Genetically modified cells to produce angiogenic protein  
3.1.2 Induce cellular production of angiogenic protein  
3.1.3 Induce prevascular network 
3.1.3.1 Endothelial cells during culture of ECM 
3.1.3.2 Grown in animal model 
3.2 Modify matrix 
3.2.1 Exogenous addition of angiogenic protein 
Pruning the initial list generated a final functions and means list with three functions, as 
seen above. These functions better suit the client’s deliverables by providing means that allow 
the scaffold to be mechanically strong and exhibit antimicrobial and angiogenic properties. The 
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means were reorganized for each function into two different groups: means that directly modify 
the matrix and means that modify the cells that produce the matrix. All of the lowest level means 
were evaluated against each other in an evaluation matrix, as discussed in section 4.2.2.  
4.2.2 Description of Alternative Designs 
After pruning the functions, a final list of means were developed. Each mean can be 
considered as an alternative design that can achieve its appropriate function.  
To satisfy the function “withstand mechanical forces similar to native dermis,” means to 
modify the matrix or modify the cells were developed. To modify the matrix to make it 
mechanically strong, the matrix can be crosslinked using chemicals, such as formaldehyde, 
hexamethylene-diisocyanate, gluteradehyde, or poly-epoxy compounds. Additionally, physical 
methods, such as UV, gamma, or heat exposure, and biological methods, such as lysl-oxidase 
and tissue transglutaminase, can also be used to crosslink the matrix. Another mean is to 
improve the matrix by adding proteoglycans. A fifth mean to modify the matrix is to grow the 
cells on a substrate to achieve optimum matrix alignment. Means that modify the cells to 
produce matrix include stimulating in a bioreactor or adding ascorbic acid to the media to 
increase collagen production. Protease inhibitors can also be added to maximize extracellular 
matrix retention.  
                To satisfy the function “actively inhibits microbial infection,” the team identified six 
alternative designs. Modifying the matrix can be achieved by conjugating an antibiotic to the 
CDM or exogenously adding metallic beads, terpenes, or antimicrobial peptides to the matrix. 
                To satisfy the function “actively establishes new blood vessel formation,” the team 
identified five alternative designs. One mean is to modify the matrix by exogenously adding an 
angiogenic protein. The other means modify the cells used to derive the matrix. In one 
alternative design, the cells are genetically modified to produce an angiogenic protein that will 
be retained in the matrix. Another design is to induce the cells to produce an angiogenic protein 
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by culturing them in hypoxic conditions. The last two alternative designs relate to inducing a 
prevascular network in the scaffold. One mean is to use endothelial cells during the culture of 
the CDM, and the other mean is to grow the scaffold up in an animal model. The final functions 
and means can be visualized in the tree below (see Figure 9). 
 
Figure 9: Final Functions/Means Tree 
4.2.3 Decision Matrix 
Following the design of metrics, the team developed a set of decision or evaluation 
matrices (see Appendix B: Metrics) to numerically quantify the means. When completed, the 
matrices established a quantitatively ordered ranking of means for each objective evaluated on 
Functions  
and Means 
Withstands 
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similar to the native 
dermis 
Chemically 
Crosslinking  
(formaldehyde, 
gluteraldehyde) 
Physically 
Crosslinking 
(UV, gamma, heat) 
Enzymatically 
Crosslinking  
(lysyl-oxisae, 
transglutaminase) 
Adding matrix 
components 
(proteoglycans, 
GAGs, fibronectin)  
Chemically inducing 
collagen production 
by ascorbic acid  
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with a bioreactor 
Growing cells on 
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using protease 
inhibitors 
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cells to produce 
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(proteoglycan, GAGs)  
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blood vessel formation 
Genetically modify 
cells to produce 
angiogenic protein 
Induce cellular 
production of 
angiogenic protein  
with hypoxia 
Induce prevascular 
network by 
endothelial cell co-
culture 
Exogenously add 
angiogenic protein 
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the matrix (see Appendix C: Decision Matrices). Each function had a corresponding design 
matrix, and each means (or “alternative design”) was scored according to the priority of the main 
objective, as well as the priority of each sub objective. The evaluation matrix was a key 
component in selecting design components that abided by the objectives and constraints of the 
project, helping the team to build a design that would fulfill the goals of the clients and team.  
4.2.3.1 Generation of the Matrices 
Each decision matrix for each function was set up and completed in the same manner. 
Each row of the decision matrix contained either an objective or constraint and each column 
contained one the alternative designs or means. The constraints applied were those listed in 
Section 3.6 (budget ($368 USD), time (21 weeks), cell-derived tissue, acellular, biodegradable, 
biocompatible, does not harm scaffold). The objectives in blue are the main or top level 
objectives of the project—structurally and mechanically similar to native dermis, bioactive, ease 
of laboratory processing, clinical ease of use, and ease of production. Each main objective was 
given a weight % value according to its priority level for the project. Each main objective was 
ranked 1-5, with 5 being the most important objective, according to the priority level of the 
objective established in the overall PCC. These values are noted on the metrics (see Appendix 
B: Metrics). The value of the objective was then divided over the sum of the value for all main 
objectives to determine the overall weighting. For example, “structurally and mechanically 
similar to native dermis” (Function 1) is the most important objective according to the overall 
PCC of the project; therefore, it receives a score of 5. The sum of all values for this objective 
would be 15. This number is derived from 5 for “structurally and mechanically similar”, 4 for 
“bioactive”, 3 for “ease of laboratory processing”, 2 for “clinical ease of use”, and 1 for “ease of 
production” (5+4+3+2+1=15). Therefore, the overall weighting of structurally and mechanically 
similar to native dermis is 15/3=0.333. This process was repeated for each of the top level 
objectives.  
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This process was repeated for lower level objectives as well. However, not all sub-
objectives were included. Because the “suture pullout strength” and “adhesion to wound bed” 
objectives were the lowest priorities of “structurally and mechanically similar” (see Table 13), 
these two objectives will not be used to rank the designs. Also, the team decided not to include 
“improved wound healing” because this objective will theoretically be met through the overall 
final design. Furthermore, the sub-objectives for “clinical ease of use” and “ease of production” 
were not scored because these two sub-objectives are ranked the lowest and should not have 
extensive bearing over the design of the project. Lastly, “minimize the difficulty of steps” was not 
listed under ease of laboratory processing. The team decided that this sub-objective was not 
worthy of being a factor for determining the means used to achieve each function. The sub-
objectives were weighted in the same manner as the main objectives. The priority level of each 
sub-objective was established in the respective PCC for each main-objective and is indicated on 
the metrics. The overall weighting for these values is listed in parenthesis.  
4.2.3.2 Completion of the Matrices 
Each alternative design was first evaluated against the constraints. The design was 
designated with either a “Y” if the means satisfied the constraint or an “N” if the means did not 
satisfy the constraint. If at least one of the constraints was not met, the alternative design was 
highlighted a light red no further evaluated as an alternative design. Next, each alternative 
design was evaluated against each objective according to the developed set of metrics. For 
example, when looking at the alternative designs for “inhibits microbial infections,” each means 
can either receive a 1 or a 2, according to the metrics. The scores given were reflections of 
judgment and literature. If the top-level objective had no relation to the alternative designs being 
evaluated, the top-level and sub-objectives were grayed out. For example, alternative designs 
for inducing antimicrobial properties were not evaluated against the objective “structurally and 
mechanically similar to native dermal tissue.” If only a sub-objective was irrelevant and not the 
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top-level objective, then an “X” was placed in the each box for each means for that one sub-
objective (e.g. inhibits microbial infection for establishing tubular construct formation). 
4.2.3.3 Calculating the Ranking of Alternative Designs 
In order for an ordered ranking of alternative designs to be produced from the matrix, the 
scores of each objective and sub-objective had to be calculated. This was completed by first 
normalizing the values. The value for each sub-objective was divided by the total number of 
scoring options available in the metrics for that sub-objective. For example, “conjugate antibiotic 
to ECM” received a score of 2 for “inhibits microbial infections.” On the metrics, there are two 
options for a score, either a 1 or a 2. Therefore, the normalized value for this sub-objective was 
2/2=1.0. The total normalized values for each sub-objective were then added up and divided by 
the total number of sub-objectives that received a score and placed in the top-level objective 
box. This value appears blue on the matrix. Next, the normalized value of the top-level objective 
was multiplied by its overall weighting to determine the weighted sum for that top-level objective. 
Then, the normalized value for each sub-objective was multiplied by its own overall weighting. 
This value was then placed in parenthesis in the weighted sum box for that sub-objective. Then, 
the weighted sum values for all the sub-objectives were multiplied by the overall weighting of the 
top-level objective. This number was also placed in parenthesis in the weighted sum box for the 
top-level objective. Finally, all the regular top-level objective values for each alternative design 
were summed and placed in a total box at the bottom of the matrix. The same was completed 
for the values in parenthesis. These latter values indicate how closely each means fits the 
prioritized sub-objectives of the project. If only the first approach is used, then the ranked means 
only reflect how well each alternative design fits the overall top-level objective, and not how 
each alternative designs fits each individual objective within each top-level.  
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4.2.4 Results of Decision Matrix 
The team was able to rank the alternative designs according to the total values listed on 
each matrix, with larger values equaling a more appropriate or better means. The results for 
each function are listed in the tables below (see Table 14-Table 16). The values on the left refer 
to the scores calculated against only the overall weighting, and the values on the right refer to 
the scores calculated against the overall weighting and the prioritized sub-objectives. The actual 
score received by each alternative design have no importance. The scores are merely a means 
for comparing the different alternatives in a manner that is consistent and relates the 
effectiveness of the means compared to each other. The system does not necessary state how 
good a design is, but rather how it compares to others. 
4.2.4.1 Withstands Mechanical Forces Similar to Native Dermis 
Table 14: Decision Matrix Results for “Withstands Mechanical Forces Similar to Native Dermis” 
 
 
 
 
 
 
 
 
 The first design alternatives included means for achieving the function “withstands 
mechanical forces similar to native dermis” (see Table 14).  Ascorbic acid ranked the highest for 
both scores, but there was variation in the second ranked means between the two systems. It is 
anticipated that using a bioreactor would be better at achieving the overall goal than biologically 
crosslinking the scaffold; however, biologically crosslinking the scaffold may fit the sub-
Design 
Overall Weighting 
Score 
Ascorbic Acid .733 
Bioreactor .617 
Biologically 
crosslink 
.616 
Protease 
Inhibitors 
.608 
Culture on 
substrate  
.567 
Design 
Prioritized Overall 
Weighting Score 
Ascorbic Acid .609 
Biologically 
crosslink 
.556 
Bioreactor .520 
Protease 
Inhibitors 
.512 
Culture on 
substrate 
.470 
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objectives of tensile strength, stiffness, shear resistance, permeability/diffusivity, and thickness 
better. 
4.2.4.2 Actively Inhibits Microbial Infection 
Table 15: Decision Matrix Results for “Actively Inhibits Microbial Infection” 
 
 The second set of matrices includes the design alternatives for inhibiting microbial 
infection (see Table 15). There was no variation in the ranking between the two scoring systems 
and using genetically engineered cells ranked first. Exogenously adding AMPs came in second 
because of the cost associated with AMPs. Instead, the team has the resources to genetically 
modify the cells, with the production of AMPs as a possibility. Antibiotics were ranked lower 
because they are also costly and terpenes would require extra labor because a conjugation 
method would need to be devised for effective antimicrobial properties.  
4.2.4.3 Actively Establishes Tubular Constructs for Enhanced in vivo Vascularization 
Table 16: Decision Matrix Results for “Actively Inhibits Microbial Infection” 
 
 
 
 
 
The final matrices correspond to establishing tubular constructs for enhanced in vivo 
vascularization. Overall, the addition of endothelial cells ranked the highest for establishing 
Design 
Prioritized Overall 
Weighting Score 
Genetically Modify 
Cells 
.609 
Exogenously Add 
AMPs 
.556 
Conjugate Antibiotic 
to ECM 
.498 
Exogenously Add 
Terpenes 
.498 
Design 
Overall Weighting 
Score 
Genetically 
Modify Cells 
.593 
Exogenously Add 
AMPs 
.589 
Conjugate 
Antibiotic to ECM 
.542 
Exogenously Add 
Terpenes 
.542 
Design 
Overall Weighting 
Score 
Endothelial 
Cell Co-Culture 
.584 
Hypoxia Stress .534 
Hypertonic 
Stress 
.509 
Design 
Prioritized Overall 
Weighting Score 
Hypoxia Stress .432 
Hypertonic Stress .398 
Endothelial Cell 
Co-Culture 
.383 
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tubular constructs. When looking at the prioritized values, however, hypoxia stress induced 
angiogenesis ranks first.   
4.3 Final Conceptual Design 
The highest ranking means from the evaluation matrix for each function were compiled 
into a final design. These means satisfy the client’s and design team’s desired objectives, as 
well as the two top functions specified for the scaffold: withstands mechanical forces similar to 
those that the native dermis are subjected and actively inhibits microbial infection. The function 
“establishes new blood vessel formation” was eliminated to focus the scope of the design. The 
final design consists of the addition of ascorbic acid to increase mechanical collagen production 
and matrix strength as well as genetically modified cells to produce antimicrobial peptides. A 
schematic of the final design is shown below (see Figure 10). 
 
Figure 10: Schematic of Final Design 
Fibroblasts will be genetically modified to produce an antimicrobial peptide. The peptide 
will include a matrix binding domain so as to improve retention in the scaffold after 
decellularization. 
L-ascorbic acid phosphate magnesium salt n-hydrate is added to the medium at a 
concentration of 50 μg/mL (Hu, 2010), has been reported to increase collagen production of 
human dermal fibroblasts. The ascorbic acid is added to standard medium components for 
fibroblasts, which include 1X Iscove’s Modified Dulbecco’s Medium (IMDM) (Mediatech, Inc), 
10% fetal bovine serum (FBS) (PAA) and 1% penicillin/streptomycin (Invitrogen). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fibroblasts 
Modified 
Fibroblasts 
Cell-Derived 
Dermis 
Matrix  
Scaffold 
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4.3.1 Design Fabrication 
Some components of the design, such as cell type, were required for product fabrication, 
but were inappropriate to rank against means for achieving our objectives. Such components 
relate more to how the scaffold will be made as opposed to attributes of the scaffold that will 
allow it to achieve the desired functions.  
4.3.1.1 Cell Type 
A list of cell types to consider for the formation of the tissue were initially collected 
according to the literature review. Cell types found in the natural dermis were considered. These 
include fibroblasts, endothelial cells, and keratinocytes. Mesenchymal stem cells have also 
been shown to contribute to collagen deposition and wound repair and were also considered 
(Fathke et al., 2004). The following decision matrix lists the pros and cons for each cell type 
(see Table 17). 
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Table 17: Cell Type Decision Chart 
Cell Type Pro Con 
Neonatal 
Fibroblasts 
 Main cells responsible for production and 
deposition of new ECM 
 Synthesizes most ECM molecules and produce 
proteases required for remodeling 
 Secretes growth factors and cytokines 
conducive to wound healing: PDFG-α, TGF-α, 
IL-6, IL-8, bFGF 
 Addition of ascorbic acid stimulates collagen I 
and III production 
 Mechanical stimulation enhances tenascin C, 
which improves mechanical strength 
 Easy to acquire and maintain 
o Isolation of neonatal fibroblasts from 
foreskins 
o Available to purchase from the WPI Pins 
Lab 
 Media available to purchase from WPI Rolle Lab 
 
Mesenchymal 
Stem Cells 
 Actively participates in skin wound healing 
 Can function as perivascular cells when 
combined with endothelial cells 
 Secrete bioactive factors 
 Can be mechanically stimulated to increase 
collagen production 
 Produces collagen I and III 
 Inconsistency in 
reports of growth 
characteristics and 
differentiation 
 Hard for design team 
to acquire and 
maintain 
Endothelial 
Cells 
 
 Can create a prevascular network when co-
cultured with fibroblasts 
o Promotes host vasculature within 4 days 
 Produce VEGF 
 Available to purchase from WPI Rolle Lab 
 Media available to purchase from WPI Rolle Lab 
 Deposits minimal to 
no matrix 
 Only beneficial in a 
co-culture system 
Keratinocytes  Main cell type of epidermis 
 Deposit growth factors and integrins into the 
acellular scaffold that will increase subsequent 
keratinocyte migration  
 Produces bFGF, which is angiogenic and a 
fibroblast growth factor 
 Available to purchase from WPI Pins Lab 
 Deposits minimal to 
no matrix 
 Only beneficial in a 
co-culture system 
 Extremely expensive 
media  
 
 
Characteristics of each cell type were evaluated as well as laboratory feasibility, 
including whether or not the design team would have immediate access the cells and their 
respective culture media. Decisions were also based on the design of a single culture system 
for the simplicity of scaffold fabrication and cost restraints. Ultimately, the final cell type choice 
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was based on which cell would provide the team with the most desired scaffold attributes with 
the smallest among of external conditioning. 
Human dermal fibroblasts were chosen as the cell type for the final design. Fibroblasts 
are responsible for production and deposition of new ECM, and secrete growth factors that are 
conducive to wound healing. These growth factors, if retained in the acellular scaffold, will 
increase the healing potential of the scaffold. Neonatal fibroblasts were chosen because they 
are more robust than adult fibroblasts. Fibroblasts are also advantageous as can be subjected 
to relatively straightforward methods to enhance their matrix production. The addition of 
ascorbic acid, which is one the means in our final design, has been shown to stimulate fibroblast 
production of collagen I and III. Mechanical stimulation can be used to increase the mechanical 
strength; this is our second highest ranked mean for its category and will be used as our next 
approach if ascorbic acid does not significantly increase the strength of the scaffold. 
Furthermore, fibroblasts are relatively easy to acquire from the Pins Laboratory and maintain. 
4.3.1.2 Decellularization Method 
 A variety of decellularization methods have been developed to remove cellular 
components from a tissue. These include physical methods, hypotonic and hypertonic solutions, 
non-ionic detergents, ionic detergents, zwitterionic detergents, enzymes and chelating agents, 
and acids and bases (Gilbert et al., 2006). The design team narrowed down three possible 
methods to examine in the laboratory. These methods were chosen based on their projected 
success in minimal matrix disruption and maximum retention of matrix components (Badylak, 
2007; Crapo, Gilbert, & Badylak, 2011). The methods were also chosen based on the feasibility 
of the completion relating to the difficulty of the process and necessary resources. 
 Non-ionic and detergents and zwitterionic were not chosen because of their destruction 
of the scaffold ultrastructure and removal of GAGs.  Enzyme and chelating agents are not 
effective alone, and would be detrimental if remnants remained in the scaffold. Acids and bases 
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were not chosen because of their damaging effects to collagen, GAGs, and growth factors 
(Gilbert et al., 2006). 
 The remaining three methods were chosen to experimentally test in the laboratory: 
freeze-thaw cycles (Ngangan & McDevitt, 2009) , ionic detergents (Elder, Eleswarapu, & 
Athanasiou, 2009), and hypotonic and hypertonic solutions (Meyer et al., 2006). These methods 
are feasible for the design team to test in the laboratory and have been successfully used in 
previous literature. There are still obvious limitations with these techniques, and laboratory 
testing for scaffold mechanical strength and retention of structure will allow the design team to 
choose the most appropriate method. 
4.4 Conclusion 
 Following the design process, the team developed a final design for the client’s acellular 
scaffold. The team started this process by brainstorming initial functions and specifications as a 
team, and then conducted a brainstorming session with the client to develop conceptual 
designs. The team used this session to develop a list of preliminary functions and means. This 
list was then revised to better fit the scope of the client’s objectives. Using evaluation matrices, 
the team ranked the alternative designs, and compiled the top ranking means into a final design. 
C-term experiments are listed in Appendix E: C-Term Gantt Chart.  
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5 Design Verification 
The conceptual design can be broken down into a four-step process. The first is genetic 
engineering of the fibroblasts to achieve antimicrobial properties within the scaffold. The second 
and third are simultaneous steps that include cell-derived sheet fabrication and the use of 
ascorbic acid to produce a robust cell-derived sheet. The final step is decellularization of the 
fabricated cell sheet, resulting in an extracellular matrix scaffold. Initial experiments were 
conducted to verify and optimize these aspects of the design. A materials list and cost estimate 
for these experiments can be found in Appendix F: Materials List. 
5.1  Developing Recombinant Cathelicidin 
Human cathelicidin is naturally synthesized as a preproprotein, hCAP-18, from the 
CAMP gene located on chromosome 3 (Sorensen et al., 2001). It is 170 amino acids long and 
contains an N-terminus signal sequence (30aa), a conserved cathelin-like domain, and a C-
terminus 37-amino acid antimicrobial peptide domain (LL-37). Figure 11 shows the sequence 
and domains of hCAP-18.               
5.1.1 Gene Design 
A recombinant form of cathelicidin was produced to include certain features that would 
allow its incorporation into a cell-derived matrix scaffold. A collagen binding domain (CBD) was 
added to the C-terminus of LL-37 in order tether the peptide to the synthesized matrix. Two 
CBDs were chosen, corresponding to the natural collagen-binding sites of fibronectin and 
Figure 11: Amino acid sequence of human 
cathelicidin, hCAP-18. The signal sequence is 
red, cathelin-like domain is blue, and the LL-37 
antimicrobial peptide is blue. 
MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLS
YKEAVLRAIDGINQRSSDANLYRLLDLDPRPTMD
GDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKD
GLVKRCMGTVTLNQARGSFDISCDKDNKRFALLG
DFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 
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collagenase. The fibronectin-derived domain, CQDSETGTFY, was chosen because it is a 
relatively short peptide and has shown good affinity for collagen types I and III (Sistiabudi & 
Ivanisevic, 2008).  Its ability to act as a biomolecular anchor was experimentally observed by 
Sistiabudi et al. (Sistiabudi & Ivanisevic, 2008). The collagenase-derived domain, TKKTLRT, 
has also shown similar specificity for binding collagen type I. Its functionality as a fusion domain 
has also been determined by a study on recombinant collagen binding VEGF (vascular 
endothelial growth factor) (Zhang et al., 2009). Two recombinant forms of cathelicidin were 
designed to include either the fibronectin collagen anchor (Fib-CBD) or the collagenase collagen 
anchor (Col-CBD). Each collagen binding site was incorporated with a FLAG-tag octapeptide, 
DYKDDDDK, so as to allow flexible anchorage of the antimicrobial peptide LL-37. This feature is 
important for both visualizing the protein’s expression as well as providing a buffer between the 
collagen bound amino acids and the dynamic activity of the AMP. A schematic of the 
recombinant cathelicidin and its added features is shown in Figure 12. The designed DNA and 
protein sequences of both recombinant forms are also included in the proceeding sections. 
Figure 12: Proposed Gene Design of Recombinant Collagen-binding Cathelicidin Insert 
 
 
Collagen Binding Domains 
Collagenase: TKKTLRT 
Fibronectin:   CQDSETGTFY 
p3xFLAG-Myc-CMV-26 Vector 
CMV promoter 
Neomycin and Ampicillin 
MCS includes EcoRI and BamHI  
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5.1.1.1 Col-CBD-Cathelicidin DNA Sequence 
 
 
 
 
 
 
 
5.1.1.2 Col-CBD-Cathelicidin Protein Sequence 
 
 
 
5.1.1.3 Fib-CBD-Cathelicidin DNA Sequence 
 
 
 
 
 
 
 
 
 
 
 
5.1.1.4 Fib-CBD-Cathelicidin Protein Sequence 
 
 
 
 
 
 
 
 
 
 
5’-CGG-AAT-TCA-ATG-AAG-ACC-CAA-AGG-GAT-GGC-CAC-TCC-CTG-GGG-CGG-TGG-TCA-
CTG-GTG-CTC-CTG-CTG-CTG-GGC-CTG-GTG-ATG-CCT-CTG-GCC-ATC-ATT-GCC-CAG-GTC-
CTC-AGC-TAC-AAG-GAA-GCT-GTG-CTT-CGT-GCT-ATA-GAT-GGC-ATC-AAC-CAG-CGG-TCC-
TCG-GAT-GCT-AAC-CTC-TAC-CGC-CTC-CTG-GAC-CTG-GAC-CCC-AGG-CCC-ACG-ATG-GAT-
GGG-GAC-CCA-GAC-ACG-CCA-AAG-CCT-GTG-AGC-TTC-ACA-GTG-AAG-GAG-ACA-GTG-
TGC-CCC-AGG-ACG-ACA-CAG-CAG-TCA-CCA-GAG-GAT-TGT-GAC-TTC-AAG-AAG-GAC-
GGG-CTG-GTG-AAG-CGG-TGT-ATG-GGG-ACA-GTG-ACC-CTC-AAC-CAG-GCC-AGG-GGC-
TCC-TTT-GAC-ATC-AGT-TGT-GAT-AAG-GAT-AAC-AAG-AGA-TTT-GCCCTG-CTG-GGT-GAT-
TTC-TTC-CGG-AAA-TCT-AAA-GAG-AAG-ATT-GGC-AAA-GAG-TTT-AAA-AGA-ATT-GTC-CAG-
AGA-ATC-AAG-GAT-TTT-TTG-CGG-AAT-CTT-GTA-CCC-AGG-ACA-GAG-TCC-GAC-TAC-AAA-
GAC-GAT-GAC-GAC-AAG-ACC-AAG-AAG-ACC-CTG-AGG-ACC-TGA-GGA-TCC-CG-3’ 
5’-CGG-AAT-TCA-ATG-AAG-ACC-CAA-AGG-GAT-GGC-CAC-TCC-CTG-GGG-CGG-TGG-TCA-
CTG-GTG-CTC-CTG-CTG-CTG-GGC-CTG-GTG-ATG-CCT-CTG-GCC-ATC-ATT-GCC-CAG-GTC-
CTC-AGC-TAC-AAG-GAA-GCT-GTG-CTT-CGT-GCT-ATA-GAT-GGC-ATC-AAC-CAG-CGG-TCC-
TCG-GAT-GCT-AAC-CTC-TAC-CGC-CTC-CTG-GAC-CTG-GAC-CCC-AGG-CCC-ACG-ATG-GAT-
GGG-GAC-CCA-GAC-ACG-CCA-AAG-CCT-GTG-AGC-TTC-ACA-GTG-AAG-GAG-ACA-GTG-TGC-
CCC-AGG-ACG-ACA-CAG-CAG-TCA-CCA-GAG-GAT-TGT-GAC-TTC-AAG-AAG-GAC-GGG-CTG-
GTG-AAG-CGG-TGT-ATG-GGG-ACA-GTG-ACC-CTC-AAC-CAG-GCC-AGG-GGC-TCC-TTT-GAC-
ATC-AGT-TGT-GAT-AAG-GAT-AAC-AAG-AGA-TTT-GCCCTG-CTG-GGT-GAT-TTC-TTC-CGG-
AAA-TCT-AAA-GAG-AAG-ATT-GGC-AAA-GAG-TTT-AAA-AGA-ATT-GTC-CAG-AGA-ATC-AAG-
GAT-TTT-TTG-CGG-AAT-CTT-GTA-CCC-AGG-ACA-GAG-TCC-GAC-TAC-AAA-GAC-GAT-GAC-
GAC-AAG-TGC-CAG-GAT-TCA-GAG-ACT-GGG-ACG-TTT-TAT-TGA-GGA-TCC-CG-3’ 
 
RNSMKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPR
PTMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDN
KRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKTKKTLRT*GS 
RNSMKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPRP
TMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDNKR
FALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKCQDSETGTFY*GS 
Red: Cathelin-like domain 
Pink: LL-37 
Green: FLAG-Tag linker 
Orange: Collagen Binding Domain (CBD) 
Purple: Restriction sites (EcoRI and 
BamHI) 
Blue: Stop Codon 
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5.1.2 Cathelicidin Isolation 
The 510bp cathelicidin insert was isolated and amplified from pANT7 cGST (DNASU 
Plasmid Repository, Clone ID HsCD00357894, GenBank Acc. No.570277) using PCR. Primers 
were designed to include and incorporate the recombinant features onto the cathelicidin insert. 
One forward and two reverse primers (corresponding to each CBD) were ordered from 
Integrated DNA Technologies (IDT). The sequences of the three primers are shown in Figure 
13. 
 
 
 
Forward primer: 
5’-CGG-AAT-TCA-ATG-AAG-ACC-CAA-AGG-GAT-GGC-3’      
Reverse primers: 
5’-CG-GGA-TCC-TCA-ATA-AAA-CGT-CCC-AGT-CTC-TGA-ATC-CTG-GCA-CTT-GTC-GTC-ATC-
GTC-TTT-GTA-GTC-GGA-CTC-TGT-CCT-GGG-TAC-AAG-3’ with fibronectin derived anchor 
5’-CG-GGA-TCC-TCA-GGT-CCT-CAG-GGT-CTT-CTT-GGT- CTT-GTC-GTC-ATC-GTC-TTT-GTA-
GTC-GGA-CTC-TGT-CCT-GGG-TAC-AAG-3’ with collagenase derived anchor 
Red: Cathelin-like domain 
Pink: LL-37 
Green: FLAG-Tag linker 
Orange: Collagen Binding Domain (CBD) 
Purple: Restriction sites (EcoRI and BamHI) 
Blue: Stop Codon 
 
Figure 13: Design of Forward and Reverse PCR Primers 
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For PCR, the samples were prepared by combining 10μL of Promega’s GoTac Green 
Mastermix, 1 μL of the template (pANT7-cGST), 1 μl forward primer, 1 μL reverse primer, and 
ddH2O to 20 μL. PCR controls included a sample with no primers, and two with primers and no 
template (the two corresponding to each of the reverse primers). The PCR thermocycler (Bio-
Rad, MyCycler) was set to 4minutes at 90°C (30s at 95°C, 30s at 55°C, 1 minute at 72°C)X30, 4 
minutes at 72°C, and ∞ at 10°C. Agarose gel electrophoresis, pre-stained with Sybr green was 
used to verify the recombinant amplified cathelicidin fragments (Figure 14). The isolated 
fragments were subsequently purified with Promega’s Wizard SV Gel and PCR Clean-up 
System (Cat. No. A9281).  
Gel electrophoresis of the PCR fragments (see Figure 14) as well as the original vector 
confirms the isolation and construction of both recombinant forms of cathelicidin. The first lane 
is the DNA ladder, the second lane represents cathelicidin with the collagenase CBD (Col-
CBD), while the third lane represents cathelicidin with the fibronectin CBD (Fib-CBD). The last 
lane is a sample of the pANT7 cGST vector. From the gel, it can be estimated that the size of 
the recombinant fragments is approximately 600bp, and the original vector is ~5000bp. To 
Figure 14 : Purified PCR 
Fragments of Recombinant 
Cathelicidin 
90 
 
compare, the expected sizes of the Col-CBD and Fib-CBD fragments were 575bp and 584bp. 
The expected size of the vector was ~5700bp. 
5.1.3 Ligation into pGEM Vector 
The purified PCR fragments were ligated into pGEM using Promega’s T-vector system. 
The ligation reactions were set up to include 5 μL Ligation Buffer, 1 μL pGEM, 2 μL PCR 
fragment, 1 μL T4 DNA ligase, and filled to 10 μL with ddH2O. A positive control was prepared 
with control DNA, instead of the PCR fragments, and a negative control was prepared without 
DNA. The ligation reaction was run overnight at 4°C.  
5.1.4 E.Coli Transformation, Screening, and pGEM Isolation 
The pGEM vectors from the ligation reactions were used to transform chemically 
competent JM109 (Promega >108cfu/μg, Cat.No. L2001) E.coli cells. For each transformation, 
50 μL of E.coli were transferred into a cold Eppendorf tube containing 2μL of the ligation 
reaction. The mixture was mixed by tapping the tube on the benchtop. It was allowed to 
incubate on ice for 20 minutes, then heat shocked in a 42°C waterbath for 60 seconds, before it 
was returned to ice for another 2 minutes. The E.coli then received 450 μL of prewarmed LB 
media and incubated at 37°C under moderate shaking for 1 hour. Prewarmed LB agar ampicillin 
plates were prepared with 20 μL of 50 mM X-Gal and 40 μL of 100mM IPTG, spread on the 
surface of the agar. Sample plates were prepared in duplicate with 150 μL of transformed E.coli 
added to each. A plate of each of the negative ligation and the positive ligation were prepared 
as controls. All of the plates were cultured overnight at 37°C and then incubated at 4°C for 6 
hours.   
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                 Blue –white colony screening  (Figure 15) was used to isolate positive (white) 
colonies and test for fragment incorporation into the vector. The pGEM vector includes the LacZ 
gene for β-galactosidase (β-gal) with the multiple cloning site (MCS) positioned in the middle of 
the gene. The expression of β-gal and the presence of X-gal, results in a blue bacterial 
phenotype. When the LacZ gene is interrupted by the insertion of a gene of interest, in this case 
cathelicidin, the β-gal is not expressed, and thus the colony phenotype is white.  
Both plates transformed with pGEM containing cathelicidin showed very few blue 
colonies. The positive and negative controls, containing pGEM ligated with a test fragment or no 
fragment respectively, showed mostly blue colonies, which means that they did not contain a 
gene insert or were inefficiently ligated. Individual colonies were screened by a miniprep 
protocol which included inoculating 3 mL of LB 1x AMP media and incubating it overnight at 
37°C. Half of the culture was used to isolate the plasmid. The cells were pelleted by 
centrifugation at 12,000 rcf for 30 seconds, and the supernatant was aspirated. A resuspension 
solution was prepared with 50mM Glucose, 25mM TRIS-HCL and 10mM EDTA at pH 8.0, 
autoclaved and vacuum sterile filtered. Then 100 μL of ice-cold resuspension solution (~4°C) 
was added to the pelleted cells. The cells were vortexed until fully resuspended. A cell lysis 
Figure 15: pGEM Transformations in JM109 E. Coli. (A) 
Cathelicidin-col-pGEM, (B) Cathelicidin-fib-pGEM, (C) 
Positive control, (D) Negative control 
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solution was freshly prepared with 100 μL NaOH (10N), 500 μL 10% SDS, and 4.4 mL of water 
and stored at room temperature until 200 μL was added to the resuspended cells, and each 
tube was inverted ten times and incubated on ice for 3 minutes. A third solution was prepared to 
precipitate the cellular debris (60 mL 5M potassium acetate, 11.5 mL glacial acetic acid, and 
28.5 mL H2O, and stored at 4°C) and 150 μL was added to the lysed cells. They were then 
vortexed in an inverted position at low speed for 10 seconds. The mixture was incubated on ice 
for 10min, and then centrifuged at 12,000rcf for 5 minutes. The 450 μL of supernatant was 
transferred to a fresh vial, and two volumes of 100% cold ethanol were added, mixed by vortex, 
and left to incubate on ice for 2 minutes. The DNA was pelleted by centrifugation at 12,000 rcf 
for 5 minutes, and the supernatant ethanol was removed by pipette. The pellet was then rinsed 
with 1 mL of 70% ethanol and left to dry for 10 minutes at room temperature. After completely 
dry, the pellet was resuspended in 50 uL of 1xTE (10mM Tris, 1mM EDTA, pH 7.5).    
5.1.5 Restriction Digest and Fragment Purification 
Restriction digests were performed to isolate the recombinant cathelicidin inserts from the 
pGEM vector. Once a colony proved positive for the vector and insert, the DNA was isolated 
with a large scale plasmid isolation, using Promega’s Midiprep Plasmid Isolation kit (Cat. No. 
A2492). The restriction reactions of the Midiprep DNA were conducted using 3 μL ligated DNA, 
2 μL 10x Buffer E (Promega), 1 μL BamHI, 1 μLEcoRI, 1 μL RNAse A, and to 20 μL total with 
ddH2O. Controls were also run; one without BamHI, one without EcoRI, and one with neither 
restriction nuclease. Gel electrophoresis was performed to verify the restrictions. One positive 
restriction of each recombinant form of the cathelicidin insert (fib and col) was run again in 
triplicate. The gel is shown in Figure 16. The isolated cathelicidin inserts were purified by 
Promega’s SV Gel Clean-up kit and protocol.  
The gel image of the restriction digest shows an unrestricted pGEM vector in the second 
lane, one digested with EcoRI alone [BamHI (-)] in the second lane, one restricted with BamHI 
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alone [EcoRI(-)] in the third lane, then the Col-CBD digestion in lanes 4-6 run triplicate, and the 
Fib-CBD digestion in lanes 7-10 also run in triplicate. Unrestricted pGEM ran at ~2500bp, but 
was expected to be 3000bp. All of the recombinant cathelicidin fragments ran at the expected 
size range of 500-600bp (see Figure 16). 
                            
Figure 16: Restriction Analysis of pGEM Containing Recombinant Cathelicidin inserts. 
5.1.6 Sequence Analysis 
DNA Sanger sequencing followed by analysis with CLC Gene Viewer 6 confirmed 100% 
consensus between designed inserts and the isolated DNA. Sequencing results for both 
cathelicidin inserts are shown in Figure 17 and Figure 18 below.  
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Figure 17: Alignment of Theoretical and Isolated Fib-CBD 
 
Figure 18: Alignment of Theoretical and Sequenced Col-CBD 
 
5.1.7 p3xFLAG Ligation, Transformation, and Verification 
The two recombinant cathelicidin inserts were ligated to form the final construct in 
p3xFLAG-Myc-CMV-26 vector (Sigma Aldrich, Cat. No. E7283), as shown in Figure 19. The 
ligation reaction was prepared with 5 μL 10x T4 ligase buffer, 2 μL p3xFLAG, 3 μL purified DNA 
inserts, 1 μL T4 ligase, to a total of 10 μL with ddH2O. A negative control was prepared with no 
insert DNA. The ligations were incubated overnight at 4°C. 
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Figure 19: Map of p3xFLAG-Myc-CMV-26 vector 
 
Transformations into JM109 E. coli were performed following the same protocol as for 
the pGEM transformations (see Figure 20). Cells were plated on LB-AMP agar plates, and 
cultured overnight at 37°C. The transformation results are shown in Figure 20. The colonies 
transformed with ligated p3xFLAG vector were selected by ampicillin resistance. The negative 
control, containing p3xFLAG with no insert, showed very few colonies, due to the improper 
ligation of the vector, resulting from the mismatching restricted ends (EcoRI and BamHI). 
The colonies were screened for properly ligated p3xFLAG and insert using the miniprep 
protocol, followed by restriction analysis. Positive colonies were then cultured and their DNA 
was isolated using Promega’s Midiprep kit. A restriction analysis of the final construct was done 
to verify the insertion of the recombinant cathelicidin inserts (see Figure 21). In the gel image, 
lane 2 represents unrestricted p3xFLAG, lanes 3 and 4 are each ligated with only one restriction 
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enzyme (EcoRI or BamHI, respectively), and lanes 5 and 6 are the digested inserts of Col-CBD 
and Fib-CBD, respectively. Unrestricted p3xFLAG ran at 6000bp, similar to its expected size of 
6332bp. Both recombinant fragments ran at approximately 600bp, close to their expected size, 
thus confirming the successful incorporation of the inserts into the p3xFLAG vector. 
 
Figure 20: E. coli Transformation of p3xFLAG Final Constructs. (A) Col-CBD transformation, (B) Fib-CBD 
transformation, (C) Negative control 
 
Figure 21: Restriction Digest of p3xFLAG with Ligated Recombinant Cathelicidin Inserts 
5.1.8 H1299 Transfection 
Because of the low transfection efficiency of primary dermal fibroblasts, human lung 
carcinoma (H1299) cells were used as a model cell type to verify the design of the construct and 
its mammalian expression. The cells were seeded to attain 80% confluence after 24 hours of 
culture. They were maintained with standard DMEM with 10% FBS on 6-well tissue culture 
plates (CellTreat, Cat. No. 229106) and incubated at 37°C. The cells were transfected with the 
two cathelicidin p3xFlag constructs using Qiagen’s Effectene lipofection kit (Cat. No. 301425) 
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and protocol. A GFP-Flag-Apoptin control vector was used to verify the success of the 
transfection (Heilman, Teodoro, & Green, 2006). Each construct was transfected in duplicate. 
5.1.9 Western Blot 
Expression of the control GFP vector was assessed 24hrs after transfection by 
examining the cells using a Zeiss Axiovert 40CFL inverted fluorescence microscope at 200x. 
The fluorescence image (Figure 22A) shows that GFP was expressed, which confirmed the 
success of the transfection.  
To prepare cell lysates for Western blot analysis, each well was scraped after 2 washes 
with 1x PBS. The cell solution from each well (in 400 µl PBS) was centrifuged at 1500rpm for 10 
minutes. The supernatant was removed and the cell pellet was resuspended in 200 µl RIPA 
lysis buffer (50mM Tris pH 7.6, 200mM NaCl, 1%NP-40, 0.1%SDS, and 2mM PMSF) and 
incubated on ice for 20 minutes. The suspension was then centrifuged at 5000rcf for 10 
minutes, and the clarified lysate was transferred to a fresh vial. Lysates were stored at -20°C 
until ready for Western analysis.  
For the Western blot, a 16% SDS-polyacrylamide resolving gel was prepared with 5.3 
mL 30% Acrylimide/0.8% Bis, 2.5 mL resolving buffer (1.5M Tris-HCL pH8.8), 0.1mM 10% SDS, 
and 2.1 mL ddH2O. The polymerization was catalyzed with 50 μL 10% ammonium persulfate 
(APS) and 7 μL TEMED. The gel was poured using a Bio-rad mini apparatus. The stacking gel 
consisted of 0.65 mL 30% Acrylamide/0.8%Bis, 1.25 mL stacking gel buffer (0.5M Tris-HCL pH 
6.8), 50 μL 10% SDS, and 3.05 mL ddH2O. The gel was polymerized with 25 μL 10% APS and 
5 μL TEMED.  
The Western samples were prepared with 20 μL of lysate and 5 μL of protein loading 
dye. The samples were denatured on a heating block at 95°C for 5 minutes before loading them 
onto the gel. Invitrogen’s Novex Sharp prestained ladder (Cat. No. LC5800) was used as the 
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standard. The gel was run in a 1x Tris-Glycine pH 8.3 running buffer ( 0.3% tris, 1.44% glycine, 
0.1% SDS), at 35mAmps for 2 hours at a constant current.  
The gel was transferred onto a nitrocellulose membrane, and run in a 1x Tris-Glycine 
(without SDS) transfer buffer containing 20% methanol, for 1 hour at 200mAmps constant 
current. Immediately after the transfer, the membrane was blocked on a shaker at 4°C overnight 
with 5% powdered milk in  1x Tris Buffered Saline Tween-20, pH 7.3 (TBS-T) (25mM Tris-HCL, 
137mM NaCl, 2.7μM KCl, to 1000 mL with ddH2O, and 0.5% tween-20).  
The blocked membrane was washed 5 times for 5 minutes each time in TBS-T, then 
incubated in α-FLAG mAb M2 1/5000 (Sigma, Cat. No. F3165-.2MG) in TBS-T for 5 hours at 
4°C and 1 hour at room temperature on an agitator. After the primary incubation, the membrane 
was washed five times for 5 minutes each in TBS-T. It was then incubated in goat α-mouse 
1/10000 antibody (Sigma, Cat. No. A4416-.5ML) for 1 hour on an agitator at room temperature. 
It was then washed five times for 5 minutes each in TBS-T and then washed two times for 5 
minutes in TBS (without Tween-20).  
Promega’s horseradish peroxidase chemiluminescence ECL reagents (Cat. No. W1001) 
was used for the detection of the secondary antibody on the membrane. The two bands on the 
Western blot confirm the expression of both Col-CBD and Fib-CBD in H1299 cells. No bands 
are seen in the lower molecular weight range (see Figure 22B). 
                                                    
Figure 22: H1299 Transfection. (A) Transfection efficiency monitored by GFP expression, (B) Western blot 
confirming expression of cathelicidin constructs by H1299 cells 
A B 
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5.2 Cell-Derived Sheet Culture 
The design team conducted various experiments to determine a method for fabricating 
fibroblast cell-derived sheets (CDSs). In most experiments, the team used human neonatal 
fibroblasts (NHF) to produce the cell sheets. However, due to the fibroblasts’ slow proliferation 
rate, the design team decided to use a model cell type for additional proof-of-concept 
experiments. Rat aortic smooth muscle cells (RASMCs) were chosen based on their fast 
proliferation rate. These cells were used only to investigate the effectiveness of anchors to hold 
down the CDS; the design team recognized that characteristics of the RASMCs other than the 
physical production of a sheet were not translatable to fibroblasts.  
In the following experiments, medium will be referred to as complete or unsupplemented. 
Two types of media were used, 1X Dulbecco’s Modified Eagle Medium (DMEM) (Mediatech, 
Inc.) and Iscove's Modification of DMEM (IMDM) (Mediatech, Inc.). Complete DMEM consisted 
of 10% fetal bovine serum (FBS) and 1% nonessential amino acids (including alanine, 
asparagine, aspartic acid, glycine, glutamic acid, proline, and serine), penicillin/streptomycin, 
sodium pyruvate, and L-glutamine. Complete IMDM consisted of 10% FBS, 1% 
penicillin/streptomycin, L-glutamine, and 25 mM HEPES. For fabricating cell sheets, the FBS 
content of the complete media was reduced to 5% in order to moderate proliferation and 
encourage matrix production.  Unsupplemented media refers to DMEM or IMDM without any 
added supplements.   
For cell sheets treated with 50 µg/mL of ascorbic acid, the media was prepared fresh 
before use. First, a 100X stock was made with 5mL of unsupplemented IMDM and 25mg of L-
ascorbic acid (Wake Pure Chemical Industries, Ltd). The stock was sterile filtered using a 0.2 
μm cellulose acetate sterile syringe filter. Next, 100μL of the 100X stock was added to 10mL of 
complete IMDM, of which 1mL was added to each well. 
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Cell sheets were characterized using histology and uniaxial tensile testing. The 
mechanical testing protocol for cell sheets can be found in Section 5.4. To obtain histological 
sections, the cell sheets were processed and stained with Hoechst, H&E, or Picrosirius 
Red/Fast Green. Hoechst stains for nuclei (blue), H&E differentiates nuclei (blue), cytoplasm 
(pink), and red blood cells (red), and Picrosirius Red/Fast Green stains collagen red and non-
collagenous fibers green. To process the samples, the cell sheets were housed in cassettes and 
fixed in formalin for 1 hour. Next, the tissues were submerged in an alcohol and xylene series, 
after which they were embedded in paraffin. A processing protocol is detailed in Appendix G. 
The paraffin blocks containing the cell sheet samples were cut into 6μm sections using a 
microtome. To stain the samples, slides containing the cell sheet sections were dehydrated 
through a series of xylene and alcohol and then stained with the appropriate stain. Afterwards 
the tissues were rehydrated using the appropriate protocol, and cover-slipped. Detailed 
protocols for Hoechst, H&E, and Pircosirius Red/Fast Green stains can be found in Appendix H: 
Staining Protocols for Paraffin Sections. 
5.2.1 Experiment 1: Fibroblast Sheets on UpCellTM Plate 
 The design team explored the use of NUNC UpCellTM 24-well plates (Thermo Fisher 
Scientific, Inc.). These plates contain temperature-responsive NIPAAM (poly(N-
isopropylacrylamide)) surfaces that allow for easy harvesting of cell sheets. When the 
temperature of the culture decreases, the NIPAAM surfaces release the adherent cells with their 
structural proteins intact (Thermo Fisher Scientific, 2010). From this experiment, the team 
wanted to develop a method for growing the cells into a sheet and harvesting these sheets.  
Human neonatal fibroblasts were grown to 80% confluence in complete DMEM at 5% 
CO2. Due to a low supply of fibroblasts only 7 wells were seeded. Fibroblasts at p10 were 
seeded in three wells at 2x106 cells/cm2 and one well at 1x106 cells/ cm2. Fibroblasts at p7 were 
seeded in three wells at 2x106 cells/cm2. The experimental set up is shown in Table 18.  
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Table 18: Experimental Setup of Fibroblast Sheets 
UpCellTM 1 2 3 4 5 6 
NHF p7 2x106 2x106 2x106 1x106                
NHF p10 2x106 2x106 2x106    
       
       
 
After 24 hours, the team observed the formation of cell sheets in all of the wells (see 
Figure 23). These sheets were dislodged from the bottom and sides of the plate and were 
beginning to form into balls. As seen in Figure 23, the media in wells 1-3, containing p7 
fibroblasts seeded at 2x106 cells/cm2, were very yellow, while the media in wells 5-7, containing 
p7 fibroblasts at the same concentration, remained pink. Because these six wells should have 
contained the same amount of cells, the media should have looked the same color after 24 
hours. Therefore, it is likely that since the media in wells 1-3 were yellow, more cells were 
delivered to those wells. Because the p10 and p7 fibroblasts were counted at different times, it 
is likely that an error occurred in the cell count. Despite this discrepancy, the design team 
reasoned that the sheets might have dislodged for three reasons: 1) both the 2x106 cells/cm2 
and 1x106 cells/ cm2 seeding densities were too high for the cells to form proper sheets, 2) the 
cells were nutrient deprived, 3) the UpCellTM surfaces were compromised due to a long storage 
period.  
The design team noticed that in wells 1-4, all of the fibroblasts were incorporated into the 
formation of the detached cell sheet. However, in wells 5-7, some fibroblasts remained attached 
to the bottom of the plate and had not been incorporated into the cell sheet. These sheets were 
further cultured as described in Experiment 1A. 
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Figure 23: Fibroblast CDSs after 24 Hours on UpCell Plate 
One floating cell sheet at each density (wells 1 and 5) were processed and stained with 
Hoechst, Hematoxylin and Eosin (H&E), and Picrosirius Red/Fast Green (see Appendix H: 
Staining Protocols for Paraffin Sections).  
Figure 24 shows the histology of the cell sheet with p10 fibroblasts (images A-C) and the 
cell sheet with p7 fibroblasts (images D-F). The images show that the fibroblasts aggregated 
into a sheet overnight. However, the Picrosirius Red/Fast Green stains (C and F) show that no 
collagen was formed in the cell sheet because no red-stained fibers are observed. This 
suggests that the cells had not been in culture long enough to produce collagen.  
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5.2.2 Experiment 1A: Fibroblast Sheets on UpCell Plate 
 Although the concentration of cells was unknown, the fibroblasts that remained on the 
bottom of the UpCellTM plate in three wells from Experiment 1 were kept in culture. These cells 
were maintained in IMDM with 5% FBS. Ascorbic acid was added at 50 μg/mL when the cells 
were fed. The media was changed (1mL) every 48 hours. While in culture, cell sheets visually 
formed on the bottom of the wells. Figure 25 shows the cell sheet after 12 days in culture. 
A D 
B 
C 
E 
F 
Figure 24: Histology of fibroblast CDSs after 24 hours on UpCell plate. Figures 
A and D are stained with Hoechst; B and E with H&E; and C and F with 
Picrosirius Red. 
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Figure 25: Fibroblast CDS after 12 Days on UpCell Plate 
After 17 days, parts of the cell sheet had begun to detach from the sides of the well. That 
same day, the sheets were harvested by placing the UpCellTM plate at 25°C for 60 minutes. 
Tweezers were used to pull the tissue off the plate. The sheets came off the plates easily and 
were placed in PBS. One CDS was removed for processing (see Appendix G). 
Figure 26 shows the histology of the CDS. Although the sheet does not look as thick and 
cohesive as the CDS from Experiment 2, the Picrosirius Red stain clearly shows that the 
production of collagen (red) was greater in these cell sheets (Figure 26C). 
 
5.2.3 Experiment 2: Anchors on RASMC Sheets 
 Because the higher density tissues dislodged from the plate overnight, the design team 
wanted to be sure that tissues with an initial lower density would not dislodge over time in 
culture. The team decided to use an anchor to restrain the cell sheets from contracting into a 
A B C 
Figure 26: Histology of Fibroblast CDSs after 17 Days on UpCell Plate. Figure A is stained with Hoechst; B 
with H&E; and C with Picrosirius Red/Fast Green. 
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ball. The anchor consisted of a porous polyethylene ring cut to the dimensions of the 2 cm 
diameter well. By using a polyethylene mesh, the cell sheet could integrate into the mesh and 
be harvested as a flat sheet. Since the polyethylene floats in media, a stainless steel washer 
was placed over the ring to secure it against the bottom. The following diagram shows the setup 
of the ring and washer in the well (see Figure 27). 
 
Figure 27: Anchor System 
Because fibroblast supply was insufficient for seeding, the team used rat aortic smooth 
muscle cells (RASMCs) this experiment. To test the effectiveness of the anchors, the team 
seeded the RASMCs at higher densities that would form tissues overnight according to 
Experiment 1. If the anchors were able to hold down these CDSs of higher densities, then the 
anchors would be an effective method to control the cell sheets. The team also seeded at lower 
densities to observe the effects of the anchors when the CDS formed from a subconfluent 
density. The cells were seeded in 6 wells each of 500,000 cm2/mL, 250,000 cm2/mL, 100,000 
cm2/mL, and 50,000 cm2/mL. Each density was plated with and without an anchor. The following 
chart shows the experimental setup of the plate (see Table 19). 
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Table 19: Experimental Setup using Anchors on RASMCs 
TCPS 1  2  3  4 5 6 
- anchor 50,000 50,000 50,000 100,000  100,000  100,000  
+ anchor  50,000 50,000 50,000 100,000  100,000  100,000  
- anchor  250,000  250,000  250,000  500,000 500,000 500,000 
+ anchor 250,000 250,000 250,000 500,000 500,000 500,000 
  
The cells were plated in 1mL of IMDM on standard tissue culture polystyrene plates and 
were observed after 24 hours. Figure 28 shows the plate after 1 day in culture. Visible cell 
sheets formed in all of the wells that had been seeded at 500,000 cells/cm2 or 250,000 cells/cm2 
(Figure 28). Regardless of the anchor, these sheets had all dislodged from the bottom of the 
plate and contracted. Figure 29 shows the cell sheets that dislodged. Figure 30 shows that the 
RASMCs seeded at lower densities with and without anchors formed sheets that remained 
attached to the bottom of the well. 
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(-) 500,000 (-) 250,000 
(+) 500,000 (+) 250,000 
Figure 29: Setup for Anchor Experiment 
Figure 28: RASMC CDSs with Anchors after 24 Hours on TCPS 
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Figure 30: RASMC CDSs at 50,000 and 100,000 cells/cm2 with and without anchors 
 Because the anchors were not able to hold down the cell sheets that formed in the 
higher density wells, the team believed that the anchors would not be useful for the lower 
density wells in a longer culture. Furthermore, the cell sheets on the UpCellTM plate with 
unknown density of fibroblasts were very easy to detach from the plate without the use of an 
anchor and had remained adhered to the well bottom for 17 days (Experiment 1A). Therefore, 
the team decided that anchors were unnecessary, and the most important aspect was growing 
these cell sheets for two weeks following a seeding at a sub-confluent density of 100,000 
cells/cm2. 
5.2.4 Experiment 3: Lower Density Fibroblast CDSs on UpCellTM Plates 
 Using the results from the proof-of-concept experiments, the team decided that the 
fibroblast cell sheets should be cultured on UpCellTM plates at densities lower than 250,000 
cells/cm2. Because Experiment 2 with RASMCs could not be completely translatable, a variety 
of densities were chosen to explore, including 100,000 cells/cm2, 50,000 cells/cm2, 25,000 
cells/cm2, and 12,500 cells/cm2.  
(-) 50,000 (-) 100,000 
(+) 50,000 (+) 100,000 
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Fibroblasts were grown in complete IMDM until passage 11. The fibroblasts were 
seeded on one plate at 100,000 cells/cm2 and 50,000 cells/cm2. To be able to observe the 
effects of ascorbic acid on the mechanical strength of the tissue, columns 1-3 were fed with 50 
μg/mL of ascorbic acid and columns 4-6 were not treated with ascorbic acid. Accordingly, a total 
of 6 samples for each density received the ascorbic acid treatment. Table 21 shows the 
experimental setup, with the cell densities shown and (+aa) corresponding to the ascorbic acid 
treatment. 
Table 20: Experimental Setup of Fibroblasts on UpCell
TM
 Plate 1 
UpCellTM Plate 1 1  
(+aa) 
2  
(+aa) 
3 
(+aa)  
4 
(-aa)  
5 
(-aa)  
6 
(-aa)  
[cells/cm2] 100,000 100,000 100,000  100,000  100,000  100,000  
[cells/cm2] 100,000 100,000 100,000  100,000  100,000  100,000  
[cells/cm2] 50,000  50,000 50,000 50,000  50,000  50,000  
[cells/cm2] 50,000  50,000 50,000 50,000 50,000 50,000 
 
On a second UpCellTM plate, cells were seeded at two lower densities (25,000 cells/cm2 
and 12,500 cells/cm2) in the event that the seeding densities in the first UpCellTM plate were still 
too high, leading to the tissues dislodging during culture. Table 21 shows the experimental 
setup. The goal was to find the maximum number of cells that could be used to create cell sheet 
formation without detaching from the bottom of the well over time.  
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Table 21: Experimental Setup of Fibroblasts on UpCell
TM
 Plate 2 
UpCellTM Plate 2 1 
(+aa)   
2 
(+aa)   
3  
(+aa) 
4 
(+aa)  
5 
(+aa)  
6 
(+aa)  
[cells/cm2] 25,000 25,000 25,000  25,000  25,000  25,000  
[cells/cm2] 12,500 12,500 12,500  12,500  12,500  12,500  
 
These cell sheets remained in culture for two weeks. Media (1mL) was changed every 
other day, and 50μg/mL of ascorbic acid was freshly added for sheets receiving treatment. To 
harvest the sheets, the UpCellTM plates were left at room temperature for 60 minutes. The 
sheets were then peeled away from bottom of the well. No noticeable damage occurred during 
harvesting, however the cell sheets contracted if not submerged in liquid. Figure 31 shows a 
freshly harvested fibroblast sheet at 100,000 cells/cm2 pinned to a PDMS platform. As seen in 
Figure 31, the sheets do not remain flat without manipulation. Figure 32 shows that noticeable 
macroscopic differences in size and opacity of the tissues can be observed between the 
100,000 cells/cm2 and 50,000 cells/cm2 grown with ascorbic acid. This was true for cell sheets 
derived from cells seeded at all initial cell seeding densities. 
    
Figure 31: Freshly harvested fibroblast sheets (100,000 cells/cm2) 
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Figure 32: Fibroblast sheets with ascorbic acid. (A) 100,000 cells/cm
2
, (B) 50,000 cells/cm
2
  
After harvesting, the CDSs were characterized. One cell sheet at each density and with or 
without ascorbic acid treatment was processed immediately. One cell sheet at each density (all 
with ascorbic acid) was subjected to either freeze-thaw, SDS, or hypertonic/hypotonic solutions 
(as described in 5.3: Decellularization, pp. 116). After processing, these sheets were sectioned 
and stained using Hoechst, H&E, and Picrosirius Red/Fast Green. Additionally, one cell sheet 
with and without ascorbic acid at each density was subjected to mechanical testing (as 
described in 5.4: Mechanical Testing of Tissues, pp. 130). 
Histology was performed to determine (1) if ascorbic acid affected collagen production 
and tissue structure and (2) which density was optimal for creating a cohesive cell sheet. 
Because the tissue samples were so small, some samples were lost during processing and 
embedding. The protocol was revised in future experiments to eliminate this problem.  
Picrosirius Red/Fast Green staining was used to observe the contribution of collagen 
production from ascorbic acid. Figure 33 shows the differences in collagen production between 
cell sheets seeded at 100,000 cells/cm2 cultured with ascorbic acid (Figure 33B) and without 
ascorbic acid (Figure 33A). The cell sheet in Figure 33B has visibly more collagen synthesis 
(red fibers); however, production was limited to only one side of the sheet. These images were 
representative of cell sheets grown at all densities.  
B A 
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Figure 33: Picrosirius Red/Fast Green Stains of CDSs. (A) Untreated, (B) 50μg/mL Ascorbic Acid 
5.2.5 Experiment 4: Final Validation of Fabricating CDSs 
The goal of this experiment was to (1) validate fibroblast sheet fabrication method, (2) 
measure tissue thickness, (3) evaluate collagen synthesis in cell sheets treated with or without 
ascorbic acid, (4) assess the strength of sheets with and without ascorbic acid, (5) assess 
strength of tissues before and after decellularization, and (6) perform histological analysis (H&E 
and Hoechst staining) on decellularized tissues to assess preservation of tissue structure and 
nuclei, respectively. 
The final fibroblast sheets were seeded at 100,000 cells/cm2 on UpCellTM plates and 
were cultured in IMDM with 5% FBS at 5% CO2 for 14 days. Media (1mL) was changed every 
other day, and 50μg/mL of ascorbic acid was freshly added for sheets receiving treatment. To 
utilize the amount of cells that the team could obtain, fibroblasts cultured to two different 
passage numbers were used (p6 and p12). Table 22 shows the experimental setup, with dark 
blue representing p6 fibroblasts and light blue representing p12 fibroblasts. Wells marked with a 
plus sign were treated with ascorbic acid, while wells with a minus sign did not receive ascorbic 
acid. 
After two weeks of culture, the sheets were harvested. After sitting at room temperature 
for 60 minutes, the sheets were peeled from the UpCellTM plates. Five cell sheet samples had 
detached from the bottom of the plate by the end of the culture period and were not used for 
testing. These included two p12 with ascorbic acid, two p6 with ascorbic acid, and one p6 
A B 
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without ascorbic acid, and are marked with X’s in Table 22. The cell sheets detaching from the 
plate while in culture was surprising, since this was not the case in Experiment 3 for the same 
cell density. 
Two sheets treated with ascorbic acid and two sheets treated without ascorbic acid were 
fixed and processed. These sheets are marked “P” in Table 222. The processing protocol was 
modified so that tissue sheets were placed inside a folded piece of filter paper, which was 
sandwiched between two sponges and then secured in a cassette. Three sheets treated with 
ascorbic acid and three sheets treated without ascorbic acid were used for mechanical testing 
immediately after harvesting (see Section 5.3.4.2.3). These sheets are marked “M” in Table 
222. Five sheets marked with “DP” or “DM” were set aside for decellularization and subsequent 
processing and mechanical testing, respectively; however the team was not able to complete 
these protocols. 
Table 22: Experimental Setup for Final Fibroblast Sheets 
UpCell PlateTM 1 2 3 4 5 6 
A (+) P (+) P (+) X (-) M (-) M (-) M 
B (+) M (+) M (+) M (+) DP (-) P (-)P  
C (+) DP (+)DM (+) DM (+) X (-) X (-) M 
D (+) X (+) X (+) DM (+) (-) (-) 
 
Figure 34 shows a picture of a fibroblast sheet, which was macroscopically 
representative of sheets grown with and without ascorbic acid. However, Figure 35 shows that 
the cellular orientation appeared to vary in sheets cultured with (Figure 35B) and without (Figure 
35A) ascorbic acid. 
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Figure 34: Freshly Harvested Fibroblast Sheet for Mechanical Testing 
 
Before harvesting, tissue thickness was determined using a Mitutoyo absolute digital 
caliper in conjunction with an Olympus CK2 confocal microscope. The microscope was focused 
on the bottom of a blank well to determine the starting distance. The change in distance was 
recorded as the position of the objective moved to where the top layer of the cell sheet became 
just out of focus, which equated to the thickness of the cell sheet. The thicknesses of the sheets 
are recorded in Table 23. T-test was used to compare the thicknesses of the two groups, and 
showed that there was a significant difference (p=0.047 < p=0.05) between the cell sheets 
grown with and without ascorbic acid. 
  
 
Figure 35: Cellular Alignment of Fibroblast Sheets. (A) Untreated Ascorbic Acid, (B) 50μg/mL 
Ascorbic Acid 
A B 
A B 
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Table 23: Cell Sheet Thickness 
 (-aa) (+aa) 
0.365 0.446 
0.337 0.283 
0.25 0.447 
0.405 0.456 
0.302 0.359 
0.296 0.423 
0.355 0.457 
0.215 0.339 
 0.281 
Average 0.315625 0.387889 
Std Dev 0.058562 0.069259 
 
Picrosirius Red/Fast Green stain was used to identify collagen production in the 
fibroblast cell sheets. This stain identifies collagen fibers in red and non-collagenous fibers in 
green. Figure 36 shows representative images of fibroblast sheets with and without ascorbic 
acid. Sheets cultured in the presence of ascorbic acid visibly had more collagen (red) 
throughout the tissue. The boxes in Figure 36 represent the areas imaged at higher 
magnification (Figure 37). Figure 37 better identifies the difference in collagen production 
between the two cell sheets. No collagen is observed in the sheets grown without ascorbic acid. 
 
A B 
 
 
Figure 36: Picrosirius Red/Fast Green Stain of Fibroblast Sheets. (A) Untreated, (B) 50μg/mL Ascorbic 
Acid 
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5.3 Decellularization 
The team evaluated three different decellularization methods—SDS, freeze-thaw, and 
hypotonic and hypertonic solutions.  As previously discussed, decellularizing tissues isolates the 
ECM and its beneficial elements while removing any components that might elicit an immune 
response in the patient (e.g., cells and cellular material). 
5.3.1 Experiment 5: SDS Decellularization 
The sodium dodecyl sulfate (SDS) decellularization (see Figure 38) was conducted 
according to a modified protocol by Elder et al. (Elder et al., 2009). Both the fabricated CDSs 
and foreskins were used for decellularization testing. Neonatal foreskins (received from UMass 
Memorial University Hospital with IRB approval) were used as a model tissue when CDSs were 
unavailable (see Appendix I: Decellularization Protocols).  Per the original protocol, sodium 
dodecyl sulfate is dissolved into 1X phosphate buffered saline (PBS) to produce a 2% working 
solution. Samples are then placed in the solution in a 37°C shaking water bath for 1 hour. The 
team modified this step by spinning the samples on a Glas-Col tube rotator (Glas-Col) at 33rpm 
due to unavailability of a shaking water bath. The samples are then washed in 1X PBS five 
times at room temperature for 10 minutes each on a Labquake tube shaker (Thermo Fisher 
Figure 37: Picrosirius Red/Fast Green Stain of Fibroblast Sheets. (A) Untreated, (B) 50μg/mL 
Ascorbic Acid 
 
A B 
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Scientific, Inc.) to conclude the protocol. The team also incorporated a DNase treatment after 
the final wash. Samples were treated with 0.5mL of DNase I (Worthington, 1mg/mL, 10mM 
MgCl2) for 15 minutes while rotating at room temperature on the Labquake, followed by three 5 
minute washes in PBS while rotating at room temperature on the Labquake. Both the original 
protocol and modified protocol are available in Appendix I: Decellularization Protocols. 
 
Figure 38: SDS Decellularization Approach 
5.3.1.1 Experiment 5A: SDS Decellularization of Foreskins 
 Foreskin samples were prepared by cutting the tissue in 1cmx1cm sized samples. The 
fatty tissue beneath the dermis was briefly scraped off. Samples were then treated according to 
the SDS protocol (see Appendix I: Decellularization Protocols) with rotation on the Glas-Col 
tube rotator (Glas-Col) at 33rpm. After completing the protocol, the samples were fixed in 
formalin for 1 hour and processed (see Appendix G). The samples were then embedded, 
sectioned, and stained with Hematoxylin and Eosin (H&E), Hoechst, and Picrosirius Red/Fast 
Green. Figure 39B illustrates the presence of nuclei throughout the dermis after treatment with 
SDS, as confirmed by the Hoechst image in Figure 40B. However, Figure 40C shows less 
defined nuclei at the dermal region farthest from the epidermis, suggesting that the SDS was 
unable to penetrate through the entire tissue. 
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5.3.1.2 Experiment 5B: SDS Decellularization of Foreskins with DNase I 
The team repeated the SDS treatment following the modified protocol that includes 
spinning on the Glas-Col and DNase treatment following the wash steps due to the high levels 
of DNA observed in Experiment 5A. Following decellularization for 1 hour at 37degrees Celsius, 
each sample was rotated on the Labquake for 1 hour at room temperature in a solution of PBS 
and 0.2mg/mL of DNase plus 10mM MgCl2 (Grauss, Hazekamp, van Vliet, Gittengerger-de 
Groot, & DeRuiter, 2003). 
Following decellularization and DNase treatment, three samples were set aside for 
mechanical testing and two samples were fixed overnight in formalin, processed, embedded, 
and stained with H&E, Hoechst, and Picrosirius Red Fast Green (see Figure 41). Figure 41A 
shows persistent cellularization on the external side of the sample and Figure 41C shows no 
noticeable disruption of DNA in the epidermis. In Figure B, however, we observed that the 
dermal region that interfaces with the subcutaneous layer lacks nuclei. Hoechst staining in 
Figure 39: H&E Staining of SDS Decellularized Foreskin. Figure A is a 
control foreskin and Figure B is of SDS decellularized foreskin. 
Figure 40: Hoechst Staining of SDS Decellularized Foreskins. Figure A is a control Foreskin; Figure B 
is the external side of SDS decellularized foreskin; and Figure C is the internal side of SDS 
decellularized foreskin. 
B 
A B C 
A 
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Figure 41D confirmed the extent of decellularization observed in H&E. While sections of the 
tissue are still cellularized, it is clear that the genetic material in other sections of the tissue have 
been highly disrupted as no distinct nuclei can be seen. In Figure 41E-F, we noted that collagen 
was retained after decellularization, as indicated by the dark red stain. 
                
5.3.1.3 Experiment 5C: SDS Decellularization of CDSs 
Following Experiment 3, in which CDSs were cultured at various densities with and 
without ascorbic acid, two CDSs were treated with SDS using the Glas-Col at 33rpm for the first 
rotation step. The tissues were harvested and immediately placed in a 1.5 Eppendorf tube with 
1 mL 2% SDS. Due to the fragility of the tissues, the team did not apply the DNase treatment in 
order to prevent complete disintegration of the tissue.  
B 
E F 
C D 
A 
Figure 41: Histology of SDS with DNase Decellularized 
Foreskins Green. Figures A and B are stained with H&E; Figures 
C and D with Hoechst; and Figures E and F with Picrosirius 
Red/Fast Green 
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Following the protocol, the tissues were processed, embedded, and stained with 
Hoechst. Figure 42A is the control tissue and is representative of all non-decellularized 
samples, regardless of the seeding density or addition of ascorbic acid; Figure 42B, however, is 
of the only surviving SDS sample after processing. At the conclusion of decellularization 
protocol, the other SDS sample had been disintegrated into pieces and was too fragile for 
processing. The remaining sample (Figure 42B) does not exhibit distinct nuclei, but rather 
fluorescence from the breakdown of the genetic material, demonstrating decellularization of the 
sheet. 
           
5.3.1.4 Experiment 5D: Final Validation of Decellularizing Foreskins using SDS 
Due to availability of the cell-derived sheets, the team continued testing on neonatal 
foreskins as proof-of-concept of the final SDS decellularization protocol. Six samples were 
treated according to the final, modified version of the protocol using the Glas-Col rotator and 
revised DNase concentration (see Appendix I: Decellularization Protocols). Samples were 
prepared by scraping off fatty tissue and cutting the tissue to the size of 0.5cm x 0.25cm and 
immediately placed in a 1.5mL conical tube with 1mL SDS and rotated at 37 degrees Celsius on 
the Glas-Col at 33rpm. In order to determine more exact specifications of the protocol, time 
points and the addition of DNase were considered. For each time point (1 hour, 5 hours, 24 
hours), one sample was treated with DNAse and one sample without DNase. Treated samples 
received 0.5mL of DNase I (Worthington, 1mg/mL, 10mM MgCl2) and were rotated on the 
A B 
Figure 42: Hoechst Stains of Decellularized CDSs. (A) Control, (B) SDS-
decellularized 
121 
 
Labquake for 15 minutes at room temperature, followed by three 5 minutes PBS washes per the 
protocol in Appendix I: Decellularization Protocols. Tissues with and without DNase treatment 
were taken from the same foreskin in order to control structural and cellular variability.  
Following decellularization, samples were fixed, embedded, processed, and stained with 
H&E (Figure 43B,D,H,L,F,J,N) and Hoechst (Figure 43A,C,G,K,E,I,M).  Control images are 
shown in Figure 43A-B, 1 hour SDS in Figure 43C-F, 5 hour SDS in Figure 43G-J, 24 hour SDS 
in Figure 43K-N, without DNAse treatment in Figure 43C,D,G,H,K,L and with DNAse treatment 
in Figure 43E,F,I,J,M,N. Figure 43C shows incomplete breakdown of genetic material 
throughout the tissue, as confirmed by nuclei remaining in the H&E (Figure 43D). In Figure 43E, 
however, the epidermis has been separated from the dermis, with Hoechst indicating 
degeneration of DNA throughout the dermis and H&E confirming decellularization of the dermis. 
Figure 43G shows partial decellularization of the dermis, but no removal of genetic material in 
the epidermis, as confirmed by nuclei present in Figure 43H. With the DNAse treatment (Figure 
43I), there is more complete decellularization in the dermis, as observed by no defined nuclei, 
unlike the epidermis which still has defined nuclei. The Hoechst images for both 24 hour 
samples show decellularization of the dermis (Figure 43K,M), as confirmed by no visible nuclei 
in the H&E (Figure 43L,N). Figure 43N shows extensive damage to the dermal region, which is 
noticeably thinner than other samples, due to the extensive SDS wash and subsequent DNAse 
treatment. This aggressive protocol may also explain the lack of genetic material in Figure 43K, 
which was not treated with DNAse. 
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5.3.2 Experiment 6: Freeze-Thaw Decellularization 
The team modified the protocol published by Ngangan and McDevitt (Ngangan & 
McDevitt, 2009). Samples are placed in a 1.5mL Eppendorf tube and immersed in liquid 
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Figure 43: Hoechst and H&E Stains of SDS-decellularized Foreskins 
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nitrogen for 2 minutes. 1mL of 1X PBS is then added to each tube and the samples are rotated 
for 5 minutes at room temperature on the Labquake tube rotator. The PBS is then aspirated and 
the process repeated for a total of three cycles. Each sample was then treated with 0.5mL of 
DNase I (Worthington, 1mg/mL, 10mM MgCl2) while rotating at room temperature on the 
Labquake. Samples are then washed three times for 5 minutes each in 1X PBS and left on the 
benchtop to sit for 8 hours. The team adapted this protocol from the original version which 
included centrifugation and did not include a DNase step. Both the original and modified 
protocols are reported in Appendix I: Decellularization Protocols.  
 
Figure 44: Freeze-Thaw Decellularization Approach 
5.3.2.1 Experiment 6A: Freeze-thaw Decellularization of Foreskins 
Five samples were decellularized according to the reported protocol without the DNase 
treatment. Samples were prepared by scraping off fatty tissue and cutting the tissue to the size 
of 1.0cmx1.0cm and immediately placed in a custom-made aluminum foil “boat” for better 
thermal conductivity. The boat was floated on the liquid nitrogen for 30 seconds. The samples 
were then rotated in 1 mL of 1X phosphate buffered saline (PBS) for five minutes at room 
temperature. Because the centrifuging step was specifically created to pellet the embryoid 
bodies in the reported experiment (Ngangan & McDevitt, 2009), this step was bypassed by the 
team. The whole freeze-thaw cycle was completed three times. Each sample was then rotated 
on the Labquake for 1 hour at room temperature in a solution of PBS and 0.2mg/mL of DNase 
plus 10mM MgCl2 (Grauss et al., 2003). 
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Following freeze-thaw treatment, three samples were set aside for mechanical testing 
and two samples were fixed overnight in formalin, processed, embedded, and stained with H&E, 
Hoechst, and Picrosirius Red/Fast Green (see Figure 45). The H&E staining in Figure 45A-B 
indicates very little decellularization in all regions of the tissue sample. This is confirmed by 
Hoechst staining in Figure 45C. Figure 45D shows that collagen has been retained after 
decellularization. 
                            
5.3.2.2 Experiment 6B: Freeze-thaw Decellularization of CDSs 
Upon availability of CDSs, freeze-thaw was performed on freshly-harvested sheets. Two 
samples from Experiment 3, in which CDSs were cultured at various densities with and without 
ascorbic acid, were frozen in liquid nitrogen for about 2 minutes using the aluminum foil boat 
method (see Figure 46). Each sample was then placed in a 1.5mL Eppendorf tube. Each tube 
received 1 mL PBS and was rotated on the Labquake for 5 minutes at room tempertature. The 
cycle was repeated for a total of 3 cycles. The samples were not treated with DNase due to 
A B 
C D 
Figure 45: Histology of Freeze-Thaw with DNase Decellularized Foreskins. 
Figures A and B are stained with H&E; Figure C with Hoechst; and Figure 
D with Picrosirius Red/Fast Green. 
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concern that the treatment and subsequent washes would completely disintegrate the cell 
sheet.  
 
Figure 46: "Boat" for Freeze-Thaw. Red arrow indicates CDS. 
After the treatment, two tissues were processed, embedded, and stained with Hoechst. 
Figure 47B positively compares to the control Figure 47, expressing distinct nuclei throughout 
the entire sheet and demonstrating no decellularization. 
                   
5.3.2.3 Experiment 6C: Final Validation of Decellularizing Foreskins using Freeze-Thaw 
Foreskins were again decellularized as proof-of-concept to finalize a freeze-thaw 
protocol. Five samples were prepared by scraping off fatty tissue and cutting the tissue to the 
size of 0.5cm x 0.25cm. In order to determine optimal conditions, 2 samples were left to sit for 8 
hours in PBS at room temperature before fixation and 2 samples were fixed immediately 
following the conclusion of the protocol. One sample from each condition received the DNase 
treatment (0.5mL of 1mg/mL DNase plus 10mM MgCl2) (Ngangan & McDevitt, 2009) 
A B 
Figure 47: Hoechst Stains of Freeze-thawed CDSs. (A) Control, (B) 
Freeze-thaw-decellularized 
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immediately following the freeze-thaw cycles. A final sample was first left to sit for 8 hours, then 
treated with DNase, and then finally fixed. Tissues with and without DNase treatment were 
taken from the same foreskin in order to control structural and cellular variability.  
At the conclusion of the protocol, samples were fixed, embedded, processed, and 
stained with H&E (Figure 48B,D,F,H,J,L) and Hoechst (Figure 48A,C,E,G,I,K).  Control images 
are shown in Figure 48A-B, without DNAse treatment in Figure 48C,D,G,H, with DNAse 
treatment in Figure 48E,F,I,J,K,L, fixed immediately in Figure 48C-F, fixed after 8 hours in 
Figure 48G-J, and treated with DNAse after waiting 8 hours in Figure 48K-L. Samples without 
DNAse treatment retained intact nuclei (Figure 48C,G); however, the sample that was fixed after 
8 hours had visually less nuclei. The more complete decellularization of the dermis in the 
sample that was fixed after 8 hours is verified by confirming Figure 48D,H. In the samples with 
DNAse treatment, the Hoechst images again show further decellularization in tissue fixed after 8 
hours Figure 48I. While there are still distinct nuclei in the epidermis of the sample fixed after 8 
hours, the dermis has been visually completed decellularized, as confirmed by the H&E Figure 
48J. The sample treated with DNase after the 8 hour waiting period shows only partial 
decellularization of the dermis and no noticeable decellularization of the epidermis (see Figure 
48K,L). 
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5.3.3 Experiment 7: Hypotonic and Hypertonic Solutions Decellularization 
Meyer et al.’s protocol (Meyer et al., 2006) was used for the hypotonic and hypertonic 
solution decellularization (see Appendix I: Decellularization Protocols). All buffers were prepared 
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Figure 48: Hoechst and H&E Stains of Freeze-thawed Foreskins 
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by the team before decellularization by dissolving the components in deionized water and all 
rotations were completed on a Labquake tube rotator. Due to availability, PMSF, a serine 
protease inhibitor, was substituted with Complete, Mini, EDTA-free Protease Inhibitor Cocktail 
Tablets (Roche Applied Science). Also, based on other protocols in literature (Ngangan & 
McDevitt, 2009; Schaner et al., 2004), the team only included the DNase I in the solution and 
did not include the RNAse A as per the original protocol. Both the original protocol and the 
team’s modified protocol are reported in Appendix I: Decellularization Protocols 
5.3.3.1 Experiment 7A: Hypotonic and Hypertonic Solutions Decellularization of 
Foreskins 
Five samples were first submerged in a hypotonic tris HCl buffer (10mM, pH 8.0) 
solution with  EDTA (5mM) and Complete, Mini, EDTA-free protease inhibitor cocktail tablets 
(Roche Applied Science) and allowed to rotate at 4 degrees Celsius. One cocktail tablet was 
used per 10 mL of buffer. After rotating in this solution for 48 hours, the samples were 
transferred to a hypertonic tris HCl buffer solution (50mM, pH 8.0) with EDTA (5mM), KCl 
(1.5M), Triton X-100 (0.5%), and the cocktail tablets instead of PMSF. Again, the samples 
rotated for 48 hours at 4 degrees Celsius. The tissues were then rinsed in a Sorensen’s buffer 
solution (pH 7.3) with DNase I (Worthington, 25mcg/mL) and MgCl2 (10mM) to activate the 
DNase. The samples were rotated in this solution for 5 hours in 37 degrees Celsius, after which 
point they were transferred to a tris base buffer (50mM, pH 9.0) with Triton X-100 (0.5%) and 
allowed to rotate for 48 hours at 4 degrees Celsius. The samples were then rotated at 4 degrees 
in 1X PBS for 72 hours, changing the wash every 24 hours. 
At the conclusion of the final was, three samples were set aside for mechanical testing 
and two samples were fixed overnight in formalin, processed, embedded, and stained with H&E, 
Hoechst, and Picrosirius Red/Fast Green (see Figure 49). Similar to SDS, H&E and Hoechst 
show cellularization in the epidermis and regions of the dermis (Figure 49A,C). In Figure 49D, 
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however, various regions of indistinct nuclei suggest partial decellularization of the dermis. 
Again, we observed collagen retention in the Picrosirius Red/Fast Green staining (Figure 49D).  
         
5.3.3.2 Experiment 7B: Hypotonic and Hypertonic Solutions Decellularization of CDSs 
After the culture of CDSs in Experiment 3, in which tissues were cultured at varying 
densities with and without ascorbic acid, two samples were decellularized using hypotonic and 
hypertonic solutions. Each sheet was placed in a 1.5mL Eppendorf tube and underwent the 
exact protocol that is listed Appendix I: Decellularization Protocols and was used in the previous 
experiment on foreskins. 
At the conclusion of the treatment, two tissues were processed, embedded, and stained 
with Hoechst. The decellularized sample (Figure 50B) resembles the control tissue (Figure 
50A), displaying distinct nuclei throughout the tissue and no visible signs of decellularization. 
Figure 49: Histology Staining of Hypotonic and Hypertonic Solutions. 
Decellularized Foreskins. Figure A is stained with H&E; Figure B with 
Picrosirius Red; and Figure D with Hoechst. 
C 
A B 
D 
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5.4 Mechanical Testing of Tissues 
The mechanical integrity of CDSs, as well as decellularized foreskins, was determined 
through tensile testing to failure on an Instron ELECTROPULS E1000, using a strain rate of 
10mm/min. Tissues were hydrated in 1X PBS until testing. Appropriate grips and load cells were 
determined through experimentation. 
5.4.1 Uniaxial Tensile Testing of Decellularized Foreskins 
A total of 12 foreskin samples were set aside for testing—three samples from each 
decellularization method and three non-decellularized control tissues. Testing dimensions 
(tissue width, tissue thickness, distance between grips) were measured with an electronic digital 
caliper (VWR). The control samples were received less than a week prior to testing and were 
held in foreskin media at 4 degrees Celsius until testing. Various sized grips were tested to 
determine the most appropriate grips (see Figure 51). The team first experimented with small 
clamps and a 50N load cell. The small clamps were unable to fully grip the tissue during the 
test. The team then tried using larger grips with a 2kN load cell, but the tissue continued to slip 
through the grips as the tissue was pulled. Sandpaper meshes (Figure 51C) were then 
implemented to hold the tissue while in the clamps (see Figure 52), which helped the tissue 
remain in the grips for an extended period of time, but the tissue still slipped before fracture. The 
team’s final approach added gauze in between the mesh to keep the ends of the tissue dry. 
A B 
Figure 50: Hoechst Stains of Hypotonic/Hypertonic-Solutions Decellularized CDSs. 
(A) Control, (B) Hypotonic/Hypertonic-decellularized 
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However, no method was able to retain the tissue during the testing procedure until failure. The 
team was unable to collect any data.  
 
                                                           
Figure 52: Decellularized Foreskin in Grips during Mechanical Testing 
5.4.2 Uniaxial Tensile Testing of CDSs 
Tensile testing was used to determine the contribution of ascorbic acid to the mechanical 
strength of the fibroblast-derived sheets. Freshly harvested fibroblast sheets from Experiments 
3 and 4 were used to develop a final protocol for uniaxial tensile testing and analysis of the 
mechanical data. The raw data was filtered using a MATLAB code developed by Jason Hu. 
5.4.2.1 Uniaxial Tensile Testing of CDS from Experiment 3 
Fibroblast cell sheets with and without ascorbic acid at densities of 100,000 cells/cm2, 50,000 
cells/cm2, 25,000cells/cm
2, and 12,500 cells/cm2 were tensile tested immediately after 
harvesting. A 50N load cell was used with small, custom grips. Gauze was placed so that it held 
each end of the cell sheet inside of each grip (Figure 53). The samples were pulled to failure on 
an Instron ELECTROPULS E1000 at a rate of 10mm/min. Preparation of the samples for 
A B C 
Figure 51: Mechanical Testing Setup Accessories. Figure A is the small grips that were first used; Figure B 
is the large grips; and Figure C is the sandpaper meshes. 
132 
 
mechanical testing included measuring the width, thickness, and distance between the clamps 
using a manual electronic caliper (VWR) when the cell sheets were loaded in the Instron. Table 
24 shows the measurements and results from this experiment. Most of the samples without 
ascorbic acid broke during preparation for mechanical testing. 
 
Figure 53: Tensile Testing of Cell-Derived Fibroblast Sheets 
Table 24: Measurements and Observations of Mechanical Testing 
Sample and  Condition Measurements 
Area 
(mm
2
) 
Maximum 
Stress (kPa) 
Observations Cell Density 
(cells/cm
2
) 
Ascorbic 
Acid 
Treatment 
Thickness 
(mm) 
Width 
(mm) 
Grip 
distance 
(mm) 
12,500 Yes 0.55 1.62 2.79 0.89 6.96 
Passed mechanical 
testing (failure achieved) 
12,500 
 
No --- --- --- --- --- Broke during prep 
25,000 Yes 0.37 2.06 4.77 0.76 7.11 
Slipped, then ripped 
during testing 
 
25,000 
 
No --- --- --- --- --- Broke during prep 
50,000 Yes 0.51 1.67 3.79 0.85 10.40 
Passed mechanical  
testing (failure achieved) 
50,000 No 0.47 1.62 3.76 0.76 11.67 
Passed mechanical  
testing (failure achieved) 
100,000 Yes 0.35 2.09 3.98 0.74 5.32 
Passed mechanical  
testing (failure achieved) 
100,000 
 
No --- --- --- --- --- Broke during prep 
 
Gauze 
Fibroblast 
Sheet 
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Most of the cell sheets cultured without ascorbic acid broke during handling and 
measurement preparation, suggesting that these sheets were less durable than the sheets 
cultured with ascorbic acid. There were not enough samples to determine any significant 
difference between the sheets cultured with and without ascorbic or between the sheets 
cultured at different densities.  However, two cell sheets of 50,000 cells/cm2 cultured with 
ascorbic acid reached an average tensile stress of 11.03 +0.9 kPa. 
5.4.2.2 Uniaxial Tensile Testing of CDS from Experiment 4 
After harvesting fibroblast sheets cultured from an initial cell density of 100,000 cells/cm2 
from Experiment 4, sheets with and without ascorbic acid were immediately loaded on to an 
Instron ELECTROPULS E1000 (Figure 54). Sample thickness was measured using a Mitutoyo 
absolute digital caliper in conjunction with an Olympus CK2 confocal microscope. Width and 
grip distances were measured using a manual electronic caliper (VWR) once the tissue was 
placed inside the custom alligator clips. The tissues were hydrated in PBS until testing. The 
samples were tensile tested to failure using a strain rate of 10mm/min and a 1N load cell.  
 
Figure 54: CDS Loaded on Instron 
The thickness, width, and area of the cell sheets were recorded in Table 25. Stress was 
determined by dividing the load output from the raw data by the cross-sectional area. Samples 
S18, S5, and S6 were not cultured in ascorbic acid, and samples S7 and S8 were cultured in 
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ascorbic acid. Figure 55 shows the stress strain curve from the tensile test. It appears that 
tissues grown with ascorbic acid have more of a viscoelastic behavior of natural tissues. The 
bar graph in Figure 56 shows the that the maximum stress for cell sheets without ascorbic acid 
range from 1 to 3 kPa, while maximum stress for tissues grown with ascorbic acid range from 2 
to 6 kPa. The data from this experiment is not statistically significant according to the t-test 
(p=0.172 > p=0.05); however, power analysis indicates that there is less likely to be a significant 
difference between the two groups if one exists due to the small sample size. 
Table 25: Measurements and Results for Tensile Testing of Fibroblast Sheets 
Sample Thickness 
(mm) 
Width 
(mm) 
Area  
(mm2) 
Grip 
Distance 
(mm) 
Max Stress 
(kPa) 
S5 (-aa) 0.337 2.19 0.74 3.15 1.44 
S6 (-aa) 0.25 2.28 0.57 3.5 3.29 
S18 (-aa) 0.296 2.54 0.75 4.71 1.09 
S7 (+aa) 0.283 3 0.85 8.76 5.83 
S8 (+aa) 0.447 2.72 1.22 3.16 2.98 
 
 
Figure 55: Stress vs. Strain for Cell Sheets with and without Ascorbic Acid 
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Figure 56: Maximum Stress of Fibroblast Sheets with and without Ascorbic Acid 
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6 Discussion 
The goal of this project was to design and fabricate a cell-derived matrix scaffold with 
tailored mechanical properties and antimicrobial and angiogenic activity. The highest objectives 
for this scaffold were that it mimics the mechanical and structural properties of native dermis as 
well as be bioactive. Due to time and resources constraints, only the mechanical and 
antimicrobial objectives were considered in the design.  
 To produce a scaffold with mechanical and structural properties of native dermis, the 
design fabricated cell sheets and optimized decellularization methods to isolate the ECM from 
these sheets. The team produced cell sheets using human neonatal dermal fibroblasts and 
used ascorbic acid as a means to increase the mechanical strength of the scaffold. The team 
was able to form cohesive fibroblast sheets that could be harvested from poly-NIPAAM 
surfaces. Additionally, the team confirmed that ascorbic acid stimulated the fibroblast to 
increase collagen production. Mechanical testing showed a trend of fibroblast sheets cultured 
with ascorbic acid tending towards a higher maximum stress; however the sample size was too 
low to see any significant difference between the groups. The addition of ascorbic acid and the 
tissue fabrication protocol was not significant enough for the cell sheets to reach strengths 
reported for current products or of native dermis, which has a tensile strength of 5-30MPa 
(Lacroix & Planell, 2009). Alloderm, a decellularized cadaveric split thickness skin graft 
produced by Life Cell, reaches an initial uniaxial tensile strength of 0.125 MPa (LifeCell, 2012). 
Additionally, DermaSpan, an acellularized dermis produced by Biomet, has been shown to 
reach a uniaxial tensile strength of 19.2 MPa (Biomet, 2012). Additional means, such as 
mechanical or additionally chemical stimulation, must be investigated for increasing the 
mechanical strength of our fibroblast sheets, which only achieved an average failure stress of 4 
kPa.  
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Hypotonic and hypertonic solutions were insufficient at decellularizing the foreskin tissue 
and fibroblast sheets. This finding is comparable to literature, which states that this method can 
effectively lyse the cells but does not remove all of the cellular debris (Gilbert et al., 2006). SDS 
was found to successfully decellularize the foreskin tissue. However, SDS is reported to 
denature proteins, which could be counterproductive to the bioactivity of the scaffold if it 
disrupted the cathelicidin (Gilbert et al., 2006). Therefore, freeze-thaw was determined to be the 
most appropriate decellularization method due to its complete removal of nuclear debris from 
the dermis of foreskin tissue. It has also been reported that freeze thaw retains maximal matrix 
components (McDevitt, 2009).  Additionally, we were able to optimize the freeze-thaw protocol 
by including an 8-hour waiting period, which improved the decellularization effects of the 
method.  
 To produce a scaffold with innate antimicrobial activity, the team designed and 
fabricated a gene construct of a chimeric antimicrobial peptide, Cathelicidin, to include one of 
two collagen binding domains (CBDs). Cathelicidin was chosen as the protein of interest due to 
its natural expression in the epidermal layer of skin as well as its wide range of bactericidal 
activity. The two CBDs were derived from fibronectin and collagenase, which were chosen 
based on their confirmed specificity for collagen I and successful incorporation into various other 
chimeric constructs by other researchers (Sistiabudi & Ivanisevic, 2008; Zhang et al., 2009). 
The fabricated cathelicidin-CBD constructs were verified against the original design by 
sequence analysis, which showed 100% concensus. The protein design was further validated 
by the successful expression of both recombinant forms of cathelicidin in H1299 lung carcinoma 
cells.  
6.1 Analysis and Limitations of Experiments 
The following sections present a detailed analysis of the methods and results, with the 
limitations addressed for each experiment. Global limitations included becoming proficient in the 
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required skills and knowledge for laboratory techniques, including mechanical testing, 
decellularization, cell culture, processing, and histology. 
6.1.1 Fabrication of Cell-derived Sheets 
Fibroblasts seeded at sub-confluent densities performed best during cell sheet culture. 
In one experiment, 100,000 cells/cm2 was confirmed to be the highest cell density at which the 
cells would remain adhered to the plate for the 14 day culture period. However, in a proceeding 
experiment, five out of twenty-four cell sheets seeded at 100,000 cells/cm2 detached midway 
through the culture period. It is possible that these cells detached because they were nutrient 
deficient, meaning that the feeding interval should be increased from every other day.  
 Images of fibroblast sheets after 14 days of culture show a difference in cellular 
alignment in the sheets grown with and without ascorbic acid. Sheets grown without ascorbic 
acid had a basket weave appearance while sheets grown in the presence of ascorbic acid 
adopted a linear alignment. It is possible that the fibroblasts sheets grown without ascorbic acid 
continued to proliferate, contributing to the random, interwoven pattern observed. Additionally, it 
is likely that the ascorbic acid reduced the proliferative phase of the fibroblasts by stimulating 
them to produce more collagen, which attributed to the cells linear alignment.  
Although cells treated with ascorbic acid may have been less proliferative, our data 
shows that these sheets were significantly thicker than the untreated cell sheets.  The thickness 
of the cell sheets grown with ascorbic acid reached a mean of 0.388 mm, with the thickest 
tissue being 0.457 mm.  These dimensions are less than that of natural dermis, which is 1-4mm 
thick. However, our tissue sheets are in the thickness range of the thinnest version of Life Cell’s 
Alloderm. Alloderm ranges from thin (0.23-0.51 mm), medium (0.53-1.02mm), thick (1.04-
2.28mm), and extra thick (2.30-3.30mm) (LifeCell, 2012). 
Picrosirius Red/Fast Green staining of the cell sheets confirmed that ascorbic acid 
stimulated the fibroblasts to produce more collagen. The histology showed that fibroblast sheets 
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grown without ascorbic acid had no visible red fibers, meaning that no collagen was present. 
Fibroblast sheets grown in the presence of ascorbic acid had red collagen patches throughout 
the cell sheets. These results were representative for all samples; however, a larger sample 
size would provide more evidence. 
Tensile testing of the cell sheets suggested a trend that sheets grown with ascorbic acid 
were tending towards a higher maximum stress. The data was not statistically significant; 
however, the power analysis suggests that there is less likely to be a significant difference if one 
exists due to the low sample size tested. The mechanical testing was limited by a variety of 
factors. The time constraint and limitation of fibroblast supply restricted the design team from 
culturing multiple cell sheets for increased sample numbers. Additionally, the design team did 
not have the resources to culture larger tissues, which could be cut into rectangles to provide for 
more accurate tensile testing dimensions. Because the tissue sheets contract when removed 
from liquid, there was no way to consistently load the cell sheets in to the Instron machine with 
consistent fiber alignment.  
6.1.2 ECM Isolation 
Three difference decellularization protocols were tested on both the cultured sheets and 
foreskins to determine the most appropriate method to isolate the ECM from the tissue. Once 
the team became familiar with the protocols, the experiments were feasible and easy to 
perform.  Due to the limitation of fibroblast supply, the design team had to optimize the 
decellularization protocols on foreskins as model tissues. The results are not completely 
translatable to fibroblast sheets, but can be predicted to work with the same efficacy since 
foreskin tissue is more robust.  
SDS was able to penetrate through both the epidermis and dermis, while freeze-thaw 
was only able to decellularize the dermis. However, because this project is focused on a dermal 
regeneration scaffold and the cell-derived sheets do not produce an epidermal-like layer, the 
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team considered both of these protocols successful. Hypotonic and hypertonic solutions only 
partially decellularized the tissues, with the majority of decellularization near in the 
interior/connective tissue region. 
The use of DNase was critical to decellularize the tissues. With the exception of the 24 
hour SDS treatment, samples required DNase treatment to break down the DNA in the nuclei. 
The team experimented with DNase concentrations from literature and determined 0.5mL of 
1mg/mL DNase to be an effective concentration. Furthermore, the team also observed that 
freeze-thawed tissues required a waiting period in which samples sat on the benchtop for 8 
hours before fixation in order for decellularization to occur. Although literature does not discuss 
this requirement, the team determined that this “waiting period” was necessary in order for the 
genetic material to diffuse out of the cell.  
6.1.3 Antimicrobial Peptide 
As confirmed by the Western blot (Figure 22B) the recombinant cathelicidin constructs 
were successfully expressed in H1299 human lung carcinoma cells as a model cell type. The 
absence of bands in the lower molecular weight range of the membrane, suggests that the 
expressed product is not being cleaved. This is a limitation of using lung carcinoma cells, as 
opposed to a cell type with the confirmed expression of neutrophil proteinase 3 and elastase, 
which cleave cathelicidin to its active peptide, LL-37 (Sorensen et al., 2001). This is important to 
consider for future experiments, in terms of expressing cathelicidin in fibroblasts and whether its 
cleavage is dependent on the presence of neutrophils.   
6.2 Impact Analysis 
In addition to its clinical need, the design team analyzed the global impact of this 
product. The team considered how the scaffold would perform in terms of economics, political 
ramifications, environmental impact, manufacturability, sustainability, societal influence, ethical 
concerns, and health and safety issues. 
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6.2.1 Economics 
In the United States alone, $25 billion is spent annually on the treatment of chronic 
wounds. This economic burden is growing with the increase in health care costs, aging 
population, and number of people diagnosed with diabetes, obesity, and other illnesses 
associated with the development of chronic wounds (Sen et al., 2009). The economic and social 
impact of wound care in our society supports the need for new regenerative therapies, rather 
than treatments.  
6.2.2 Environmental Impact 
The majority of this product’s impact on the environment stems from the manufacture of 
laboratory plasticware required to produce the scaffold. Furthermore, any waste produced 
during fabrication will be considered biohazard and will have to be properly disposed. In 
addition, adequate bovine sources will be required to isolate the FBS to supplement the 
fibroblast media. If the need becomes great enough, land and resources will be affected to 
maintain the bovine population. Finally, power for running the manufacturing facilities requires 
natural resources for operation. 
6.2.3 Societal Influence 
The desired healing capabilities of our novel extracellular matrix scaffold will have a 
tremendous impact on society. Currently, no artificial skin therapy exists that can completely 
mimic natural skin, lacking nerve endings, hair follicles, and sweat glands. Additionally, no 
scaffold exists that can regenerate skin so that its total functionality returns. Having the ability to 
overcome these limitations will greatly increase the quality of life of patients with burns, ulcers, 
and other full-thickness wounds. Especially in the case of burn victims, the psychological trauma 
of their disfiguration will endure long after the wound has been clinically healed; their physical 
appearance will never return to normal (Smith, Smith, & Rainey, 2006). Our hope is that this 
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scaffold can also be a cosmetic treatment for the patient so that skin will regenerate back to its 
initial appearance.  
6.2.4 Political Ramifications 
The United States, Europe and Japan account for 80% of world’s wound care products. 
The global wound care market is projected to reach $20.3 billion by 2015 (Global Wound Care, 
2010).  As a leader in this market, the United States can only strengthen its position by offering 
governmental funding towards regenerative wound therapy. Additionally, such research funding 
can be used towards specifically healing soldiers who have been significantly wounded.  The 
economic, ethical, and societal burdens created by chronic wounds, are directly related to 
healthcare, and must be heavily considered by political figures. 
6.2.5 Ethical Concerns 
In order to be validated as a successful, therapeutic product, our scaffold will have to 
undergo multiple animal trials before it can be testing in clinical trials. Scientific testing on 
animals has brought forth many ethical concerns; proper animal care and scientific protocol 
must be followed according to the Institutional Animal Care and Use Committees standards. 
The animals must have living conditions that are appropriate for their species, and procedures 
should minimize discomfort and pain, using methods of euthanasia only when appropriate.  
Additionally, potential users may disagree with the genetic engineering method that is 
used to fabricate the scaffold. Whether personally or due to religious beliefs, some people may 
feel that reprogramming a cell to perform a function that it was not created to perform is an 
ethical breech. However, some people believe that exogenous or synthetic materials should not 
be placed inside the body. Therefore, our scaffold eliminates this concern due to its potential to 
be fabricated from autologous cells.  
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6.2.6 Health and Safety Issues 
Our scaffold addresses the limitation of infections that plagues many surgical 
procedures. Hospitals have struggled with procedure-induced infections, and the loss of barrier 
function makes skin wounds the most susceptible. The addition of a defense mechanism 
against infection built into this scaffold will further protect the patient’s health and allow for better 
healing. The safety of this scaffold will be determined through multiple animal and clinical trials 
according to FDA regulations. It is important that our scaffold is completely decellularized to 
eliminate the risk of disease transmission from the cell source.  
6.2.7 Manufacturability 
Although our product has the potential to improve the health of patients with hard-to-heal 
wounds, it is limited by its manufacturability. The scaffold will require more extensive 
maintenance and resources for production. Materials, equipment, and labor will be required for 
cell culture, tissue culture, decellularization, and transfection. Fabricating these scaffolds is at 
this stage a manual process, making it difficult to produce the product on a large-scale basis.  
6.2.8 Sustainability 
Because our product is completely cell-derived, the only materials required for 
production are those required for cell culture. However, because the supplies used to support 
cell and tissue growth are single-use only, the process is not very sustainable. Also, the 
production of tissue culture polystyrene, pipettes, and other required plastic/glass tools do not 
currently operate on renewable energy. However, once the scaffold is produced, only minimal 
energy is required to store the product until usage. If operations for the disposable resources 
were to use renewable energy, the process would become much more sustainable and would 
not have a major negative impact on the biological/ecological environment.  
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7 Final Design and Validation 
The final design was developed through iterations of the design process. Using the 
allotted time and material resources, three components of the design were finalized, including 
fibroblast sheet fabrication, ECM isolation using decellularization, and construction of a unique 
cathelicidin construct. Our final approach (Figure 57) brings these three components together: 
genetically modified fibroblasts are cultured into a cell sheet, which is then decellularized to 
isolate the final ECM scaffold with tailored mechanical strength and antimicrobial activity.   The 
following sections detail the final design components. 
 
7.1 Part 1: Fabricating Fibroblast Sheets 
Human neonatal fibroblasts were grown at 5% CO2 in IMDM containing 10% FBS, 
penicillin/streptomycin, L-glutamine, and 25 mM HEPES. Fibroblasts were seeded at 100,000 
Figure 57: Final Design Approach 
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cells/cm2 on NIPAAM (poly(N-isopropylacrylamide)-coated UpCellTM 24-well plates (Thermo 
Fisher Scientific, Inc.) and cultured for 14 days. Tissues received 1mL of IMDM containing 5% 
FBS with 50μg/mL of L-ascorbic acid to increase collagen production, which was changed every 
2 days. To harvest the tissues, the UpCellTM was incubated at 25˚C for 60 minutes.  
7.2 Part 2: Isolating the ECM via Decellurization 
Samples were placed in a 1.5mL Eppendorf tube and immersed in liquid nitrogen for 2 
minutes. PBS  (1mL) was added to each tube and the samples were rotated for 5 minutes on a 
Labquake tube rotator. The PBS was then aspirated. This process was repeated for a total of 
three cycles. Each sample was then treated with 0.5mL of DNase (Worthington, 1mg/mL, 10mM 
MgCl2) while rotating on the Labquake. Samples were washed three times for 5 minutes each in 
PBS while rotating and left on the bench top to sit for 8 hours. 
7.3 Part 3: Incorporating Antimicrobial Protein into the ECM 
A construct for human cathelicidin was designed to include a collagen binding domain to 
assure retention of the protein in the extracellular matrix scaffold. The construct was also 
designed with FLAG epitopes for verification of cell expression of the constructs using Western 
blot.  
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8 Conclusions and Recommendations 
The following discussion presents recommendations for overcoming our project 
limitations as well as future methods for realizing the successful production of our novel cell-
derived ECM scaffold for dermal wound healing. 
8.1 Future Work 
Future direction includes optimizing the structure and mechanics of the scaffold. The 
fibroblast sheets will be decellularized using the freeze-thaw protocol as stated in the final 
design. The effects of freeze-thaw on the scaffold will be assessed, including mechanical 
integrity, retention of matrix components, and retention of cellular debris. The mechanical 
integrity of the scaffold will be determined by mechanically testing the fibroblast sheets before 
and after decellularization.  The retention of matrix components will be assessed after freeze-
thaw using histology and quantification techniques. Components include collagen, GAG, 
fibronectin, and cathelicidin. Additionally, gel electrophoresis will be used to determine DNA 
fragment length of any remaining DNA in the scaffold. The fragment length of the DNA cannot 
be greater than 200 base pairs (Crapo et al., 2011). Quant-iTTM PicoGreen dsDNA Assay Kit 
(Invitrogen) will be used to verify that the DNA concentration is below the accepted limit for 
decellularized tissues. The scaffold cannot contain more than 50 ng of double stranded DNA per 
mg of ECM dry weight (Crapo et al., 2011).  
In order for the novel recombinant cathelicidin to be incorporated into a matrix scaffold, 
the next steps would include validating its activity. It is expected that the signal peptide which 
cathelicidin naturally possesses will allow for the secretion of the protein from the cell. Because 
the p3xFLAG vector fused three FLAG epitopes directly to the signal peptide on the N-terminal 
domain of the cathelicidin protein, it would need to be verified that the signal peptide is still fully 
functional. The localization of the protein would have to be tested by immunocytochemistry and 
cell fractionation experiments. Additionally, the collagen affinity and retention rate of the two 
147 
 
constructs would need to be analyzed to select the best recombinant form compatible with the 
tissue decellularization process of fabricating a matrix scaffold. 
Natural cathelicidin is known to have a broad range of activity against both Gram 
positive and Gram negative bacteria (Sorensen et al., 2001). It is expected that the addition of 
either of the collagen binding domains, with the FLAG linker, will not have significantly altered 
the activity of the peptide. The recombinant cathelicidin will need to be tested for its potency 
against common strains of microbes found in chronic wounds: Staphylococcus aureus, 
Enterococcus faecalis, and Pseudomonas aeruginosa.  
The recombinant cathelicidin would ultimately need to be expressed in primary dermal 
fibroblasts, which would synthesize both the extracellular matrix and the antimicrobial peptide. It 
would need to be verified that these cells could produce the peptide in sufficient concentrations, 
and secrete it into their extracellular matrices to allow for its cleavage by proteinases and 
adhesion to the collagen within the matrix. The scaffold should destroy at least 99.9% of 
bacteria to be comparable to current antimicrobial therapies (Dowling, 2012).   
8.2  Recommendations 
Through the various experiments, the team was able to determine which methods work 
best for our design and modifications we would make to improve the project. The following are 
recommendations that we advise in order to better the design and validation testing. 
8.2.1 Fibroblast Sheet Fabrication 
For future fibroblast cell sheet fabrication, we recommend changing the media every 
day, as opposed to every other day, to provide more nutrients. This may resolve the problem of 
the cell sheets dislodging from the plate before 14 days of culture. Additionally, sheet fabrication 
should be further explored on transwell inserts. This will allow for better media access to both 
sides of the tissue, which may enhance collagen production. We recommend using Thermo 
Scientific UpCellTM Surface Technology to increase the thickness of the fibroblast sheets. Six 
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well multidish UpCellTM plates with 9.6 cm2 culture surface area include membranes the can be 
used for 3D tissue culture. The membranes are applied to the sheet before detachment, which 
are both then placed directly on top of a new sheet. Since multiple layers can be added to 
increase thickness, this allows for flexibility in the desired cell sheet thickness. 
8.2.2 Histological Analysis 
For future analysis of the cell sheets, we recommend using Picrosirius Red stains to 
quantify collagen using Image J (NIH) or MATLAB image analysis. This will provide for a 
quantitative analysis of the increase in collagen production contributed by the ascorbic acid. 
8.2.3 Mechanical Testing 
The mechanical testing procedure can be improved through the following considerations. 
Thickness measurements should be obtained using an Apotome microscope. This will allow for 
more accurate measurements by focusing on the top and bottom Z-planes of the tissue.  For 
additional tensile testing, the dimensions of the scaffold should be optimized. We recommend 
growing larger samples in six well plates so that they can be cut into rectangles that are at least 
5 times longer than they are wide. Alternatively, dog bone molds can be used to grow the 
tissues so that they are harvested with ASTM dimensions for uniaxial tensile testing. 
Additionally, a method should be determined for controlling fiber orientation and direction so that 
they are the same for every tissue loaded onto the Instron. The cell sheets should also undergo 
cyclic pre-loading to better prepare the sheets for testing. However, we also recommend that 
testing on cell sheets be switched to biaxial mechanical testing using an inflation device. This is 
because we predict that the fiber alignment in the fibroblast sheets is anisotropic; therefore, 
uniaxial testing does not properly reflect the strength of the sheet. 
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8.2.4 Mechanical Strength of the Cell Sheets 
Mechanical strength of the fibroblast sheets can be enhanced chemically or 
mechanically. Other components, in addition to ascorbic acid, can be explored for their 
enhancement of mechanical strength, including epidermal growth factor, insulin, and cytokines 
(Throm, Liu, Lock, & Billiar, 2010). Cyclic mechanical stimulation has been shown to induce 
tenasin-C in fibroblasts, which enhances mechanical strength (Chiquet, Gelman, Lutz, & Maier, 
2009). We recommend that the fibroblast sheets be mechanically stimulated using the FlexCell 
equibiaxial stretching device. The vacuum pressure used to provide a uniform stretch of the 
tissue was shown to increase the mechanical strength of fibroblast sheets by 100 kPa 
(Balestrini & Billiar, 2006). 
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Appendices 
Appendix A: B-Term Gantt Chart 
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Appendix B: Metrics 
Structurally and mechanically similar to native dermal tissue—5 
Objective: Scaffold achieves a tensile strength of similar value to native dermis—5 
Specification: Dermis has tensile strength of 5-30 MPa 
Units: Rating the strength of the scaffold 
1) Not within 100 +/- 20% of native dermis 
2) Within 100 +/- 20% of native dermis 
 
Objective: Scaffold achieves a stiffness of similar value to native dermis—5 
Specification: Dermis has a modulus of elasticity of 15-150 MPa 
Units: Rating the stiffness of the scaffold 
1) Not within 100 +/- 20% of native dermis 
2) Within 100 +/- 20% of native dermis 
 
Objective: Scaffold achieves a shear resistance of similar value to native dermis—4 
Specification: Dermis has a shear resistance within 435-6620 Pa  
Units: Rating the shear resistance of the scaffold 
1) Not within 100 +/- 20% of native dermis 
2) Within 100 +/- 20% of native dermis 
 
Objective: Scaffold is permeable to cells—3 
Specification: Scaffold has pores of 20-125 µm 
Units: Rating the porosity of the scaffold to determine permeability 
1) Not within 100 +/- 20% of native dermis 
2) Within 100 +/- 20% of native dermis 
 
Objective: Biomolecules should be able to diffuse at a natural rate—3 
Specification: Scaffold has pores of 20-125 µm 
Units: Rating the porosity of the scaffold to determine diffusion rate 
1) Not within 100 +/- 20% of native dermis 
2) Within 100 +/- 20% of native dermis 
 
Objective: Scaffold has a thickness similar to native dermis—2 
Specification: Scaffold has a thickness of 1-4 mm 
Units: Rating the thickness of the scaffold 
1) Not within 100 +/- 20% of native dermis 
2) Within 100 +/- 20% of native dermis 
 
Objective: Scaffold has a high suture pullout strength—1 
Not used as an objective for alternative design evaluations 
 
Objective: Scaffold firmly adheres to wound bed—1 
Not used as an objective for alternative design evaluations 
 
Bioactive—4 
Objective: Scaffold actively inhibits microbial infections—3  
Specification: Scaffold kills 99.9% of streptococcus aureus, enterococcus faecalis, and 
pseudomonas aeruginosa (and candida) 
Units: Rating the amount of dead microbes using MIC90 and MBC analysis 
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1) Less than 99.9% 
2) 99.9% or greater 
 
Objective: Scaffold promotes angiogenesis—2 
Specification: Scaffold shows signs of blood vessel formation when reseeded with 
endothelial cells 
Units: Rating the ability to form vessels 
1) Promotes vasculature 
2) Promotes and produces vasculature 
 
Objective: Improved wound healing—1 
Not used as an objective for alternative design evaluations 
 
Ease of Laboratory Processing—3 
Objective: Repeatable process to minimize variation in results—5  
Specification: Process can be repeatable with a variation in quantitative results of 5% or 
less  
Units: Rating the variation of quantitative results 
1) Variation is greater than 5% 
2) Variation is 5% or less 
 
Objective: Minimize production costs—4  
Specification: Supplies for scaffold fabrication require minimal charges 
Units: Rating the amount of time and money 
1) Requires extensive time and money 
2) Requires minimal time and money 
 
Objective: Minimize the production area—3  
Specification: Scaffold production requires an area no larger than a standard-sized lab 
bench, hood, and incubator 
Units: Rating the size of the production area 
1) Production uses more area than specified 
2) Production uses the amount of area specified or less 
 
Objective: Minimize the equipment and technology required—2  
Specification: Scaffold can be produced with standard laboratory equipment 
Units: Rating the availability of equipment and technology 
1) Necessary equipment and technology needs to be purchased 
2) Necessary equipment and technology needs to be borrowed 
3) Necessary equipment and technology does not need to be purchased or borrowed (already 
available) 
 
Objective: Minimize the difficulty of process steps—1  
Specification: Scaffold can be produced with minimal expertise 
Units: Rating the laboratory experience required for scaffold production 
1) Much experience is necessary 
2) Some experience is necessary 
3) No experience is necessary 
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Clinical Ease of Use—2 
Objective: Scaffold can be easily implanted—minimal preparation from shelf to body—3 
Specification: Scaffold can be transported directly from the package to the patient 
Units: Rating the time and extent of preparation required before implantation 
1) Major preparation is necessary (more than 1 hour) 
2) Minor preparation is necessary (less than 1 hour) 
3) No preparation is necessary 
 
Objective: Scaffold can be easily implanted—can be handled without tearing—3 
Specification: Scaffold does not rip or tear during handling or implantation 
Units: Rating the durability of the scaffold 
1) Major rips or tears occur 
2) Minor rips or tears occur 
3) No rips or tears occur 
 
Objective: Scaffold can be easily implanted—simple in-vivo attachment to wound bed—3 
Specification: Scaffold attachment to wound bed can be quickly completed with minimal 
expertise 
Units: Rating the attachment method 
1) Attachment requires major additional training 
2) Attachment requires minor additional training 
3) Attachment requires no additional training 
 
Objective: Scaffold can be used to treat various wound sizes and shapes—3 
Specification: Scaffold can be formed into multiple shapes 
Units: Rating the number of shapes and sizes 
1) Scaffold comes in 1 size/shape 
2) Scaffold comes in 2 size/shapes 
3) Surgeon can form scaffold into any shape 
 
Objective: Treatment with scaffold uses a minimal number of applications—2 
Specification: Treatment only requires one scaffold application 
Units: Rating the number scaffold applications required 
1) More than 2 applications are necessary 
2) More than 1 application is necessary 
3) Only 1 application is necessary 
 
Objective: Scaffold can be stored for extended periods of time—1  
Specification: Scaffold remains functional after 1 year of storage 
Units: Rating the amount of time the scaffold can be stored and still usable 
1) Can be stored less than 6 months 
2) Can be stored for 6 months-1 year 
3) Can be stored for 1 year or more 
 
Ease of Production—1 
Objective: Scaffold requires minimal costs for production—2 
Specification: Scaffold fabrication requires minimal use of materials and time to fabricate 
scaffold 
Units: Rating the amount of time and supplies needed 
1) Requires extensive use of materials and time 
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2) Requires minimal use of materials and time 
  
Objective: Scaffold can be manufactured in large quantities—1 
Specification: Scaffold fabrication requires minimal use of labor and time to scale-up 
production 
Units: Rating the amount of labor and time needed 
3) Requires extensive use of labor and time 
4) Requires minimal use of labor and time 
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Appendix C: Decision Matrices 
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Appendix D: Conceptual Designs 
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Appendix E: C-Term Gantt Chart 
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Appendix F: Materials List 
 
*Total cost does not reflect the amount spent by the design team, or account for tissue culture and 
histology costs 
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Appendix G: Tissue Processing Protocol 
 
    Foreskins  Fibroblast Sheets 
Formalin   Overnight  60 Min 
70% Alcohol   15 Min  15 Min or Overnight 
80% Alcohol   15 Min  15 Min 
90% Alcohol   20 Min  20 Min 
95% Alcohol   30 Min  25 Min 
100% Alcohol  30 Min  25 Min 
100% Alcohol  30 Min  25 Min 
100% Alcohol  30 Min  25 Min 
Xylene   45 Min  30 Min  
Xylene   45 Min  30 Min 
Paraffin   45 Min  30 Min  
Paraffin   45 Min  30 Min 
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Appendix H: Staining Protocols for Paraffin Sections 
Hematoxylin and Eosin Staining 
1. Xylene…………………………………………………………… 
2. Xylene…………………………………………………………… 
3. Xylene…………………………………………………………… 
4. 100% ETOH………………………….…………………………. 
5. 100% ETOH…………………………………………………….. 
6. 95% ETOH…..………………………………………………….. 
7. 70% ETOH………………………………………………...……. 
8. Rinse in running H20………………………………………….. 
9. Harris Hematoxylin…………………………………………….. 
10. Rinse in running H20………………………………………….. 
11. Differentiate sections in 1% HCL mixed in 70% ETOH 
(0.25ml HCl to 100 ml of 70% ETOH)……………………….. 
12. Rinse in running H20……….…………………………………. 
13. Blue sections in ammonia solution…………………………... 
14. Rinse in running warm H20………………………………….... 
15. 95% ETOH…………………………………………..………….. 
16. Counterstain in Eosin-Y……………………………………….. 
17. 70% ETOH…………………………………..………………….. 
18. 95% ETOH……………………………………..……………….. 
19. 95% ETOH…………………………………………..………….. 
20. 100% ETOH…………………………………………………….. 
21. 100% ETOH…………………………………………………….. 
22. 100% ETOH…………………………………………………….. 
23. Xylene……………………………..…………………………….. 
24. Xylene…………………………………..……………………….. 
25. Xylene…………………………………………………………… 
 
Results: 
Nuclei = blue 
Cytoplasm = pink 
Blood = red 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Minutes 
3 Minutes 
3 Minutes 
3 Minutes 
3 Minutes 
1 Minute 
1 Minute 
Until Clear 
5 Minutes 
Until Clear 
2-3 quick dips 
 
30 seconds 
1 Minute 
5 Minutes 
30 seconds 
1 Minute 
30 seconds 
30 seconds 
30 seconds 
1 Minute 
1 Minute 
1 Minute 
1 Minute 
1 Minute 
1 Minute 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Picrosirius Red Staining 
Reagents: 
0.1%Sirius Red Solution 
 
1. Xylene……………………………………………………………………3 Minutes 
2. Xylene……………………………………………………………………3 Minutes 
3. Xylene……………………………………………………………………3 Minutes 
4. 100% ETOH……………………………………………………………..3 Minutes 
5. 100% ETOH………………………………………………………….….3 Minutes 
6. 95% ETOH……………………………………………………………….1 Minute 
7. 95% ETOH……………………………………………………………….3 Minute 
8. 70% ETOH……………………………………………………………….3 Minute 
9. Rinse in running H20……………………………………………………Until Clear 
10. Picrosirius Fast Green……………………………………………..…...30 minutes 
11. 17. 80% ETOH…………………………………………………………..1 min 
12. 18. 95% ETOH…………………………………………………………..1 min 
13. 19. 95% ETOH…………………………………………………………..1 min 
14. 100% ETOH……………………………………………………….…..…5 min 
15. 100% ETOH………………………………………………………………5 min 
16. 100% ETOH……………………………………………………………...10 min 
17. Xylene……………………………………………………………..………3 min 
18. Xylene……………………………………………………………...…..…3 min 
19. Xylene……………………………………………………………….….…3 min 
 
Results: 
Collagen fibers = red 
Other tissue fibers = green 
 
 
 
 
 
 
 
  
  
 
Hoechst Staining 
1. Xylene……………………………………………………………………3 Minutes 
2. Xylene……………………………………………………………………3 Minutes 
3. Xylene……………………………………………………………………3 Minutes 
4. 100% ETOH………………………………………………………….….3 Minutes 
5. 100% ETOH……………………………………………………….…….3 Minutes 
6. 95% ETOH…………………………………………………………...….1 Minute 
7. 70% ETOH……………………………………………………………….1 Minute 
8. Rinse in running H20……………………………………………….…..Until Clear 
9. 1 mL Hoescht/1 mL diH2O…………………………………………..…2 Minutes 
10. PBS……………………………………………………………………….5 Minutes 
11. PBS……………………………………………………………………….5 Minutes 
12. PBS……………………………………………………………………….5 Minutes 
13. Coverslip with Prolong Gold 
 
Results: 
Neon blue = nuclei 
  
  
 
Appendix I: Decellularization Protocols 
Original SDS Decellularization (Elder et al., 2009) 
1. Place the specimens in 2% SDS in a 37°C shaking water bath for 1 hour 
2. Wash with agitation 5 times in phosphate-buffered saline (PBS) for periods of 10 
minutes each 
 
Modified SDS Decellularization (for small tissues) 
1. Dissolve SDS in diH20 to produce a 2% working solution 
2. Place tissue in 15mL conical tube and add 10mL of SDS solution 
3. Spin tubes on Glas-Col rotator at 33rpm for 1 hour at 37°C 
4. Aspirate SDS 
5. Add 10mL 1X PBS to tube and rotate on Labquake on 10 minutes at room temperature. 
Repeat this step for a total of 5 washes. 
6. Aspirate PBS 
7. Add 0.5mL of 1mg/mL DNase (plus 10mM MgCl2) to tube and rotate for 15 minutes on 
Labquake rotator at room temperature 
8. Aspirate DNase solution 
9. Add 10mL 1X PBS to tube and rotate on Labquake for 5 minutes at room temperature. 
Repeat this step for a total of 3 washes. 
Original Freeze-Thaw Decellularization (Ngangan & McDevitt, 2009) 
1. Immerse tube with tissue into liquid nitrogen and allow liquid nitrogen to boil off 
2. Add 1mL PBS to tube while rotating sample for 5 minutes at room temperature 
3. Centrifuge for 2 minutes at 18000 rcf at room temperature 
4. Repeat 3 times 
 
Modified Freeze-Thaw Decellularization (for small tissues) 
1. Place sample in 1.5mL Eppendorf tube 
2. Submerge tube in liquid nitrogen and allow to freeze for 2 minutes 
3. Remove tube and add 1mL of 1X PBS to tube 
4. Rotate tube on Labquake for 5 minutes at room temperature. 
5. Aspirate PBS 
6. Repeat steps 2-5 for a total of 3 cycles 
7. Add 0.5mL of 1mg/mL DNase (plus 10mM MgCl2) to tube and rotate for 15 minutes on 
Labquake rotator at room temperature 
8. Aspirate DNase solution 
9. Add 10mL 1X PBS to tube and rotate on Labquake for 5 minutes at room temperature. 
Repeat this step for a total of 3 washes. 
10. Let sample sit in PBS at room temperature for 8 hours 
  
 
Original Hypontonic and Hypertonic Solutions Decellularization (Meyer et al., 2006) 
1. Rinse in saline solution (PBS) 
2. Hypotonic tris buffer (10mM, pH 8.0) with 0.1mM PMSF and 5mM EDTA for 48h for 4 
degrees celsius 
3. Hypertonic Tris buffer solution (50mM, pH 8.0, PMSF 0.1 mM, EDTA 5mM, KCL 1.5M) 
with 0.5% Triton X-100 for 48 hr at 4 degrees celsius 
4. Rinse in Sorensen’s buffer (pH 7.3) containing DNase I (25 mcg/mL), RNase A (10 
mcg/mL) and MgCl2 (10 mM) for 5 hr at 37 degrees Celsius 
5. Tris buffer (base)(50mM, pH 9.0, Triton X-100 0.5%) for 48 hr at 4 degrees Celsius 
6. PBS wash at 4 degrees Celsius for 72 hr, changing the solution every 24 hr 
 
Modified Hypotonic and Hypertonic Solutions Decellularization (for small tissues) 
1. Rinse samples in 1X PBS 
2. Dissolve tris HCl (10mM), cOmplete mini cocktail tablet (1 tablet/10mL), and EDTA 
(5mM) in diH2O to produce a hypotonic solution (pH 8.0). Rotate samples in 10mL of 
solution on a Labquake rotator for 48 hours at 4 degrees Celsius 
3. Aspirate hypotonic solution. 
4. Dissolve tris HCl (50mM), cOmplete mini cocktail tablet (1 tablet/10mL), EDTA (5mM), 
KCl (1.5M), and Triton X-100 (0.5%) in diH20 to produce a hypertonic solution (pH 8.0). 
Rotate samples in 10mL of solution on a Labquake rotator for 48 hours at 4 degrees 
Celsius. 
5. Prepare Sorenson’s buffer 
6. Add DNase I (25mcg/mL) and MgCl2 (10mM) to Sorenson’s buffer and rotate samples in 
10mL of solution on a Labquake rotator for 5 hours at 37 degrees Celsius 
7. Aspirate Sorenson’s buffer solution 
8. Disolve Trizma base and Triton X-100 (0.5%) in diH20 to produce the final tris buffer 
9. Rotate samples in 10mL of final tris buffer on a Labquake rotator for 48 hours at 4 
degrees Celsius. 
10. Aspirate buffer. 
11. Add 10mL 1X PBS to samples and rotate on Labquake for 72 hours at 4 degrees 
Celsius, changing the wash every 24 hours. 
 
 
 
 
